Research Triangle Institute

Consolidated Financial Statements as of and for the Years Ended September 30, 2024 and 2023, Federal Awards Supplemental Information as of and for the Year Ended September 30, 2024, and Independent Auditor’s Report

RESEARCH TRIANGLE INSTITUTE

TABLE OF CONTENTS

Deloitte.

Deloitte & Touche LLP
621 Hillsborough St
Suite 400
Raleigh NC 27603
USA

Tel: +1 919 546 8000
Fax: +1 919 833 3276
www.deloitte.com

INDEPENDENT AUDITOR'S REPORT

To the Board of Governors of
Research Triangle Institute:

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the consolidated financial statements of Research Triangle Institute and subsidiaries (the "Institute"), which comprise the consolidated balance sheets as of September 30, 2024 and 2023, and the related consolidated statements of revenue, costs, and changes in net assets and cash flows for the years then ended, and the related notes to the consolidated financial statements (collectively referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Institute as of September 30, 2024 and 2023, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Institute and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Institute's ability to continue as a going concern for one year after the date that the financial statements are issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Institute's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Institute's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we have also issued our report dated December 4, 2024 on our consideration of the Institute's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Institute's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Institute's internal control over financial reporting and compliance.

Deloitte & Touche LLP

December 4, 2024, except for the subsequent event in Note 1 related to the effects of terminations and stop-work orders, as to which the date is June 27, 2025

RESEARCH TRIANGLE INSTITUTE

CONSOLIDATED BALANCE SHEETS
AS OF SEPTEMBER 30, 2024 AND 2023
(In thousands)

	2024	2023
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	$ 27,401	$ 29,012
Restricted cash	22,251	9,782
Short-term investments	226,168	188,837
Accounts receivable—net of allowance of $740 and $889, respectively	95,006	92,570
Unbilled costs, fees, and contract assets	217,385	184,139
Prepaid expenses and other current assets	28,628	22,687
Total current assets	616,839	527,027
PROPERTY AND EQUIPMENT—Net	146,950	150,685
OPERATING LEASE RIGHT-OF-USE-ASSETS—Net	8,761	17,848
INVESTMENTS	103,561	93,367
GOODWILL—Net	5,591	6,717
OTHER NONCURRENT ASSETS	54,215	26,114
TOTAL ASSETS	$935,917	$821,758
LIABILITIES AND NET ASSETS		
CURRENT LIABILITIES:		
Accounts payable and accrued expenses	$175,375	$136,644
Operating lease liabilities current	7,089	7,012
Current portion of long-term debt	29,280	30,610
Accrued compensated absences	30,745	29,855
Deferred revenue and contract liabilities	71,088	56,811
Total current liabilities	313,577	260,932
LONG-TERM LIABILITIES:		
Long-term debt	66,949	38,094
Operating lease liabilities noncurrent	8,933	13,306
Other long-term liabilities	17,247	15,052
Total liabilities	406,706	327,384
COMMITMENTS AND CONTINGENCIES (Note 17)		
NET ASSETS:		
Net assets without donor restrictions:		
Undesignated net assets	519,826	483,776
Board-designated net assets	8,976	9,919
Total net assets without donor restrictions	528,802	493,695
Net assets with donor restrictions	409	679
Total net assets	529,211	494,374
TOTAL LIABILITIES AND NET ASSETS	$935,917	$821,758

See notes to consolidated financial statements.

RESEARCH TRIANGLE INSTITUTE

CONSOLIDATED STATEMENTS OF REVENUE, COSTS, AND CHANGES IN NET ASSETS
FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023
(In thousands)

	2024	2023
REVENUE:		
Revenues from contracts and contribution awards	$ 1,347,033	$ 1,216,436
Contributions of nonfinancial assets	19,362	13,347
Total revenue	1,366,395	1,229,783
DIRECT COSTS:		
Salaries and employee benefits	389,341	362,716
Other direct costs	543,935	456,858
Total direct costs	933,276	819,574
INDIRECT COSTS	436,244	410,114
Total direct and indirect costs	1,369,520	1,229,688
(DEFICIT) EXCESS OF REVENUE OVER DIRECT AND INDIRECT COSTS	(3,125)	95
INVESTMENT INCOME—Net	53,894	28,368
OTHER EXPENSE—Net	(9,164)	(12,351)
INTEREST EXPENSE—Net	(6,532)	(857)
OPERATING INCOME BEFORE INCOME TAX EXPENSE	35,073	15,255
INCOME TAX EXPENSE	(1,111)	(960)
NET OPERATING INCOME	33,962	14,295
POSTRETIREMENT CHANGES OTHER THAN NET PERIODIC BENEFIT COSTS	1,145	3,973
INCREASE IN NET ASSETS WITHOUT DONOR RESTRICTIONS	35,107	18,268
DECREASE IN NET ASSETS WITH DONOR RESTRICTIONS	(270)	(48)
Total increase in net assets	34,837	18,220
TOTAL NET ASSETS:		
Beginning of year	494,374	476,154
End of year	$ 529,211	$ 494,374

See notes to consolidated financial statements.

RESEARCH TRIANGLE INSTITUTE

CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023
(In thousands)

	2024	2023
CASH FLOWS FROM OPERATING ACTIVITIES:		
Increase in net assets	$ 34,837	$ 18,220
Adjustments to reconcile change in net assets to cash used in operating activities:		
Depreciation and amortization	21,585	15,764
Noncash lease expense	6,852	6,840
Dividends reinvested	(5,618)	(13,152)
Realized and unrealized gain on investments—net	(46,616)	(12,314)
Realized and unrealized loss (gain) on derivatives—net	3,170	(1,440)
Postretirement changes other than net periodic pension cost	(1,145)	(3,973)
Other loss—net	6,872	7,734
Changes in other operating assets and liabilities:		
Accounts receivable, unbilled costs and fees, and contract assets	(35,541)	(31,748)
Other operating assets	(34,918)	(3,306)
Accounts payable and accrued expenses	36,895	11,788
Deferred revenue and contract liabilities	14,276	541
Other operating liabilities	(5,311)	(1,441)
Net cash used in operating activities	(4,662)	(6,487)
CASH FLOWS FROM INVESTING ACTIVITIES:		
Proceeds from sale of investments	29,256	22,987
Purchases of investments	(25,341)	(28,192)
Acquisition of property and equipment	(16,287)	(12,447)
Net cash used in investing activities	(12,372)	(17,652)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds from lines of credit	545,546	246,341
Payments on lines of credit	(545,546)	(246,341)
Payments on variable rate term loan	(4,000)	(4,000)
Payments on bonds payable	(3,365)	(3,160)
Proceeds from issuance of long-term debt	35,452	-
Payments on bond issuance cost	(195)	-
Net cash provided by (used in) financing activities	27,892	(7,160)
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH	10,858	(31,299)
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH:		
Beginning of year	38,794	70,093
End of year	$ 49,652	$ 38,794

(Continued)

RESEARCH TRIANGLE INSTITUTE

CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023
(In thousands)

	2024	2023
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION—		
Cash paid during the year for:		
Income taxes	$ 958	$ 752
Interest	$ 3,355	$ 2,231
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION—Noncash transactions:		
Construction in process accruals	$ 910	$ 952
Bond issuance cost accruals	$ 297	$ -
Receivable from investment liquidation held at escrow	$ 803	$ -
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION—Reconciliation of cash, cash equivalents, and restricted cash reported in consolidated balance sheets:		
Cash and cash equivalents	$ 27,401	$ 29,012
Restricted cash	22,251	9,782
Total cash, cash equivalents, and restricted cash	$ 49,652	$ 38,794

See notes to consolidated financial statements. (Concluded)

1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization—Research Triangle Institute (the "Institute"), which operates under the trade name RTI International, is one of the world's leading independent nonprofit research organizations, dedicated to conducting research and development that improves the human condition by turning knowledge into practice. The Institute was established in 1958 by a joint action of Duke University, the University of North Carolina, and North Carolina State University (the latter two are governed under the University of North Carolina System), as the founding tenant of Research Triangle Park, North Carolina. The Institute is a separately operated North Carolina nonprofit corporation that performs multidisciplinary research, development, and technical services under contract to clients in federal and foreign governments, industry, and public service agencies and is exempt from taxation under Section 501(c)(3) of the Internal Revenue Code (IRC). With a worldwide staff of more than 6,100 employees, the Institute offers a full spectrum of multidisciplinary services in health, education and workforce development, energy and environment, food security and agriculture, international development, and innovation.

Four individuals from the Institute's founding institutions—Duke University and the University of North Carolina System—serve as the members of the Institute and are responsible for electing the Board of Governors (the "Board"). Corporate oversight is provided by the Board, which consists of representatives from the founding institutions, members elected from business and professional communities, and the president of the Institute. The Institute collaborates with its founding institutions on research programs and projects and maintains such relationships as adjunct faculty appointments, cooperative research programs, and other professional contacts. During the years ended September 30, 2024 and 2023, revenues from these activities amounted to $14.1 million and $10.9 million, respectively. Further, for the years ended September 30, 2024 and 2023, expenditures related to these activities amounted to $71.3 million and $24.5 million, respectively.

Basis of Presentation—The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The consolidated financial statements include the accounts of the Institute and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated.

The preparation of the consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated financial statements. Actual results could differ from those estimates.

Subsequent Events— Subsequent to September 30, 2024, and through June 27, 2025, pursuant to executive orders issued by the new U.S. Administration or actions taken by the Department of Government Efficiency ("DOGE"), the Institute received notices for termination-for-convenience of approximately $426.6 million and for stop-work orders of approximately $8.1 million of remaining funded contract value, respectively. Had the terminations-for-convenience occurred prior to September 30, 2024, the aggregate amount of our contract transaction price that remained for future revenue recognition, excluding time and materials and unfunded contract balances, would have been reduced by approximately 21.6%. Further, had these terminations-for-convenience occurred prior to September 30, 2024, the aggregate amount of conditional promises to be received in future years related to the Institute's ongoing operating programs would have been reduced by approximately 39.4%.

Business Combinations—Business combinations are accounted for using the acquisition method of accounting. Under the acquisition method of accounting, acquired assets and assumed liabilities are included with the acquirer's accounts as of the date of acquisition at estimated fair value, with any excess of purchase price over the fair value of the net assets acquired (including certain identifiable intangible assets), capitalized as goodwill. Certain intangible assets are recognized as an asset apart from goodwill when it arises from contractual or other legal rights or if it is capable of being separated or divided from the acquired entity and sold, transferred, licensed, rented, or exchanged. Intangible assets related to noncompetition agreements or customer-related intangibles are recognized as part of goodwill. In addition, acquisition-related costs and restructuring costs are recognized as period expenses as incurred.

Revenue Recognition—The Institute's sources of revenue include contract and contribution revenues primarily from agreements with agencies of the federal government.

Generally, it has been concluded that fixed fee, fee-bearing cost reimbursable, and time and materials contracts are exchange transactions subject to Accounting Standards Codification (ASC) 606, *Revenue from Contracts with Customers* (ASC 606), and grants, cooperative agreements, and non-fee-bearing cost reimbursable contracts are contributions subject to ASC 958, *Not-for-Profit Entities* (ASC 958).

Exchange Transactions—In accordance with ASC 606 for exchange transactions, the Institute recognizes revenue when, or as performance obligations are satisfied under a contract. A performance obligation is the unit of account for revenue recognition and refers to a promise in a contract to transfer a distinct service or good to the customer. For the majority of contracts, the Institute combines multiple promises into a single performance obligation due to the multiple promises being either highly interrelated or through providing a significant integration of services that represent a combined output. Performance obligations may be satisfied over time or at a point in time, but the majority of the Institute's performance obligations are satisfied over time.

The Institute evaluates whether it has an enforceable contract with a customer when rights of the parties and payment terms are identified, and collectability is probable. The Institute also evaluates if a contract has multiple promises and if each promise should be accounted for as separate performance obligations or as a single performance obligation.

The transaction price is the estimated amount of consideration expected to be received for performance under the Institute's contracts. Contract terms may contain variable consideration. The Institute includes variable consideration in the transaction price only to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. The Institute does not include unfunded contract balances in the transaction price until funding is provided from the customer.

For the majority of its exchange transactions, the Institute recognizes revenue over time as there is a continuous transfer of control to the customer over the contract's period of performance.

Generally, the cost-to-cost method is used to recognize revenue over time for fixed price and cost reimbursement contracts. The cost-to-cost method recognizes revenue based on the entity's efforts or inputs to the satisfaction of a performance obligation relative to the total expected inputs to the satisfaction of that performance obligation. The cost-to-cost method is considered a faithful representation of the delivery of services as efforts to complete a contract are expended over the period of performance. Changes in estimates of costs to complete result in the recognition of a cumulative effect adjustment in the period a change in estimate occurs. Estimated losses on agreements are provided for in the period the losses are first determined.

The Institute recognizes revenue using the right to invoice practical expedient for time and materials contracts as the Institute can invoice the customer in an amount that corresponds directly with the value received by the customer for performance completed to date.

Contributions—Grants, cooperative agreements, and non-fee-bearing cost reimbursable contracts are classified as contributions in instances where there is not an exchange of commensurate value. In general, the Institute recognizes revenue over the contribution agreement's period of performance and not at the time of its award. Where these agreements contain barriers and restrictions with a right of return, contribution revenue is recognized upon satisfaction of the indicated conditions, which is generally by the occurrence of an allowable cost. The Institute has elected to present contributions whose restrictions are met in the same reporting period that revenue is recognized as net assets without donor restrictions.

The Institute also enters into cost-sharing arrangements in which it receives in-kind contributed services or supplies from third-party contractors. In-kind contributions received by the Institute are valued at fair value and recorded as revenue in the consolidated statements of revenue, costs, and changes in net assets. Likewise, in-kind contributions received by the Institute are recognized as an expense on the related project and are reflected as direct costs in the consolidated statements of revenue, costs, and changes in net assets.

Expense Recognition—Direct and indirect costs are expensed as incurred. Direct costs are those costs that can be specifically identified with a particular project. Indirect costs represent overhead costs, which primarily consist of salaries and benefits, materials and services, strategic initiatives, depreciation, rent, and utilities expenditures.

Internal Service Center Allocations—Indirect labor and other costs of certain service centers, such as information technology services and facilities, are charged directly to contracts and overhead cost centers as direct or indirect services.

Concentration of Credit Risk—Financial instruments that potentially subject the Institute to concentration of credit risk consist principally of cash and cash equivalents. The Institute places its cash and cash equivalents in the United States primarily in federally insured financial institutions, which limits its credit exposure. At times, these cash amounts may be in excess of the Federal Deposit Insurance Corporation insurance limits. In addition, as of September 30, 2024 and 2023, the Institute had approximately $5.1 million and $3.8 million, respectively, of international cash deposits in financial institutions that may not be insured to the same extent as monies in U.S. institutions. In order to mitigate this risk, the Institute maintains cash accounts in international financial institutions with certain required credit ratings and maintains minimal necessary balances in smaller international financial institutions.

The federal government is the Institute's major client, making up 85.0% and 84.3% of revenue for the years ended September 30, 2024 and 2023, respectively. As of September 30, 2024 and 2023, accounts receivable from the federal government amounted to $51.5 million and $55.6 million, respectively.

Cash and Cash Equivalents and Restricted Cash—All highly liquid investments purchased with an original maturity of three months or less are considered cash equivalents. As of September 30, 2024, restricted cash primarily includes $16.6 million in bond proceeds received, which are restricted to pay for costs associated with the acquisition and installation of a cloud-based enterprise resource planning software, and $5.2 million in customer advances that must be returned if not expended by the Institute. As of September 30, 2023, restricted cash consists of $9.1 million in customer advances that must be returned if not expended by the Institute.

Accounts Receivable—Accounts receivable consists of costs that have been incurred for which the Institute has invoiced the client in accordance with the contractual terms and conditions of the underlying agreements. Receivables are recorded at approved rates for services and goods. As of September 30, 2023, the Institute has established an allowance for uncollectible accounts based upon historical performance. Beginning in fiscal year ending September 30, 2024, the Institute implemented the new guidance of Financial Accounting Standards Board (FASB) Accounting Standard Update (ASU) 2016-13, *Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments* (ASU 2016-13), and an allowance based upon expected lifetime losses is recorded for all in-scope accounts receivable.

The Institute evaluates the receivables pool and assesses a loss reserve to account for inherent non-payment. The Institute applies the historical 3-year average of bad debt to the entire portfolio of billed accounts receivable at year end. The Institute then addresses the contract assets and deferred revenue. This population is separated into pools of exchange and non-exchange transactions, as well as federal and non-federal clients. Non-exchange transactions are scoped out of the assessment required under Topic 326.

Of the remaining portfolio, the Institute assessed the federal unbilled receivables by owing agency and area specific risk factors. There are no agencies that present risk of future nonpayment due to budget considerations, financial stability, or inherent market risk. Accordingly, the Institute notes zero expected loss on this section of the portfolio. Of the remaining population, the Institute then assessed the risk of loss due to environmental risk factors such as geographical unrest, general business risk, and financial instability.

Changes in the allowance for credit losses for the year ended September 30, 2024, were as follows (in thousands):

	2024
Balance, beginning of the period	$ 889
Impact of adoption of the new credit loss standard	40
Provisions	384
Write off, net of recoveries	(573)
Balance, end of period	$ 740

Unbilled Costs, Fees, and Contract Assets/Deferred Revenue and Contract Liabilities—The timing of revenue recognition may differ from the timing of billing and cash receipts from customers. Amounts are invoiced as work progresses, typically monthly in arrears, or upon achievement of contractual milestones. The Institute records an asset when revenue is recognized prior to invoicing, or a contract liability when cash is received in advance of recognizing revenue. Contract assets are recognized on exchange transactions and represent a right to consideration that is conditional upon factors other than the passage of time. Contract assets include unbillable receivables but exclude billed and billable receivables. Billed and billable receivables are rights to consideration, which are unconditional other than to the passage of time. Contract liabilities include customer advances and deferred revenue. Contract assets and liabilities are recorded net on a contract by contract basis and are generally classified as current based on the Institute's contract operating cycle.

Accounts Payable and Accrued Expenses—Accounts payable and accrued expenses consist of costs which have been incurred but have not yet been paid. As of September 30, 2024 and 2023, accounts payable and accrued expenses amounted to $175.4 million and $136.6 million, respectively, consisting primarily of $38.2 million and $21.8 million of vendor invoices, $75.2 million and $51.4 million of accrued subcontractor and consultant expenses, and $44.0 million and $36.8 million of mostly employee related expenses.

Debt and Equity Securities—Debt securities and equity securities with readily determinable fair values are recorded at fair value. Certain investments' fair value is measured using net asset value (NAV) per share, based on the fair value of the respective fund's underlying investments less the fund's liabilities. Unrealized gains and losses associated with these securities are recognized in the consolidated statements of revenue, costs, and changes in net assets.

For equity securities without readily determinable fair values, the Institute has elected a measurement alternative whereby these securities are recorded at cost, adjusted for changes resulting from observable price changes (in orderly transactions for the identical or similar investment of the same issuer), and less impairment. To determine impairment, a qualitative assessment is performed and if this assessment indicates that impairment exists, an estimate of fair value is determined. Any impairments are recognized in the consolidated statements of revenue, costs, and changes in net assets.

Certain debt securities are classified as available-for-sale (AFS) and evaluated for impairment. As of September 30, 2023, when a decline in fair value below a security's cost was determined to be other-than-temporary, an impairment charge was recorded in the consolidated statements of revenue, costs, and changes in net assets. During the year ended September 30, 2024, the Institute implemented the guidance from ASU 2016-13, and when a security's fair value and the present value of expected cash flows are less than the security's cost, the Institute recognizes an allowance for the expected credit loss, limited by the difference between fair value and cost.

While the Institute believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

Equity Method Investments—Equity method investments include those in which the Institute does not have control but has the ability to exercise significant influence over operating and financial policies. These investments are initially recorded at cost and are subsequently adjusted for the Institute's share of earnings and cash contributions and distributions. The Institute analyzes other-than-temporary impairment of these investments regularly. Other-than-temporary impairments are recognized in the consolidated statements of revenue, costs, and changes in net assets.

Property and Equipment—Property and equipment is composed of land, research facilities, office space, furniture, computer equipment, internal-use software, and leasehold improvements, which are recorded at cost and depreciated over the asset's useful life using the straight-line method as follows:

Buildings and improvements	10 to 45 years
Equipment, software, and furniture	3 to 10 years

Leasehold improvements are amortized over the life of the related asset or the life of the lease, whichever is shorter.

Expenditures for maintenance and repairs of property and equipment, which do not materially prolong the useful lives or significantly increase the productive capacity of the assets, are charged to indirect costs as incurred. Major expenditures for betterments or renovations are capitalized and depreciated.

The Institute incurs costs to develop internal-use software that are not hosted by third-party vendors and are not considered service contracts. Costs incurred to develop internal-use software during the application development stage or for upgrades and enhancements that result in additional functionality are capitalized. Costs related to preliminary project activities and post implementation activities are expensed as incurred. Once a development project is substantially complete and the software is ready for its intended use, capitalization ceases, and amortization begins.

The Institute also acquires equipment and furniture under its contracts with agencies of the federal government. The Institute does not have title to these assets, and the assets are not included in the consolidated balance sheets. The Institute must maintain an inventory and return the assets to the government entity as instructed.

Leases—The Institute leases property and equipment under operating leases and determines if an arrangement is a lease at the inception of the contract. Right-of-use ("ROU") assets represent the Institute's right to use the underlying assets for the lease term, and lease liabilities represent the Institute's obligation to make lease payments arising from the leases. For leases with terms greater than 12 months, the related ROU assets and lease liabilities are recorded at the present value of the future lease payments over the term of the lease. The initial measurement of the ROU asset is equal to the initial lease liability plus any indirect costs and prepayments, less any lease incentives.

The Institute made an accounting policy election not to recognize ROU assets and lease liabilities for leases with a term of 12 months or less. Lease payments for these leases are recognized as lease costs on a straight-line basis over the lease term.

The Institute has elected to account for lease components and the associated non-lease components in contracts as a single lease component for all classes of underlying assets. Further, as the Institute generally does not know the implicit rate for its leases, in calculating lease liabilities, the Institute has elected to use the risk-free rate of return across the portfolio of leases with similar durations.

The Institute's operating leases are primarily for real estate, including office space, research facilities and equipment. Certain of the Institute's real estate leases contain options to renew or extend the terms of the lease, as well as termination options that could shorten the original lease term, which are included in the determination of the ROU assets and lease liabilities when it is reasonably certain that the Institute will exercise the option.

The Institute recognizes lease costs on a straight-line basis over the remaining lease term, except for variable lease payments that are expensed in the period in which the obligation for those payments is incurred. Lease agreements do not contain any material residual value guarantees, restrictions, or covenants.

Goodwill and Other Intangible Assets—Goodwill represents the excess purchase price over the fair value of the net assets acquired. The Institute has elected to amortize goodwill on a straight-line basis over 10 years and has made the elections to perform goodwill impairment triggering event evaluation as of the end of the annual reporting period and to perform goodwill impairment tests at the entity level. Goodwill is evaluated for impairment whenever events or changes in circumstances would indicate impairment. Should a triggering event occur, and the estimated fair value of the Institute is less than its respective carrying value, including goodwill, an impairment charge equal to the difference between the Institute's fair value and carrying value will be incurred. Goodwill is reported separately in the consolidated balance sheets.

Other intangible assets consist of customer relationships, acquired customer backlog, developed technology, trademarks, and noncompete agreements. Other intangible assets are stated at amortized cost and amortized based upon the asset's economic life. Other intangible assets are tested for impairment whenever factors indicate the carrying amount may not be recoverable. Other intangible assets are recorded in other noncurrent assets in the consolidated balance sheets.

Cloud Computing Service Arrangements—The Institute incurs costs to implement cloud computing arrangements (CCAs) that are hosted by third-party vendors under service contracts. Costs incurred in the preliminary project and postimplementation stages are expensed, while certain costs incurred during the application development stage are capitalized and recorded in prepaid expenses and other current assets and other noncurrent assets in the consolidated balance sheets. Capitalized costs are amortized on a straight-line basis over the reasonably certain term of the hosting arrangement for each module or component of the related hosting arrangement when it is ready for its intended use. Expenses related to the capitalized implementation costs are presented in the same line item of the consolidated statements of revenue, costs, and changes in net assets as the fees associated with the hosting element of the arrangement.

Impairment of Long-lived Assets—The Institute evaluates the potential impairment of long-lived assets whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. If the carrying value of long-lived assets held and used exceeds the sum of the undiscounted expected future cash flows, the carrying value is written down to fair value. In order for long-lived assets to be considered held for disposal, the Institute must have committed to a plan to dispose of the assets. Once deemed held for disposal, the assets are stated at the lower of the carrying amount or fair value. In addition, the Institute may decide to abandon an asset. A decision to abandon an asset requires the establishment of a plan of abandonment, which occurs when the Institute has committed to a plan to abandon the asset before the end of its previously estimated useful life, and there is no expectation that the Institute will re-use or re-purpose the asset.

Derivative Instruments—Derivatives are recognized at fair value in the consolidated balance sheets.

Accrued Compensated Absences—Accrued compensated absences are paid leave, which may be used by employees for time away from work for vacation, as well as for illness of the employee or family members. Full-time and part-time employees are eligible for accrued compensated absences and accrue time off at various rates depending on years of service.

Self-Insurance—The Institute has self-insured medical and dental plans, which cover the majority of its employees, Consolidated Omnibus Reconciliation Act participants, and all non-Medicare eligible retirees. These plans are administered by separate third party administrators. The Institute is also self-insured for workers' compensation. The Institute purchases, per occurrence, stop-loss insurance policies to cover medical and workers' compensation claims in excess of the policy deductibles. The appropriateness of stop-loss deductible limits is evaluated annually and adjusted as warranted.

Included in the estimated liability are estimates of incurred, but not reported claims and incremental claim adjustments. As of September 30, 2024 and 2023, the Institute had related reserves approximating $5.1 million and $3.7 million, respectively, reflected in accounts payable and accrued expenses in the consolidated balance sheets.

Income Taxes—As provided by Section 501(c)(3) of the IRC and the Internal Revenue Service's determination, the Institute's charitable, scientific, and educational operations are exempt from corporate income taxes and no provision for corporate income tax is generally required. However, this tax exemption does not pertain to activities unrelated to the Institute's exempt purposes. The Institute's presence in certain foreign countries results in income taxation in these countries. Additionally, the Institute has several for-profit entities subject to corporate income taxation. These for-profit entities' operating losses and goodwill impairments have primarily contributed to a $7.9 million and a $7.8 million net deferred tax asset that has been offset with a full valuation allowance as of the years ended September 30, 2024 and 2023, respectively. Income taxes associated with foreign operations, unrelated business income, and income generated by the Institute's for-profit entities are not material for the Institute.

All not-for-profit organizations, including the Institute, are subject to the provisions of ASC 740, *Income Taxes*, related to the accounting for uncertainty in tax positions, including the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The tax benefit from an uncertain tax position is only recognized in the consolidated balance sheets if the tax position is more likely than not to be sustained upon an examination, based on the technical merits of the position. Interest and penalties, if any, are included in tax expense in the consolidated statements of revenue, costs, and changes in net assets. As of September 30, 2024 and 2023, the Institute had no uncertain tax positions that qualify for recognition or disclosure in the consolidated financial statements. The Institute's earliest open tax year for U.S. federal income tax purposes is its fiscal year ended September 30, 2021.

Foreign Currency—For reporting purposes, the Institute translates the assets and liabilities of its foreign entities at the exchange rates in effect at year end. Revenue and costs are reported using average exchange rates in effect during the period. Gains and losses from foreign currency translation are credited or charged to net assets in the accompanying consolidated statements of revenue, costs, and changes in net assets. Realized exchange gains and losses are included in net operating results for the years presented.

Net Assets—Net assets without donor restrictions include undesignated amounts as well as amounts designated by the Board for a specific purpose. The undesignated net assets are available for the overall operations of the Institute. The Board-designated net assets are to be used for multi-lateral collaborative initiatives by and among the Institute, Duke University, the University of North Carolina System, and other parties as determined by the University Research Collaboration Committee of the Board.

Net assets with donor restrictions include contributions and other inflows of assets whose use is limited by donor-imposed stipulations that either expire by passage of time or can be fulfilled and removed by actions of the Institute pursuant to those stipulations.

Net assets with donor restrictions also include contributions and other inflows of assets whose use by the Institute is limited by donor-imposed stipulations in perpetuity. These assets include earned income and distributions from the Institute's liquidated interest in the George Watts Hill Foundation trust (the "Trust"), which the Institute retained when the Trust was modified to release the Institute's interest during fiscal year ended September 30, 2022 (the "Modification"). These earnings and distributions are designated for certain facility costs defined by the Modification and are classified as restricted until the costs are incurred.

Consolidated Statements of Revenue, Costs, and Changes in Net Assets—The Institute utilizes a business financial reporting model similar to the accounting guidance on comprehensive income. This includes identification and use of a measure that is the functional equivalent of income from continuing operations of a for-profit organization (i.e., a performance indicator). The caption in the consolidated statements of revenue, costs, and changes in net assets titled "Net operating income" represents such a performance indicator. Net operating income includes all changes in net assets without donor restrictions except for actuarial or experience gains and losses of other postretirement benefit plans (as well as prior service costs or credits).

2. RECENT ACCOUNTING PRONOUNCEMENTS

Recently Adopted—

FASB ASU 2016-13—In June 2016, the FASB issued guidance that amends the impairment guidance for financial instruments and adds the current expected credit loss (CECL) model. The amended guidance requires entities to estimate lifetime expected credit losses for certain trade and other receivables, including those that are current with respect to payment terms, along with other financial instruments which may result in earlier recognition of credit losses. The new guidance also modifies the impairment model for AFS securities and requires an estimate of expected credit losses to be recorded through an allowance for credit losses account.

The Institute adopted ASU 2016-13 effective October 1, 2023. The adoption of this ASU did not have a material impact on the Institute's consolidated balance sheets and consolidated statements of revenue, costs, and changes in net assets.

Pending Adoption—There are certain new and revised ASUs pending adoption after September 30, 2024, which are not expected to have a material impact on the Institute's financial statements in the current or future reporting periods or on foreseeable future transactions.

3. REVENUE RECOGNITION

Revenue recognized for exchange transactions and contributions totaled $1,366.4 million and $1,229.8 million for the years ended September 30, 2024 and 2023, respectively, and is reported in revenue in the consolidated statements of revenue, costs, and changes in net assets. For the years ended September 30, 2024 and 2023, the Institute recognized revenues from exchange transactions of $822.4 million and $749.0 million, respectively, and contributions of $544.0 million and $480.8 million, respectively.

Exchange Transactions—The Institute disaggregates its revenue from contracts with customers by contract type and customer type, as management believes that they best depict how the nature, amount, timing, and uncertainty of the Institute's revenue and cash flows are affected by economic factors. The following table summarizes revenue from contracts with customers by contract type and customer type for the years ended September 30, 2024 and 2023 (in thousands):

	2024		
Contract Types	**Federal**	**Nonfederal**	**Total**
Cost reimbursable	$ 381,154	$ 2,254	$ 383,408
Fixed price	79,300	138,784	218,084
Time and materials	167,709	46,860	214,569
Other	5,885	480	6,365
Total revenues	$ 634,048	$ 188,378	$ 822,426

	2023		
Contract Types	**Federal**	**Nonfederal**	**Total**
Cost reimbursable	$ 356,070	$ 2,909	$ 358,979
Fixed price	81,087	127,448	208,535
Time and materials	127,872	48,412	176,284
Other	3,527	1,625	5,152
Total revenues	$ 568,556	$ 180,394	$ 748,950

At year end, contracts remain active and have periods of performance that extend into subsequent fiscal years. As of September 30, 2024 and 2023, the aggregate amount of contract transaction price that remains for future revenue recognition, excluding time and materials and unfunded contract balances, was $695.5 million and $693.2 million, respectively, the majority of which the Institute expects to recognize in revenue over the next 24 months.

The components of contract balances associated with contract assets and contract liabilities associated with exchange transactions as of September 30, 2024 and 2023, consisted of the following (in thousands):

Contract Balances	**Consolidated Balance Sheet Line Item**	**2024**	**2023**
Contract assets	Unbilled costs, fees, and contract assets	$ 118,848	$ 105,267
Billable receivables	Unbilled costs, fees, and contract assets	7,073	4,284
Contract liabilities	Deferred revenue and contract liabilities	59,722	42,047

The increase in unbilled receivables was primarily due to the timing of billings and revenue recognized on certain contracts. The increase in deferred revenue was primarily due to the timing of advance payments from customers partially offset by revenue recognized during the year ended September 30, 2024.

The Institute expects to bill its customers for a majority of the September 30, 2024, contract assets during the next 12 months. During the years ended September 30, 2024 and 2023, the Institute recognized revenues of $33.8 million and $28.7 million, respectively, relating to amounts that were included as a contract liability as of September 30, 2023, and September 30, 2022, respectively. It is anticipated that the majority of the deferred revenue balance as of September 30, 2024, will be recognized as revenue during the next 12 months.

The Institute recognized impairment losses on contract assets of $0.4 million in other direct costs in the consolidated statements of revenue, costs, and changes in net assets during the year ended September 30, 2023. There were no impairment losses during the year ended September 30, 2024.

Contributions—The table below summarizes contributions received, exclusive of contributions of nonfinancial assets, by type and funding source, for the years ended September 30, 2024 and 2023 (in thousands):

	2024		
Agreement Types	**Federal**	**Nonfederal**	**Total**
Cooperative agreement	$ 313,527	$ 365	$ 313,892
Grant	83,669	14,975	98,644
Non-fee-bearing cost reimbursable	111,360	711	112,071
Total revenues	$ 508,556	$ 16,051	$ 524,607

	2023		
Agreement Types	**Federal**	**Nonfederal**	**Total**
Cooperative agreement	$ 294,606	$ -	$ 294,606
Grant	67,586	11,627	79,213
Non-fee-bearing cost reimbursable	92,430	1,242	93,672
Total revenues	$ 454,622	$ 12,869	$ 467,491

As of September 30, 2024 and 2023, the aggregate amount of conditional promises to be received in future years related to the Institute's ongoing operating programs totaled $665.0 million and $700.3 million, respectively. The Institute had billable receivables of $91.5 million and $74.6 million for contributions as of September 30, 2024 and 2023, respectively, and is included in the unbilled costs, fees, and contract assets line in the consolidated balance sheets. The amounts are expected to be billed and received within one year.

Contributed Nonfinancial Assets—For the years ended September 30, 2024 and 2023, contributed nonfinancial assets recognized within the consolidated statements of revenue, costs, and changes in net assets consisted of the following (in thousands):

	2024	**2023**
Professional services	$ 15,977	$ 5,801
Equipment and supplies	3,385	7,546
Total contributed nonfinancial assets	$ 19,362	$ 13,347

The Institute recognizes contributed nonfinancial assets, consisting of professional services, and equipment and supplies. These assets are utilized in the ongoing mission of the Institute, to improve the human condition, through its varied project work both domestically and internationally. These projects include research, community building, medical and educational services, research and development, and logistical and administrative assistance. Contributed nonfinancial assets did not have donor-imposed restrictions.

Contributed professional services recognized comprise professional services in fields such as medicine, education, research, and retail services. Contributed services are valued and are reported at the estimated fair value in the consolidated financial statements based on the rates of similar services in the jurisdiction where the services were performed.

Contributed equipment and supplies consist of technology, such as laptops and peripherals, as well as research and educational supplies. In valuing contributed equipment and supplies, the Institute estimated the fair value on the basis of estimates of wholesale values that would be received for selling similar products in the jurisdiction the equipment and supplies were provided.

4. FUNCTIONAL EXPENSES

The Institute performs applied and basic research and technical services under contract to clients in business, industry, public service agencies, and federal and foreign governments. Costs are allocated in accordance with Cost Accounting Standards established by the federal government. Expenses, by function, related to providing these services during the years ended September 30, 2024 and 2023, are as follows (in thousands):

	2024	2023
Programs expense (including research and other projects):		
Salaries and employee benefits	$ 584,191	$ 545,767
Subcontractor and consultant costs	369,008	299,471
Other direct program costs	275,404	258,677
Total programs expense	1,228,603	1,103,915
Support expense (principally general and administrative):		
Salaries and employee benefits	116,978	107,743
Other support costs	23,939	18,030
Total support expense	140,917	125,773
Total	$ 1,369,520	$ 1,229,688

5. LIQUIDITY

The Institute's financial assets available for general expenditure within one year of September 30, 2024 and 2023, include the following (in thousands):

	2024	2023
Cash and cash equivalents	$ 27,401	$ 29,012
Short-term investments	226,168	188,837
Accounts receivable—net	95,006	92,570
Unbilled costs, fees, and contract assets	217,385	184,139
Total financial assets	565,960	494,558
Less: Board-designated funds for future use	8,976	9,919
Financial assets available to meet general expenditures over the next twelve months	$ 556,984	$ 484,639

None of the financial assets are subject to donor or other contractual restrictions that make them unavailable for general expenditures within one year of the consolidated balance sheet date. The accounts receivable balance is subject to implied time restrictions but are expected to be collected within one year. The Institute has a goal to maintain financial assets, which consist of cash, cash equivalents, and investments, on hand to meet 15% of the Institute's annual revenue, which is approximately $205.0 million as of September 30, 2024. The Institute has a policy to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due. In addition, as part of its liquidity management, the Institute invests cash in excess of daily requirements in various short-term investments. As more fully described in Note 10, the Institute also has an operating line of credit, which matures in April 2025, and can be drawn up to $75 million and $50 million, as of September 30, 2024 and 2023, respectively, in the event of an unanticipated liquidity need.

6. INVESTMENTS

Short-term investments and noncurrent investments consisted of the following as of September 30, 2024 and 2023 (in thousands):

	2024	2023
Short-term investments—debt and equity securities	$ 226,168	$ 188,837
Noncurrent investments:		
GEM investment fund	91,777	78,568
Debt securities	430	430
Other noncurrent investments	11,354	14,369
Total noncurrent investments	103,561	93,367
Total investments	$ 329,729	$ 282,204

Realized and unrealized gains and losses on investments are recorded in investment income, net in the consolidated statements of revenue, costs, and changes in net assets.

Debt and Equity Securities and Warrants—Short-term debt and equity securities are primarily composed of U.S. Treasury securities, U.S. government and agency bonds and mortgage-backed securities, corporate equity and debt obligations, and multi asset mutual funds. These securities are recorded at fair value.

During the year ended September 30, 2022, certain investments in preferred stock and warrants were liquidated. The investment liquidation granted the Institute the right to receive earnout distributions based upon the privately held company achieving certain future qualifying sales. These earnout distributions are considered gain contingencies and are recognized at such time when related assets received or held are readily convertible to known amounts of cash or claims to cash. For the year ended September 30, 2023, $2.2 million in earnout distributions related to the liquidated investment were recognized in investment income, net in the consolidated statements of revenue, costs, and changes in net assets. There were no earnout distributions related to this investment liquidation for the year ended September 30, 2024.

GEM Investment Fund—The Institute has an investment in a global multi asset fund, Global Endowment Fund II (GEM), with a cost basis of $50 million and estimated net asset value of $91.8 million and $78.6 million as of September 30, 2024 and 2023, respectively. Withdrawals from the fund have restrictions, and certain distributions require approval of the general partner, as such, this investment has been classified as noncurrent within the consolidated balance sheets.

Debt Securities—As of September 30, 2024 and 2023, the Institute held convertible notes with a privately held company totaling $0.4 million. These securities are recorded at fair value and generally mature within two years of issuance. Each note has similar conversion features, such as upon qualified or nonqualified financing, corporate transaction, or maturity. During the years ended September 30, 2024 and 2023, there were no recorded unrealized gains on these securities.

During the year ended September 30, 2023, the Institute recognized an other-than-temporary impairment related to a convertible note of $1.6 million in other expense in the consolidated statements of revenue, costs, and changes in net assets.

Equity Method Investments—The Institute has investments in common stock of several privately held companies, which are accounted for under the equity method. For the years ended September 30, 2024 and 2023, no equity method income or losses were recorded for these common stock investments.

During the year ended September 30, 2024, the Institute liquidated investments in common stock of privately held companies and received $1.2 million in cash proceeds. In addition to the cash received in connection with the liquidation, the Institute has the right to receive earnout distributions based upon the privately held companies achieving certain commercial sale milestones, which are considered gain contingencies to be recognized when realizable. There were no earnout distributions related to these investment liquidations for the year ended September 30, 2024.

Other Noncurrent Investments—As of September 30, 2024 and 2023, the Institute had $0.4 million and $3.0 million, respectively, invested in noncontrolling interests in equity investments in several privately held companies through preferred stock and Simple Agreement for Future Equity (SAFE) notes. These equity securities are recorded at initial cost, adjusted for observable transactions, less impairment, given they are equity securities with no readily determinable fair value. During the years ending September 30, 2024 and 2023, no observable transactions, impairments, or upward or downward adjustments have been recorded on these investments.

During the year ended September 30, 2024, the Institute invested in two privately held companies through SAFE notes, totaling $0.6 million. Subsequently, the Institute liquidated a preferred stock and a SAFE note investment and received $3.6 million in cash proceeds. In addition to the cash received, the Institute also has the right to receive earnout distributions based upon the privately held company achieving certain future qualifying revenue, which are considered gain contingencies to be recognized when realizable. There were no earnout distributions related to this investment liquidation for the year ended September 30, 2024.

As of September 30, 2024 and 2023, the Institute had $6.4 million invested in two limited partnership investment funds. The Institute owns less than 3% of both partnerships. As the partnerships do not have readily determinable fair values, the Institute's interests are measured at cost, adjusting for observable transactions, less impairment. Since acquisition, no observable transactions, impairments, or upward or downward adjustments have been recorded on these investments.

As of September 30, 2024 and 2023, the Institute had $4.6 million and $4.9 million invested in four private equity partnerships through the Commonfund. The Institute has committed future funds totaling $0.9 million to these four different partnerships as of September 30, 2024. When fully funded, the Institute will have 3% or less ownership in each partnership. As these partnerships do not have a readily determinable fair value, the Institute's interest is measured at cost, adjusting for observable transactions, less impairment. Since acquisition, no observable transactions, impairments, or upward or downward adjustments have been recorded on these investments. During the years ended September 30, 2024 and 2023, the Institute recognized realized gains of $0.8 million and $0.4 million, respectively, through the Commonfund partnerships.

7. PROPERTY AND EQUIPMENT

Property and equipment as of September 30, 2024 and 2023, consisted of the following (in thousands):

	2024	2023
Land	$ 2,674	$ 2,674
Buildings and improvements	252,753	255,359
Equipment, software, and furniture	108,243	103,231
Construction in process	3,648	7,309
Total property and equipment at cost	367,318	368,573
Less: accumulated depreciation	220,368	217,888
Property and equipment—net	$ 146,950	$ 150,685

Depreciation expense for the years ended September 30, 2024 and 2023 was $20.1 million and $14.2 million, respectively.

During the year ended September 30, 2024, the Institute completed abandonment plans resulting in the recognition of abandonment charges of $5.7 million and impairment charges of $0.7 million related to property and equipment which are recorded as accelerated depreciation expense in indirect costs and in other expense, respectively, in the consolidated statements of revenue, costs, and changes in net assets. For the year ended September 30, 2023, the Institute recognized an impairment charge of $5.8 million to reduce the carrying value of previously capitalized internal-use software costs to zero, as it was no longer probable the software being developed would be completed and placed in service.

8. LEASES

Lessee—The following table presents the components of our ROU assets and liabilities related to leases as of September 30 (in thousands):

	2024	2023
Operating lease right-of-use assets—net	$ 8,761	$ 17,848
Operating lease liabilities, current portion	$ 7,089	$ 7,012
Operating lease liabilities—net of current portion	8,933	13,306
Total lease liabilities	$ 16,022	$ 20,318

Total operating lease costs are comprised of the following for the year ended September 30 (in thousands):

	2024	2023
Operating lease cost	$ 7,077	$ 6,874
Variable lease cost	1,074	1,011
Short-term lease cost	1,316	1,493
Total lease cost	$ 9,467	$ 9,378

Operating lease costs are included in other direct costs or indirect costs in the consolidated statements of revenue, costs, and changes in net assets, depending on the project type.

During the year ended September 30, 2024, the Institute concluded, based on the Institute's quantitative fair value analyses, that certain long-lived assets were not recoverable resulting in the recognition of impairment charges of $6.0 million related to ROU assets which are recorded in other expense in the consolidated statements of revenue, costs, and changes in net assets. There were no impairment charges during the year ended September 30, 2023.

The following table presents other supplemental operating lease information as of and for the year ended September 30 (in thousands):

	2024	2023
ROU assets obtained in exchange for new operating lease liabilities	$ 3,267	$ 3,338
Net increase in ROU assets due to modifications and remeasurements	$ 18	$ 426
Cash paid for amounts included in the measurement of operating lease liabilities	$ 8,616	$ 8,451
Weighted-average remaining lease term	3.15 years	3.80 years
Weighted-average discount rate	2.28 %	1.64 %

Future maturities of operating lease liabilities as of September 30, 2024 are presented in the following table (in thousands):

Years Ending September 30	
2025	$ 7,302
2026	5,721
2027	1,750
2028	355
2029	322
Thereafter	1,142
Total lease payments	16,592
Less: imputed interest	570
Total lease obligations	16,022
Less: current obligations	7,089
Long-term lease obligations	$ 8,933

9. GOODWILL, OTHER INTANGIBLE ASSETS, AND CLOUD COMPUTING SERVICE ARRANGEMENTS

Goodwill—The following table details the changes in goodwill for the years ended September 30, 2024 and 2023 (in thousands):

	Goodwill	**Accumulated Impairment**	**Accumulated Amortization**	**Goodwill—Net**
September 30, 2022	$ 24,526	$ (13,272)	$ (3,412)	$ 7,842
Amortization	-	-	(1,125)	(1,125)
September 30, 2023	24,526	(13,272)	(4,537)	6,717
Amortization	-	-	(1,126)	(1,126)
September 30, 2024	$ 24,526	$ (13,272)	$ (5,663)	$ 5,591

Amortization is applied on a straight-line basis over a period of 10 years and is recorded in other expense in the consolidated statements of revenue, costs, and changes in net assets.

Other Intangible Assets—Other intangible assets are included within other noncurrent assets in the accompanying consolidated balance sheets and consist of the following for the years ended September 30, 2024 and 2023 (in thousands):

	2024		
	Gross Carrying Value	Accumulated Amortization	Net Carrying Value
Customer relationships	$ 4,510	$ 3,202	$ 1,308
Other	1,690	1,606	84
Total other intangible assets	$ 6,200	$ 4,808	$ 1,392

	2023		
	Gross Carrying Value	Accumulated Amortization	Net Carrying Value
Customer relationships	$ 4,510	$ 2,833	$ 1,677
Other	1,690	1,540	150
Total other intangible assets	$ 6,200	$ 4,373	$ 1,827

Amortization expense for other intangible assets was $0.4 million for the years ended September 30, 2024 and 2023. Each intangible asset is amortized on a straight-line basis and is recorded in other expense in the consolidated statements of revenue, costs, and changes in net assets. In the aggregate, as of September 30, 2024, these assets had a weighted-average expected useful life of 13 years from the date of acquisition. Estimated future amortization expense associated with other intangible assets as of September 30, 2024, is as follows (in thousands):

Years Ending September 30	
2025	$ 435
2026	321
2027	112
2028	57
2029	57
Thereafter	410
	$ 1,392

Cloud Computing Service Arrangements—As of the years ended September 30, 2024 and 2023, capitalized implementation costs, accumulated amortization, and amortization expense related to CCAs under service contracts are as follows (in thousands):

	2024	2023
Capitalized implementation costs	$ 31,971	$ 2,359
Accumulated amortization	1,068	353
Net carrying value	$ 30,903	$ 2,006
Amortization expense	$ 715	$ 221

Capitalized implementation costs and accumulated amortization related to CCAs under service contracts are included in prepaid expenses and other current assets and other noncurrent assets in the consolidated balance sheets. Amortization expense of capitalized cloud computing costs under service contracts is recorded in indirect costs in the consolidated statements of revenue, costs, and changes in net assets.

10. DEBT

A summary of Institute's debt as of September 30, 2024 and 2023, is as follows (in thousands):

	2024	2023
Variable-rate term loan	$ 36,000	$ 40,000
Variable-rate Series 2007 Revenue Bonds	23,245	24,610
Fixed-rate Series 2010 Revenue Bonds	2,035	4,035
Fixed-rate Series 2024 Revenue Bonds	31,810	-
Plus unamortized premium and costs of issuance	3,139	59
Total outstanding debt	96,229	68,704
Less: current maturities of long-term debt	7,450	7,365
Less: current classification due to redemption features	21,830	23,245
Total current maturities of long-term debt	29,280	30,610
Total long-term debt	$ 66,949	$ 38,094

The combined aggregate amount of maturity and annual mandatory sinking fund requirements for the years subsequent to the year ended September 30, 2024, are as follows (in thousands):

Years Ending September 30	
2025	$ 7,450
2026	8,350
2027	8,550
2028	8,765
2029	8,985
2030 and thereafter	50,990
Total	$ 93,090

Lines of Credit—The Institute has an unsecured revolving line of credit of $75.0 million as of September 30, 2024 and $50.0 million as of September 30, 2023. On February 1, 2024, the Institute amended its unsecured revolving line of credit increasing the line from $50.0 million to $75.0 million, adding in an unused fee equal to 0.125% per annum, and extending the maturity date through April 25, 2025. No balances were outstanding under the revolving line of credit as of September 30, 2024 and 2023. For 2024 and 2023, there were issued outstanding letters of credit in the amount of $3.0 million and $3.3 million, respectively, reducing the available balance on the revolving line of credit to $72.0 million and $46.7 million as of September 30, 2024 and 2023, respectively. Interest is accrued at an interest rate indexed to the Daily Simple Secured Overnight Financing Rate (SOFR) plus 1.34%.

Variable Term Loan—On January 1, 2018, the Institute entered into a $60.0 million term loan to finance the construction of an office building and parking deck located on the Institute's campus in Research Triangle Park (RTP). The term loan will mature on January 1, 2033. The term loan requires annual principal payments of $4.0 million with interest payments due monthly. Upon the cessation of the London Interbank Offered Rate (LIBOR) on June 30, 2023, borrowings under the term loan bear an interest rate indexed to SOFR, plus a LIBOR benchmark replacement adjustment of 0.11% and a 0.8% spread.

To mitigate changes in interest rates, upon entering the loan agreement, the Institute simultaneously entered an interest rate swap to achieve an effective fixed interest rate of 2.49%. Refer to Note 11 for additional information.

Series 2007 Revenue Bonds—In November 2007, the Durham County Industrial Facilities and Pollution Control Financing Authority (Durham County) issued the Series 2007 Revenue Bonds on behalf of the Institute. The payment of the principal and interest on the bonds is currently secured by an additional irrevocable, direct pay letter of credit. The Series 2007 Revenue Bonds were issued to provide funds to finance (a) the cost of constructing and equipping an office building and parking deck located on the RTP campus; (b) the cost of refinancing certain indebtedness previously incurred by the Institute to finance improvements on the Institute's campus; and (c) certain expenses incurred in connection with the authorization and issuance of the bonds, including certain initial costs associated with the issuance of the letter of credit.

The Series 2007 Revenue Bonds are subject to optional, extraordinary, and mandatory redemption, including redemption at par, and optional and mandatory tender for purchase prior to the stated maturity of September 2037. The bonds bear interest at a weekly rate, determined by prevailing market conditions and payable monthly in arrears. The Series 2007 Revenue Bonds are subject to mandatory sinking fund redemption payments on September 1 annually through 2037.

The irrevocable, direct pay letter of credit was issued to ensure bond payments to the bondholders and to enhance the credit rating of the bonds. In the event the Series 2007 Revenue Bonds are not successfully remarketed, the Institute would be obligated to reimburse the letter of credit holder for any bonds tendered and not remarketed. The direct pay letter of credit expires in July 2027. Given the Series 2007 Revenue Bonds' redemption features and the irrevocable, direct-pay letter of credit's material adverse event clause, this debt is presented as a current liability.

Additionally, the Institute executed a 30-year floating to fixed interest-rate swap to provide interest rate protection for the Series 2007 Revenue Bonds and effectively created synthetic fixed rate debt at a borrowing rate of 3.75%. Refer to Note 11 for additional information.

Series 2010 Revenue Bonds—In February 2010, Durham County issued $23.0 million, 15-year tax exempt fixed rate Series 2010 Revenue Bonds on behalf of the Institute. The Series 2010 Revenue Bonds were issued pursuant to indentures between Durham County and trustee and are payable pursuant to a loan agreement between Durham County and the Institute. The Series 2010 Revenue Bonds were issued to provide funds to (a) finance the construction and equipping of a new office building and related parking deck on the RTP campus and (b) pay and reimburse the Institute for paying certain expenses incurred in connection with the issuance of the Series 2010 Revenue Bonds.

The Series 2010 Revenue Bonds were issued at a premium of $1.9 million. The average coupon rate of the bonds approximated 4.37% and the effective interest rate approximated 3.14%.

The Series 2010 Revenue Bonds are not subject to optional redemption before maturity but are subject to extraordinary mandatory redemption prior to the stated maturity of February 1, 2025.

Series 2024 Revenue Bonds—In September 2024, Public Finance Authority of the state of Wisconsin (the "Authority") issued $31.8 million, 10-year tax exempt fixed rate Series 2024 Revenue Bonds on behalf of the Institute. The Series 2024 Revenue Bonds were issued pursuant to indentures between the Authority and trustee and are payable pursuant to a loan agreement between the Authority and the Institute. The Series 2024 Revenue Bonds were issued to (a) finance the acquisition and installation of cloud-based enterprise resource planning software and (b) pay and reimburse the Institute for paying certain expenses incurred in connection with the issuance of the Series 2024 Revenue Bonds.

The Series 2024 Revenue Bonds were issued at a premium of $3.7 million. The average coupon rate of the bonds approximated 5.00% and the effective interest rate approximated 3.18%.

The Series 2024 Revenue Bonds are not subject to optional redemption before maturity but are subject to extraordinary mandatory redemption prior to the stated maturity of September 1, 2034.

Debt Covenants—Certain of the Institute's loan agreements and direct-pay letters of credit contain various covenants, including cross-default provisions and certain financial covenants. As of September 30, 2024, the Institute believes it was in compliance with all covenants that were in effect on such date.

11. DERIVATIVE INSTRUMENTS

The following table summarizes the fair value of the Institute's derivatives by type as of September 30, 2024 and 2023 (in thousands):

		Fair Value	
Financial Instrument	**Balance Sheet Account**	**2024**	**2023**
Interest rate swap	Other long-term liabilities	$ (2,036)	$ (1,131)
Interest rate swap	Other non-current assets	2,504	4,719
Total		$ 468	$ 3,588

Interest Rate Swaps—During the year ended September 30, 2017, the Institute entered a floating-to-fixed interest-rate swap to manage fluctuations in cash flows resulting from the variable term loan entered during fiscal year 2017. The swap has a notional amount of $60.0 million with an effective date of January 1, 2018, and a termination date of January 1, 2033. As of September 30, 2024, the swap had a remaining notional amount of $36.0 million. Under the interest rate swap, the Institute receives LIBOR-based variable interest payments and makes fixed interest rate payments at 2.49%. Upon the cessation of LIBOR on June 30, 2023, the Institute transitioned from receiving LIBOR-based variable interest payments to receiving SOFR-based variable interest payments. The Institute did not designate the interest rate swap as a hedge in accordance with the accounting standards on derivatives and hedging.

The Institute also entered a floating-to-fixed interest-rate swap to manage fluctuations in cash flows resulting from the issuance of the Series 2007 Revenue Bonds. The swap had an original notional amount of $40.6 million and termination date of September 1, 2037. As of September 30, 2024, the swap had a remaining notional amount of $23.2 million. Under the interest rate swap, the Institute receives LIBOR-based variable interest payments and makes fixed interest rate payments at 3.75%. Upon the cessation of LIBOR on June 30, 2023, the Institute transitioned from receiving LIBOR-based variable interest payments to receiving SOFR-based variable interest payments. The Institute did not designate the interest rate swap as a hedge in accordance with the accounting standards on derivatives and hedging.

Foreign Currency Forward Contracts—From time to time, the Institute enters into currency rate protection agreements ("FX forward contracts") to manage the foreign currency exchange exposure risk on transactions denominated in foreign currencies. The Institute had a nominal amount of FX forward contracts outstanding as of September 30, 2024 and 2023. These FX forward contracts typically have maturity dates ranging from less than a year to two years. The Institute did not designate these contracts for hedge accounting in accordance with the accounting standards on derivatives and hedging.

The following table summarizes the earning effects of derivatives in the consolidated statements of revenue, costs, and changes in net assets for the years ended September 30, 2024 and 2023 (in thousands):

Financial Instrument	**Location of Gain (Loss)**	**Gain (Loss) Recognized 2024**	**Gain (Loss) Recognized 2023**
Interest rate swap	Interest expense—net	$ (3,120)	$ 1,486
FX currency forward contracts	Other expense—net	(50)	(46)
Total		$ (3,170)	$ 1,440

Financial instruments, including derivatives, expose the Institute to credit loss in the event of nonperformance by counterparties. The Institute manages its exposure to counterparty credit risk through procedures to monitor the counterparty's financial standing. If a counterparty fails to meet the terms of an arrangement, the Institute's exposure is limited to the net amount that would have been received, if any, over the arrangement's remaining life. Currently, the Institute does not anticipate nonperformance by any counterparty and no material loss is expected from such nonperformance.

12. FAIR VALUE MEASUREMENTS

Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between independent market participants at the measurement date. To increase consistency and comparability in fair value measurements, a fair value hierarchy was established that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:

Level 1—Quoted prices for identical instruments in active markets.

Level 2—Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model derived valuations whose inputs are observable or whose significant value drivers are observable, such as interest rates, credit risks, and net asset value.

Level 3—Significant unobservable inputs (including the Institute's own assumptions in determining the fair value of assets and liabilities).

The following sections provide a description of the valuation methodologies used for instruments measured at fair value as well as the general classification of such instruments pursuant to the fair value hierarchy:

Investment Securities—Where quoted prices are available in an active market, securities are classified within Level 1 of the valuation hierarchy. Level 1 securities would include highly liquid government bonds, such as Treasury securities and exchange-traded equities. If quoted market prices are not available, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics, discounted cash flow, or at net asset value per share. Level 2 securities would include U.S. government agency securities; obligations of states and political subdivisions; and certain corporate, asset-backed, multi asset fund, and other securities. In certain cases where there is limited activity or less transparency around inputs to the valuation, securities are classified within Level 3 of the valuation hierarchy.

Nonqualified Deferred Compensation Plan—Mutual Funds—These are valued at the daily closing price as reported by the fund. Mutual funds held by the plan are open-ended mutual funds that are registered with the Securities and Exchange Commission. These funds are required to publish their daily net asset value and to transact at that price. The mutual funds held by the plan are deemed to be actively traded; thus, the investment is classified within Level 1 of the valuation hierarchy.

Derivatives—Derivative instruments include interest rate swaps and are valued on a recurring basis using quoted market prices, dealer quotes, or third-party pricing models that are primarily sensitive to market observable data. Current outstanding interest rate swap derivatives are classified as Level 2 within the fair value hierarchy.

Financial assets and liabilities recorded at fair value on a recurring basis as of September 30, 2024 and 2023, were as follows (in thousands):

	2024			
Description	**Total**	**Level 1**	**Level 2**	**Level 3**
Assets				
Short-term investments:				
U.S. Treasury securities	$ 30,857	$ 30,857	$ -	$ -
Federal agency securities	7,827	-	7,827	-
Corporate debt obligations	4,219	-	4,219	-
Multiasset fund	183,265	-	183,265	-
Total short-term investments	226,168	30,857	195,311	-
Noncurrent assets:				
Nonqualified deferred compensation plan—mutual funds	10,880	10,880	-	-
Derivatives—interest rate swaps	2,504	-	2,504	-
Debt securities	430	-	-	430
GEM investment fund—measured at net asset value	91,777	-	-	-
Total noncurrent assets	105,591	10,880	2,504	430
Total assets	$ 331,759	$ 41,737	$ 197,815	$ 430
Liabilities				
Other long-term liabilities:				
Derivatives—interest rate swaps	$ 2,036	$ -	$ 2,036	$ -
Nonqualified deferred compensation plan obligation	10,880	10,880	-	-
Total other long-term liabilities	12,916	10,880	2,036	-
Total liabilities	$ 12,916	$ 10,880	$ 2,036	$ -

Description	2023 Total	Level 1	Level 2	Level 3
Assets				
Short-term investments:				
U.S. Treasury securities	$ 29,857	$ 29,857	$ -	$ -
Federal agency securities	6,426	-	6,426	-
Corporate debt obligations	3,715	-	3,715	-
Multiasset fund	148,839	-	148,839	-
Total short-term investments	188,837	29,857	158,980	-
Securities with donor restrictions	9	-	9	-
Noncurrent assets:				
Nonqualified deferred compensation plan—mutual funds	9,123	9,123	-	-
Derivatives—interest rate swaps	4,719	-	4,719	-
Debt securities	430	-	-	430
GEM investment fund—measured at net asset value	78,568	-	-	-
Total noncurrent assets	92,840	9,123	4,719	430
Total assets	$ 281,686	$ 38,980	$ 163,708	$ 430
Liabilities				
Other long-term liabilities:				
Derivatives—interest rate swaps	$ 1,131	$ -	$ 1,131	$ -
Nonqualified deferred compensation plan obligation	9,123	9,123	-	-
Total other long-term liabilities	10,254	9,123	1,131	-
Total liabilities	$ 10,254	$ 9,123	$ 1,131	$ -

As of September 30, 2024 and 2023, debt securities were measured at a Level 3 fair value of $0.4 million. During the year ended September 30, 2023, a $1.6 million other-than-temporary impairment of a convertible note debt security was recognized in other expense in the consolidated statements of revenue, costs, and changes in net assets. See Note 6 for further details.

The carrying value of the Institute's other financial instruments, including cash and cash equivalents, accounts receivable, unbilled costs, fees and contract assets, prepaid expenses and other current assets, accounts payable and accrued expenses, and deferred revenue and contract liabilities, approximates fair value as of September 30, 2024 and 2023.

There were no changes during the periods presented to the valuation techniques the Institute used to measure asset and liability fair values on a recurring basis.

Certain of the Institute's nonfinancial assets and liabilities are subject to impairment analysis, including long-lived assets, intangible assets, and goodwill. The significant inputs utilized in these analyses are classified as Level 3 in the fair value hierarchy. See Note 7 for the capitalized internal-use software impairment and long-lived asset impairment recognized. See Note 8 for the ROU lease asset impairment recognized and details of the valuation methods and inputs used in these analyses. The Institute did not have any other nonfinancial assets or liabilities that were required to be measured at fair value on a nonrecurring basis for the year ended September 30, 2024 or 2023.

13. EMPLOYEE RETIREMENT PLANS

The Institute has a defined contribution plan covering all U.S.-based employees who are 19 years of age or older with one year of 500 hours or more of continuous service during the plan year. Each U.S. employee of the Institute is immediately eligible to make elective deferrals under the plan. Employees are eligible to receive Institute contributions once they have completed one year of continuous service.

The Institute's contributions to the plan for the year ended September 30, 2024 were $33.5 million with $0.7 million in applied forfeitures. The Institute's contributions to the plan for the year ended September 30, 2023 were $29.9 million with $0.4 million in applied forfeitures.

14. DEFERRED COMPENSATION PLANS

The Institute maintains an Employee Retirement Income Security Act of 1974 nonqualified deferred compensation plan under IRC Section 457 to permit eligible employees to save for their retirement.

A Salary Deferral Arrangement 457(b) plan is available to certain highly compensated employees. Participation is voluntary and permits eligible employees to defer compensation up to a maximum annual amount established by federal law. There are no Institute contributions associated with this deferred compensation plan. Invested employee deferrals are recorded at fair value, which totaled $10.9 and $9.1 million as of September 30, 2024 and 2023, respectively, and are included in other noncurrent assets with an offsetting deferred compensation obligation recorded in other long-term liabilities. Deferred amounts ultimately payable to the participants are based on the value of the underlying investments.

15. POSTRETIREMENT BENEFITS OTHER THAN PENSIONS

The Institute provides medical and dental benefits to certain retired employees under the Research Triangle Institute Retiree Health Plan (the "Plan"). This plan has been frozen. As a result, no new participants can enter the plan, and no additional benefit obligations will accumulate.

Cost of Postretirement Benefits—The cost of providing retiree medical and dental benefits is actuarially determined and accrued over the active service period of eligible employees. The components of the net periodic postretirement benefit cost for the years ended September 30, 2024 and 2023, are presented in the following table (in thousands):

	2024	2023
Interest cost	$ 388	$ 527
Expected return on Plan assets	(851)	(779)
Amortization of prior service credit	(51)	(51)
Net gain	(315)	(33)
Net periodic postretirement benefit cost	$ (829)	$ (336)

The net periodic postretirement benefit cost is reflected in the consolidated statements of revenue, costs, and changes in net assets as indirect costs.

Benefit Obligations and Accrued Costs—The funded status of the postretirement benefit plan is measured as the difference between the fair value of the Plan assets and the benefit obligation.

The following table sets forth the changes in the Institute's benefit obligations and the benefit plan's funded status for the years ended September 30, 2024 and 2023 (in thousands):

	2024	2023
Change in benefit obligation:		
Postretirement benefit obligation at beginning of year	$ 7,160	$ 10,350
Interest cost	388	527
Plan amendment	168	-
Actuarial loss (gain)	461	(3,461)
Plan participant contributions	276	217
Benefits paid	(658)	(473)
Postretirement benefit obligation at end of year	7,795	7,160
Fair value of Plan assets at end of year	17,029	14,420
Funded status	$ 9,234	$ 7,260

The funded status as of September 30, 2024 and 2023, was in an overfunded position. The funded status of the Plan is reflected in the consolidated balance sheets as other noncurrent assets. The funded status is dependent upon many factors, including returns on invested assets and the level of market interest rates.

A summary of amounts included in net assets without donor restrictions as of September 30, 2024 and 2023, that have not been recognized as components of net periodic benefit cost is as follows (in thousands):

	2024	2023
Net actuarial gain	$ (7,183)	$ (5,819)
Prior service credit	(200)	(419)
Total	$ (7,383)	$ (6,238)

Amounts recognized as a change in Institute's net assets, but reflected outside of the performance indicator for the years ended September 30, 2024 and 2023, were as follows (in thousands):

	2024	2023
Net actuarial gain	$ (1,679)	$ (4,057)
Prior service cost	168	-
Reclassification of amortization of prior service credit and actuarial gain	366	84
Total	$ (1,145)	$ (3,973)

The following weighted-average assumptions were used in calculating the above benefit obligations, net periodic benefit cost, and fair value of Plan assets as of September 30, 2024 and 2023:

	2024	2023
Discount rate used to determine benefit obligation	4.7 %	5.6 %
Expected return on Plan assets	6.0	6.0

The change in the discount rate is attributed to fluctuations in the interest rate environment resulting from the Federal Reserve monetary policy and global economic pressures during the current year. The Plan seeks to achieve a total return on Plan assets (price appreciation, plus dividends) that, over a majority of market cycles, exceeds the estimated discount rate used to determine the benefit obligation, which the benefit obligation discount rate is assumed to be 4.7% per annum. The total expected long-term rate of return on the Plan portfolio is based upon the portfolio's historical allocated fund performance since the funds' inception.

Health care cost trends do not have a significant effect on the obligation or net periodic benefit costs.

Postretirement Plan Assets—The following table sets forth the changes in the fair value of Plan assets for the years ended September 30, 2024 and 2023 (in thousands):

	2024	2023
Fair value of Plan assets at beginning of year	$ 14,420	$ 13,300
Return on Plan assets, less trustee's fee	2,991	1,376
Plan participant contributions	276	217
Benefits paid	(658)	(473)
Fair value of Plan assets at end of year	$ 17,029	$ 14,420

The investment objectives of the Institute's Plan are designed to generate returns that will enable the Plan to meet its future obligations. The Plan's targeted strategic allocation to each asset class was determined in collaboration with Wells Fargo Institutional Retirement and Trust using its asset risk tolerance modeling. The Institute currently targets a "Balanced Income" strategic asset allocation that provides for an allocation range around target of plus or minus 5% for each asset category. The Plan will, at times, also invest in money market funds as it seeks to rebalance the strategic asset allocation, reinvest portfolio capital gains and/or dividends, or reinvest maturing bond proceeds. The fair values of Plan assets and related strategic asset allocations as of September 30, 2024 and 2023, are as follows (in thousands):

	Fair Value [a]		Asset Allocation
Asset Category	**2024**	**2023**	**Target**
Cash and cash equivalents	$ 351	$ 378	- %
Bond mutual funds (investment grade)	7,988	6,868	50
Equity mutual funds:			-
Large/mid cap	5,795	4,829	30
Small cap	701	575	10
International	2,194	1,770	10
Total equity mutual funds	8,690	7,174	50
Noninvestment assets	17,029	14,420	100 %
Total Plan assets	$ 17,029	$ 14,420	

[a] All investments, excluding cash and cash equivalents, held by the Plan are considered Level 1 assets within the fair value hierarchy.

The Institute contributes to the Plan based on actuarially determined amounts necessary to provide assets sufficient to meet benefits to be paid to Plan members. The Institute's policy is to fund the above-mentioned benefits quarterly. Attributed to the overfunded status of the Plan, the Institute did not make contributions to postretirement plan assets in fiscal year 2024 and does not anticipate making contributions to postretirement plan assets in fiscal year 2025.

The following schedule summarizes net benefit payments that are expected to be made in the years ending September 30, which reflect expected future service (in thousands):

Years Ending September 30	
2025	$ 653
2026	747
2027	733
2028	722
2029	679
Five subsequent years ending 2033	2,770
Total	$ 6,304

16. NET ASSETS

The following table details the changes in net assets for the years ended September 30, 2024 and 2023 (in thousands):

	Net Assets Without Donor Restrictions				
	Undesignated	**Board-Designated**	**Total**	**Net Assets with Donor Restrictions**	**Total Net Assets**
Balance—October 1, 2022	$ 465,324	$ 10,103	$ 475,427	$ 727	$ 476,154
Increase (decrease) in net assets	18,509	(241)	18,268	(48)	18,220
Transfer	(57)	57	-	-	-
Balance—September 30, 2023	483,776	9,919	493,695	679	494,374
Increase (decrease) in net assets	36,050	(943)	35,107	(270)	34,837
Balance—September 30, 2024	$ 519,826	$ 8,976	$ 528,802	$ 409	$ 529,211

During the year ended September 30, 2022, as part of its Board-designated activity, the Institute committed to providing $3.5 million of conditional funding, plus an additional $1.5 million in the Institute's services, over the next five years to the University of North Carolina for a collaborative research project among North Carolina State University, Duke University, and North Carolina Central University. Expenses are recognized when the specified conditions are met. As of September 30, 2024 and 2023, $2.2 million and $3.1 million in conditional funding and $1 million and $1.4 million in the Institute's services remain to be expensed, respectively.

17. COMMITMENTS AND CONTINGENCIES

Legal and Regulatory Matters—The Institute is involved in litigation, administrative proceedings, and regulatory examinations arising in the normal course of business. Management believes that the ultimate outcome of these matters will not have a material impact on the Institute's net assets, operations, or cash flows.

During fiscal year 2020, the Institute received notice of a tax assessment from the United Republic of Tanzania's Revenue Authority (TRA) related to several taxation matters including vendor withholding and skill development levy taxes. The tax assessment covered fiscal years 2010 through 2018 and totaled over $2.3 million (utilizing September 30, 2024 translation rates) including penalties and interest. The Institute believes that it has complied with Tanzanian law and has contested the assessment through the TRA's appeals process. While the Institute is unable to ascertain the ultimate outcome of this matter based on the information currently available nor the amount of time it will take to work through the appeals process, the Institute believes that a partial loss with respect to this matter is probable and has recorded a liability of $1.3 million as of September 30, 2023, in other long-term liabilities in the consolidated balance sheets and in indirect costs in the consolidated statements of revenue, costs and changes in net assets. As of September 30, 2024, the liability of $1.3 million remains in other long-term liabilities in the consolidated balance sheets. In November 2024, the Institute and TRA settled the matter for an amount not substantially different from the loss accrued as of September 30, 2024.

Unconditional Promise—During the year ended September 30, 2023, the Institute made an unconditional promise to give $3.0 million in support of creating economic opportunity across the state of North Carolina and accrued the amount in other expense in the consolidated statements of revenue, costs, and changes in asset. As of September 30, 2024 and 2023, $2.3 million remains unpaid with equal installments due each year of the next four years. As of September 30, 2024, the current unpaid portion $0.6 million is included in accounts payable and accrued expenses, and the noncurrent unpaid portion $1.7 million is included in other long-term liabilities in the consolidated balance sheets. As of September 30, 2023, the $2.3 million is included in other long-term liabilities in the consolidated balance sheets.

Other Contingencies—The Institute has negotiated and settled final indirect costs through fiscal year 2022 with its cognizant federal agency, the Department of Health and Human Services (DHHS). Contract costs on federal government contracts, including indirect costs, are subject to audit by the federal government and adjustments pursuant to negotiation between the Institute and government representatives. Revenue on federal government contracts has been recorded in amounts that are expected to be realized upon final settlement of the Institute's indirect rates. As of September 30, 2024, management believes that the final settlement of indirect rates will not have a material impact on the Institute's net assets, operations, or cash flows.

International Resources Group Ltd. (IRG) is a 100% owned subsidiary of the Institute acquired in 2017. IRG is required to separately negotiate final indirect cost rates with its cognizant federal agency, the United States Agency for International Development (USAID). IRG and USAID have negotiated and settled IRG's final indirect cost rates through the final year of IRG operations (fiscal year 2021) and adjusted billings on contracts to which those rates apply. There are no further IRG indirect cost rates pending finalization.

* * * * * *

FEDERAL AWARDS SUPPLEMENTAL INFORMATION
AS OF AND FOR THE YEAR END SEPTEMBER 30, 2024

Deloitte & Touche LLP
621 Hillsborough St
Suite 400
Raleigh NC 27603
USA

Tel: +1 919 546 8000
Fax: +1 919 833 3276
www.deloitte.com

INDEPENDENT AUDITOR'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH *GOVERNMENT AUDITING STANDARDS*

To the Board of Governors of
Research Triangle Institute:

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*), the consolidated financial statements of Research Triangle Institute and subsidiaries (the "Institute") as of and for the year ended September 30, 2024, and the related notes to the consolidated financial statements, which collectively comprise the Institute's consolidated financial statements, and have issued our report thereon dated December 4, 2024.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered the Institute's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Institute's internal control. Accordingly, we do not express an opinion on the effectiveness of the Institute's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the Institute's financial statements will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Institute's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the consolidated financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Institute's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Institute's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Deloitte & Touche LLP

December 4, 2024

Deloitte & Touche LLP
621 Hillsborough St
Suite 400
Raleigh NC 27603
USA

Tel: +1 919 546 8000
Fax: +1 919 833 3276
www.deloitte.com

INDEPENDENT AUDITOR'S REPORT ON COMPLIANCE FOR EACH MAJOR FEDERAL PROGRAM; REPORT ON INTERNAL CONTROL OVER COMPLIANCE; AND REPORT ON SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS REQUIRED BY THE UNIFORM GUIDANCE

To the Board of Governors of
Research Triangle Institute:

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited Research Triangle Institute and subsidiaries' (the "Institute") compliance with the types of compliance requirements identified as subject to audit in the OMB *Compliance Supplement* that could have a direct and material effect on each of the Institute's major federal programs for the year ended September 30, 2024. The Institute's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the Institute complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended September 30, 2024.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*); and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the Institute and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the Institute's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to Institute's federal programs.

Auditor’s Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Institute’s compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the Institute’s compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance, we

- exercise professional judgment and maintain professional skepticism throughout the audit.
- identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the Institute’s compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- obtain an understanding of the Institute’s internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of the Institute’s internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Other Matters

The results of our auditing procedures disclosed an instance of noncompliance which is required to be reported in accordance with the Uniform Guidance and which is described in the accompanying schedule of findings and questioned costs as item 2024-001. Our opinion on each major federal program is not modified with respect to this matter.

Government Auditing Standards requires the auditor to perform limited procedures on the Institute’s response to the noncompliance finding identified in our compliance audit described in the accompanying schedule of findings and questioned costs. The Institute’s response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

Report on Internal Control Over Compliance

A *deficiency in internal control over compliance* exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance

We have audited the consolidated financial statements of the Institute as of and for the year ended September 30, 2024, and have issued our report thereon dated December 4, 2024, except for the subsequent event in Note 1 related to the effects of terminations and stop-work orders, as to which the date is June 27, 2025, which contained an unmodified opinion on those consolidated financial statements. Our audit was performed for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by the Uniform Guidance and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated in all material respects in relation to the consolidated financial statements as a whole.

Deloitte & Touche LLP

June 27, 2025

RESEARCH TRIANGLE INSTITUTE
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2024

Federal Assistance		Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity	Amount Passed Through to Subrecipients	Amount Expended
10	001	59-8040-3-004	AGRICULTURAL RESEARCH_BASIC AND APPLIED RESEARCH	RESEARCH AND DEVELOPMENT	$ 104,194	$ 696,252,320	Y			-	$ 104,194
43	001	80NSSC21K1167	SCIENCE	RESEARCH AND DEVELOPMENT	77,487	696,252,320	Y			10,632	$ 77,487
98	001	9782	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	RESEARCH AND DEVELOPMENT	190,681,747	696,252,320	N	Magee-Womens Research	9782	-	$ 725,869
85	002	95332419T0019	MCC FOREIGN ASSISTANCE FOR OVERSEAS PROGRAMS	RESEARCH AND DEVELOPMENT	105,109	696,252,320	Y			-	$ 105,109
12	006	W911NF2420110	NATIONAL DEFENSE EDUCATION PROGRAM	RESEARCH AND DEVELOPMENT	336,701	696,252,320	Y			17,788	$ 108,448
12	006	HQ00342010045	NATIONAL DEFENSE EDUCATION PROGRAM	RESEARCH AND DEVELOPMENT	336,701	696,252,320	Y			10,366	$ 228,253
12	007	0072FEDac	MILITARY HEALTH SERVICES RESEARCH (MHSR)	RESEARCH AND DEVELOPMENT	50,975	696,252,320	N	BVARI	0072FEDac	-	$ 50,975
11	016	CB20ADR0160003	STATISTICAL, RESEARCH, AND METHODOLOGY ASSISTANCE	RESEARCH AND DEVELOPMENT	(56)	696,252,320	Y			-	$ (56)
19	017	SLMAQM18CA2096	ENVIRONMENTAL AND SCIENTIFIC PARTNERSHIPS AND PROGRAMS	RESEARCH AND DEVELOPMENT	37,432	696,252,320	Y			-	$ (865)
19	017	SLMAQM20CA2370	ENVIRONMENTAL AND SCIENTIFIC PARTNERSHIPS AND PROGRAMS	RESEARCH AND DEVELOPMENT	37,432	696,252,320	Y			17,322	$ 38,297
16	026	19333	OVW RESEARCH AND EVALUATION PROGRAM	RESEARCH AND DEVELOPMENT	10,098	696,252,320	N	Univ of Illinois Chicago	19333	-	$ 10,098
66	034	COVID-19, 02D46023	COVID-19 - SURVEYS, STUDIES, RESEARCH, INVESTIGATIONS, DEMONSTRATIONS, AND SPECIAL PURPOSE ACTIVITIES RELATING TO THE CLEAN AIR ACT	RESEARCH AND DEVELOPMENT	231,929	696,252,320	Y			-	$ 152,909
66	034	RTI-SC001	SURVEYS, STUDIES, RESEARCH, INVESTIGATIONS, DEMONSTRATIONS, AND SPECIAL PURPOSE ACTIVITIES RELATING TO THE CLEAN AIR ACT	RESEARCH AND DEVELOPMENT	231,929	696,252,320	N	CleanAIRE NC	RTI-SC001	-	$ 29,331
66	034	TRTC-18-2024	SURVEYS, STUDIES, RESEARCH, INVESTIGATIONS, DEMONSTRATIONS, AND SPECIAL PURPOSE ACTIVITIES RELATING TO THE CLEAN AIR ACT	RESEARCH AND DEVELOPMENT	231,929	696,252,320	N	Tule River Tribe	TRTC-18-2024	-	$ 49,689
47	041	Master Agreement 01-01	ENGINEERING	RESEARCH AND DEVELOPMENT	421,195	696,252,320	N	North Carolina State Univ	Master Agreement 01-01	-	$ 191,436
47	041	2039584	ENGINEERING	RESEARCH AND DEVELOPMENT	421,195	696,252,320	N	Clemson University	2039584	-	$ 31,008
47	041	TO 2021-2062-01	ENGINEERING	RESEARCH AND DEVELOPMENT	421,195	696,252,320	N	North Carolina State Univ	TO 2021-2062-01	-	$ 49,164
47	041	2144382	ENGINEERING	RESEARCH AND DEVELOPMENT	421,195	696,252,320	Y			-	$ 118,559
47	041	COVID-19, EEC-2135080	COVID-19 - ENGINEERING	RESEARCH AND DEVELOPMENT	421,195	696,252,320	N	University of Pittsburgh	EEC-2135080	-	$ 31,028
16	043	31726-A2300-57-S01	BJA Veteran Treatment	RESEARCH AND DEVELOPMENT	3,816	696,252,320	N	American University	31726-A2300-57-S01	-	$ 3,816
16	045	15PNIJ-22-GK-03016-CVIP	NIJ CVIPI Eval Grnsboro	RESEARCH AND DEVELOPMENT	82,150	696,252,320	Y			-	$ 82,150
16	048	15PBJS-23-GK-05496-NOHA	NIBRS Hate Crime	RESEARCH AND DEVELOPMENT	69,883	696,252,320	N	IJIS Institute	15PBJS-23-GK-05496-NOHA	-	$ 69,883
84	305A	R305A180050	EDUCATION RESEARCH, DEVELOPMENT AND DISSEMINATION	RESEARCH AND DEVELOPMENT	1,379,142	696,252,320	Y			-	$ 231,302
84	305A	R305A210146	EDUCATION RESEARCH, DEVELOPMENT AND DISSEMINATION	RESEARCH AND DEVELOPMENT	1,379,142	696,252,320	Y			-	$ 450,392
84	305A	R305A220032	EDUCATION RESEARCH, DEVELOPMENT AND DISSEMINATION	RESEARCH AND DEVELOPMENT	1,379,142	696,252,320	Y			-	$ 540,194
84	305A	GR100504.SUB00000143	EDUCATION RESEARCH, DEVELOPMENT AND DISSEMINATION	RESEARCH AND DEVELOPMENT	1,379,142	696,252,320	N	University of Virginia	GR100504.SUB00000143	-	$ 83,224
84	305A	R305A240078	EDUCATION RESEARCH, DEVELOPMENT AND DISSEMINATION	RESEARCH AND DEVELOPMENT	1,379,142	696,252,320	Y			-	$ 74,030
84	305R	R305R210007	EDUCATION RESEARCH, DEVELOPMENT AND DISSEMINATION	RESEARCH AND DEVELOPMENT	920,718	696,252,320	Y			264,496	$ 920,718
84	305S	23681005711001	EDUCATION RESEARCH, DEVELOPMENT AND DISSEMINATION	RESEARCH AND DEVELOPMENT	146,611	696,252,320	N	TX Texas Education Agency	23681005711001	-	$ 146,611
93	065	1 NU88EH001333-01-00	LABORATORY LEADERSHIP, WORKFORCE TRAINING AND MANAGEMENT DEVELOPMENT, IMPROVING PUBLIC HEALTH LABORATORY INFRASTRUCTURE	RESEARCH AND DEVELOPMENT	17,911	696,252,320	Y			-	$ 17,911
93	067	GH21-2147- PHIS3	GLOBAL AIDS	RESEARCH AND DEVELOPMENT	149,252	696,252,320	N	APIN Public Health Init.	GH21-2147- PHIS3	-	$ 149,252
97	067	45-0108-1008-201	HOMELAND SECURITY GRANT PROGRAM	RESEARCH AND DEVELOPMENT	1,439,967	696,252,320	N	Univ of Nebraska Omaha	45-0108-1008-201	-	$ 1,439,967
93	068	1 U18DP006707-01-00	CHRONIC DISEASES: RESEARCH, CONTROL, AND PREVENTION	RESEARCH AND DEVELOPMENT	988,578	696,252,320	Y			-	$ 356,651
93	068	1001DP006758-01-00	CHRONIC DISEASES: RESEARCH, CONTROL, AND PREVENTION	RESEARCH AND DEVELOPMENT	988,578	696,252,320	Y			-	$ 631,927
47	070	1939111	COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	RESEARCH AND DEVELOPMENT	(2)	696,252,320	Y			-	$ (2)
93	070	1U01TS000301-01-00	ENVIRONMENTAL PUBLIC HEALTH AND EMERGENCY RESPONSE	RESEARCH AND DEVELOPMENT	599,528	696,252,320	Y			108,166	$ 600,681
93	070	4-95611	ENVIRONMENTAL PUBLIC HEALTH AND EMERGENCY RESPONSE	RESEARCH AND DEVELOPMENT	599,528	696,252,320	N	University at Albany	4-95611	-	$ (1,153)
47	076	SCON-00003563	EDUCATION AND HUMAN RESOURCES	RESEARCH AND DEVELOPMENT	216,879	696,252,320	N	University of Southern CA	SCON-00003563	-	$ 175,932
47	076	5052101A-10-12-2018C	EDUCATION AND HUMAN RESOURCES	RESEARCH AND DEVELOPMENT	216,879	696,252,320	N	California State Monterey	5052101A-10-12-2018C	-	$ 40,947
93	077	5132973	FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH	RESEARCH AND DEVELOPMENT	19,609	696,252,320	N	UNC Chapel Hill	5132973	-	$ 12,644
93	077	MSA 01-016	FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH	RESEARCH AND DEVELOPMENT	19,609	696,252,320	N	UNC Chapel Hill	MSA 01-016	-	$ 6,965
47	079	MSA 01-011	OFFICE OF INTERNATIONAL SCIENCE AND ENGINEERING	RESEARCH AND DEVELOPMENT	39,077	696,252,320	N	UNC Chapel Hill	MSA 01-011	-	$ 39,077
47	083	NSF-228-01	INTEGRATIVE ACTIVITIES	RESEARCH AND DEVELOPMENT	64,501	696,252,320	N	Pomona College	NSF-228-01	-	$ 64,501
47	084	58706F-23-0083 RTI-SUB-INT	NCET Engines Type 1	RESEARCH AND DEVELOPMENT	202,175	696,252,320	N	UNC Wilmington	58706F-23-0083 RTI-SUB-INT	-	$ 100,400
47	084	S6275, PO# 1025344	MIT NSF CONV MVINE ROBOT	RESEARCH AND DEVELOPMENT	202,175	696,252,320	N	MIT	S6275, PO# 1025344	-	$ 36,039
47	084	260487D	CROPS NSF Eng Advis Sup t	RESEARCH AND DEVELOPMENT	202,175	696,252,320	N	NC Agri & Tech State Univ	260487D	-	$ 14,066
47	084	24-S26	EAGER PBI Entrep Ecos	RESEARCH AND DEVELOPMENT	202,175	696,252,320	N	George Washington Univ	24-S26	-	$ 2,724
47	084	A24-0067-SRVA002-RTI	IIT TechForward NSF Art	RESEARCH AND DEVELOPMENT	202,175	696,252,320	N	Illinois Tech	A24-0067-SRVA002-RTI	-	$ 48,946
81	086	7800007566	CONSERVATION RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT	626,267	696,252,320	N	University of Kentucky	7800007566	-	$ 5,111
81	086	83824	CONSERVATION RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT	626,267	696,252,320	N	Stony Brook University	83824	-	$ 125,169
81	086	DE-EE0009415	CONSERVATION RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT	626,267	696,252,320	Y			-	$ 495,987
81	087	DE-EE0008509	RENEWABLE ENERGY RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT	1,823,221	696,252,320	Y			62,778	$ 537,082
81	087	DE-EE0008918	RENEWABLE ENERGY RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT	1,823,221	696,252,320	Y			-	$ 640,588
81	087	DE-EE0009262	RENEWABLE ENERGY RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT	1,823,221	696,252,320	Y			277,346	$ 434,717
81	087	21E085-02	RENEWABLE ENERGY RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT	1,823,221	696,252,320	N	Texas Tech Univ	21E085-02	-	$ 93,950
81	087	DE-EE0010457	RENEWABLE ENERGY RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT	1,823,221	696,252,320	Y			-	$ 116,884
93	087	FY22.1161.001	ENHANCE SAFETY OF CHILDREN AFFECTED BY SUBSTANCE ABUSE	RESEARCH AND DEVELOPMENT	(1,242)	696,252,320	N	Univ of Colorado Denver	FY22.1161.001	-	$ (1,242)

(Continued)

RESEARCH TRIANGLE INSTITUTE
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2024

Federal Assistance		Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity	Amount Passed Through to Subrecipients	Amount Expended
81	089	DE-FE0031590	FOSSIL ENERGY RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT	6,161,032	696,252,320	Y			64,628	$ (87,454)
81	089	DE-FE0031764	FOSSIL ENERGY RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT	6,161,032	696,252,320	Y			-	$ (6,119)
81	089	SubAward:UTAUS-SUB00000250AM2	FOSSIL ENERGY RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT	6,161,032	696,252,320	N	AEC	SubAward:UTAUS-SUB00000250AM2	-	$ 20,162
81	089	DE-FE0031945	FOSSIL ENERGY RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT	6,161,032	696,252,320	N	EPRI	DE-FE0031945	-	$ 1,570,307
81	089	DE-FE0032099	FOSSIL ENERGY RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT	6,161,032	696,252,320	Y			179,762	$ 367,979
81	089	21-BIOSYS-212511-RTI	FOSSIL ENERGY RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT	6,161,032	696,252,320	N	Auburn University	21-BIOSYS-212511-RTI	-	$ 16,120
81	089	DE-FE0032218	FOSSIL ENERGY RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT	6,161,032	696,252,320	Y			-	$ 635,486
81	089	DE-FE0032220	FOSSIL ENERGY RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT	6,161,032	696,252,320	Y			-	$ 2,101,413
81	089	23-BIOSYS-212513-RTI	FOSSIL ENERGY RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT	6,161,032	696,252,320	N	Auburn University	23-BIOSYS-212513-RTI	-	$ 289,656
81	089	DE-FE0032241	FOSSIL ENERGY RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT	6,161,032	696,252,320	Y			227,469	$ 1,029,483
81	089	DE-FE0032419	FOSSIL ENERGY RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT	6,161,032	696,252,320	Y			-	$ 223,999
93	092	90AP2694-01-00	AFFORDABLE CARE ACT (ACA) PERSONAL RESPONSIBILITY EDUCATION PROGRAM	RESEARCH AND DEVELOPMENT	241,305	696,252,320	Y			-	$ 241,305
93	103	026072D	FOOD AND DRUG ADMINISTRATION_RESEARCH	RESEARCH AND DEVELOPMENT	99,945	696,252,320	N	Iowa State University	026072D	-	$ 99,945
97	108	23STFRG00022-01-00	HOMELAND SECURITY, RESEARCH, TESTING, EVALUATION, AND DEMONSTRATION OF TECHNOLOGIES	RESEARCH AND DEVELOPMENT	76,574	696,252,320	Y			-	$ 76,574
93	110	56401-600-151-24-03	MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	RESEARCH AND DEVELOPMENT	147,834	696,252,320	N	Assoc of Public Hlth Labs	56401-600-151-24-03	-	$ 140,670
93	110	00047805	MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	RESEARCH AND DEVELOPMENT	147,834	696,252,320	N	NC DHHS	00047805	-	$ 7,164
93	113	1U2CES030857-01	ENVIRONMENTAL HEALTH	RESEARCH AND DEVELOPMENT	2,095,722	696,252,320	Y			1,134,356	$ 1,475,088
93	113	SubAward no. UWSC13846	ENVIRONMENTAL HEALTH	RESEARCH AND DEVELOPMENT	2,095,722	696,252,320	N	University of Washington	SubAward no. UWSC13846	-	$ 2,158
93	113	1U24ES035214-01	ENVIRONMENTAL HEALTH	RESEARCH AND DEVELOPMENT	2,095,722	696,252,320	N	UNC Chapel Hill	1U24ES035214-01	-	$ 3,972
93	113	1U01ES027254-01	ENVIRONMENTAL HEALTH	RESEARCH AND DEVELOPMENT	2,095,722	696,252,320	Y			-	$ 21,284
93	113	1R21ES030142-01A1	ENVIRONMENTAL HEALTH	RESEARCH AND DEVELOPMENT	2,095,722	696,252,320	Y			-	$ 31,057
93	113	Awd101249(SuB00000367	ENVIRONMENTAL HEALTH	RESEARCH AND DEVELOPMENT	2,095,722	696,252,320	N	University of Chicago	Awd101249(SuB00000367	-	$ 63,720
93	113	1R21ES033311-01A1	ENVIRONMENTAL HEALTH	RESEARCH AND DEVELOPMENT	2,095,722	696,252,320	Y			1,806	$ 218,288
93	113	1R21ES035913-01	ENVIRONMENTAL HEALTH	RESEARCH AND DEVELOPMENT	2,095,722	696,252,320	Y			6,080	$ 210,261
93	113	1R24ES036127-01	ENVIRONMENTAL HEALTH	RESEARCH AND DEVELOPMENT	2,095,722	696,252,320	Y			-	$ 67,653
93	113	Agreement effective 3/24/21	ENVIRONMENTAL HEALTH	RESEARCH AND DEVELOPMENT	2,095,722	696,252,320	N	North Carolina State Univ	Agreement effective 3/24/21	-	$ 2,241
84	411A	VA 24-0090	INVESTING IN INNOVATION (I3) FUND	RESEARCH AND DEVELOPMENT	44,329	696,252,320	N	Univ of Alaska Fairbanks	VA 24-0090	-	$ 44,329
84	411C	S411C220065	INVESTING IN INNOVATION (I3) FUND	RESEARCH AND DEVELOPMENT	833,826	696,252,320	Y			265,345	$ 833,826
81	135	DE-AR0000811	ADVANCED RESEARCH PROJECTS AGENCY - ENERGY	RESEARCH AND DEVELOPMENT	4,547,042	696,252,320	Y			-	$ 66,139
81	135	DE-AR0001479	ADVANCED RESEARCH PROJECTS AGENCY - ENERGY	RESEARCH AND DEVELOPMENT	4,547,042	696,252,320	Y			2,431,105	$ 3,570,338
81	135	DE-AR0001717	ADVANCED RESEARCH PROJECTS AGENCY - ENERGY	RESEARCH AND DEVELOPMENT	4,547,042	696,252,320	Y			172,023	$ 910,565
93	136	1U01CE003216-01-00	INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	RESEARCH AND DEVELOPMENT	1,219,550	696,252,320	Y			26,429	$ 56,007
93	136	1 U01CE003482-01-00	INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	RESEARCH AND DEVELOPMENT	1,219,550	696,252,320	Y			294,058	$ 713,919
93	136	1 R01CE003191-01-00	INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	RESEARCH AND DEVELOPMENT	1,219,550	696,252,320	Y			63,188	$ 336,188
93	136	WSU22118	INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	RESEARCH AND DEVELOPMENT	1,219,550	696,252,320	N	Wayne State Univ	WSU22118	-	$ 113,436
93	143	MSA 01-013	NIEHS SUPERFUND HAZARDOUS SUBSTANCES_BASIC RESEARCH AND EDUCATION	RESEARCH AND DEVELOPMENT	244,589	696,252,320	N	UNC Chapel Hill	MSA 01-013	-	$ 182,435
93	143	303-003559	NIEHS SUPERFUND HAZARDOUS SUBSTANCES_BASIC RESEARCH AND EDUCATION	RESEARCH AND DEVELOPMENT	244,589	696,252,320	N	Duke University	303-003559	-	$ 62,154
93	172	2U41HG007050-05	HUMAN GENOME RESEARCH	RESEARCH AND DEVELOPMENT	2,343,038	696,252,320	Y			-	$ 38,034
93	172	Agreement Number 01-01	HUMAN GENOME RESEARCH	RESEARCH AND DEVELOPMENT	2,343,038	696,252,320	N	UNC Chapel Hill	Agreement Number 01-01	-	$ 344,044
93	172	1U24HG012556-01	HUMAN GENOME RESEARCH	RESEARCH AND DEVELOPMENT	2,343,038	696,252,320	Y			-	$ 1,938,505
93	172	1R01HG011926-01	HUMAN GENOME RESEARCH	RESEARCH AND DEVELOPMENT	2,343,038	696,252,320	Y			-	$ 22,455
93	173	142247-WSU001142	RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	RESEARCH AND DEVELOPMENT	671	696,252,320	N	Washington State Univ	142247-WSU001142	-	$ 671
93	213	1R01AT010773-01	RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	RESEARCH AND DEVELOPMENT	83,957	696,252,320	Y			86,942	$ 83,957
93	242	521828	MENTAL HEALTH RESEARCH GRANTS	RESEARCH AND DEVELOPMENT	5,093,331	696,252,320	N	UNC Chapel Hill	521828	-	$ 38,038
93	242	1U24MH137696-01	MENTAL HEALTH RESEARCH GRANTS	RESEARCH AND DEVELOPMENT	5,093,331	696,252,320	Y			-	$ 1,732
93	242	MSA Dt 01-01	MENTAL HEALTH RESEARCH GRANTS	RESEARCH AND DEVELOPMENT	5,093,331	696,252,320	N	UNC Chapel Hill	MSA Dt 01-01	-	$ 7,848
93	242	1R01MH122196	MENTAL HEALTH RESEARCH GRANTS	RESEARCH AND DEVELOPMENT	5,093,331	696,252,320	Y			9,536	$ 63,530
93	242	1R01MH121148-01A1	MENTAL HEALTH RESEARCH GRANTS	RESEARCH AND DEVELOPMENT	5,093,331	696,252,320	Y			433,173	$ 858,524
93	242	1R01MH124438-01	MENTAL HEALTH RESEARCH GRANTS	RESEARCH AND DEVELOPMENT	5,093,331	696,252,320	Y			219,349	$ 367,861
93	242	1R34MH124628-01	MENTAL HEALTH RESEARCH GRANTS	RESEARCH AND DEVELOPMENT	5,093,331	696,252,320	Y			9,021	$ 93,710
93	242	1R21MH126358-01	MENTAL HEALTH RESEARCH GRANTS	RESEARCH AND DEVELOPMENT	5,093,331	696,252,320	Y			69,044	$ 94,014
93	242	5120620	MENTAL HEALTH RESEARCH GRANTS	RESEARCH AND DEVELOPMENT	5,093,331	696,252,320	N	UNC Chapel Hill	5120620	-	$ 21,870
93	242	12845sc	MENTAL HEALTH RESEARCH GRANTS	RESEARCH AND DEVELOPMENT	5,093,331	696,252,320	N	Univ of California SF	12845sc	-	$ 13,458
93	242	1R01MH125671-01A1	MENTAL HEALTH RESEARCH GRANTS	RESEARCH AND DEVELOPMENT	5,093,331	696,252,320	Y			283,552	$ 691,506
93	242	13213sc	MENTAL HEALTH RESEARCH GRANTS	RESEARCH AND DEVELOPMENT	5,093,331	696,252,320	N	Univ of California SF	13213sc	-	$ 13,325
93	242	AWD00004478 (136628-3)	MENTAL HEALTH RESEARCH GRANTS	RESEARCH AND DEVELOPMENT	5,093,331	696,252,320	N	University of Pittsburgh	AWD00004478 (136628-3)	-	$ 13,080
93	242	5124258	MENTAL HEALTH RESEARCH GRANTS	RESEARCH AND DEVELOPMENT	5,093,331	696,252,320	N	UNC Chapel Hill	5124258	-	$ 37,065
93	242	1R01MH127955-01A1	MENTAL HEALTH RESEARCH GRANTS	RESEARCH AND DEVELOPMENT	5,093,331	696,252,320	Y			354,833	$ 767,490

(Continued)

RESEARCH TRIANGLE INSTITUTE
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2024

Federal Assistance Listing		Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity	Amount Passed Through to Subrecipients	Amount Expended
93	242	5125213	MENTAL HEALTH RESEARCH GRANTS	RESEARCH AND DEVELOPMENT	5,093,331	696,252,320	N	UNC Chapel Hill	5125213	-	$ 59,524
93	242	72052223CA00001A	MENTAL HEALTH RESEARCH GRANTS	RESEARCH AND DEVELOPMENT	5,093,331	696,252,320	N	Univ of California SF	72052223CA00001A	-	$ 152,627
93	242	13947SC	MENTAL HEALTH RESEARCH GRANTS	RESEARCH AND DEVELOPMENT	5,093,331	696,252,320	N	Univ of California SF	13947SC	-	$ 7,664
93	242	303002086	MENTAL HEALTH RESEARCH GRANTS	RESEARCH AND DEVELOPMENT	5,093,331	696,252,320	N	Duke University	303002086	-	$ 49,156
93	242	1R01MH132602-01	MENTAL HEALTH RESEARCH GRANTS	RESEARCH AND DEVELOPMENT	5,093,331	696,252,320	Y			432,978	$ 710,453
93	242	0001181795	MENTAL HEALTH RESEARCH GRANTS	RESEARCH AND DEVELOPMENT	5,093,331	696,252,320	N	Fred Hutchinson Cancer	0001181795	-	$ 155,792
93	242	1R01MH131565-01A1	MENTAL HEALTH RESEARCH GRANTS	RESEARCH AND DEVELOPMENT	5,093,331	696,252,320	Y			62,847	$ 593,452
93	242	000536327-SC002	MENTAL HEALTH RESEARCH GRANTS	RESEARCH AND DEVELOPMENT	5,093,331	696,252,320	N	Univ Alabama Birmingham	000536327-SC002	-	$ 401
93	242	100-1181791-97169	MENTAL HEALTH RESEARCH GRANTS	RESEARCH AND DEVELOPMENT	5,093,331	696,252,320	N	Research Found of SUNY	100-1181791-97169	-	$ 58,782
93	242	1R01MH135136-01	MENTAL HEALTH RESEARCH GRANTS	RESEARCH AND DEVELOPMENT	5,093,331	696,252,320	Y			-	$ 196,710
93	242	900366RTI	MENTAL HEALTH RESEARCH GRANTS	RESEARCH AND DEVELOPMENT	5,093,331	696,252,320	N	Drexel Univ	900366RTI	-	$ 8,599
93	242	5131371	MENTAL HEALTH RESEARCH GRANTS	RESEARCH AND DEVELOPMENT	5,093,331	696,252,320	N	UNC Chapel Hill	5131371	-	$ 4,305
93	242	MSA 01-0111	MENTAL HEALTH RESEARCH GRANTS	RESEARCH AND DEVELOPMENT	5,093,331	696,252,320	N	UNC Chapel Hill	MSA 01-0111	-	$ 2,457
93	242	5131225	MENTAL HEALTH RESEARCH GRANTS	RESEARCH AND DEVELOPMENT	5,093,331	696,252,320	N	UNC Chapel Hill	5131225	-	$ 8,611
93	242	500411	MENTAL HEALTH RESEARCH GRANTS	RESEARCH AND DEVELOPMENT	5,093,331	696,252,320	N	Univ of Pennsylvania	500411	-	$ 1,747
93	243	1H79FG000030-01	SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES_PROJECTS OF REGIONAL AND NATIONAL SIGNIFICANCE	RESEARCH AND DEVELOPMENT	87,974	696,252,320	Y			75,007	$ 87,974
10	253	59-5000-0-0054R	CONSUMER DATA AND NUTRITION RESEARCH	RESEARCH AND DEVELOPMENT	(7,100)	696,252,320	Y			(6,982)	$ (7,100)
93	262	5123098	OCCUPATIONAL SAFETY AND HEALTH PROGRAM	RESEARCH AND DEVELOPMENT	153,919	696,252,320	N	UNC Chapel Hill	5123098	-	$ 116,823
93	262	Agreement 4/12/2023	OCCUPATIONAL SAFETY AND HEALTH PROGRAM	RESEARCH AND DEVELOPMENT	153,919	696,252,320	N	UNC Chapel Hill	Agreement 4/12/2023	-	$ 37,096
84	326K	5131909	SPECIAL EDUCATION_TECHNICAL ASSISTANCE AND DISSEMINATION TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES	RESEARCH AND DEVELOPMENT	7,310	696,252,320	N	UNC Chapel Hill	5131909	-	$ 7,310
93	273	1R01AA022882-01	ALCOHOL RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	3,884,957	696,252,320	Y			-	$ (45)
93	273	1R01AA022235-01A1	ALCOHOL RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	3,884,957	696,252,320	Y			-	$ (3,827)
93	273	9R01AA030509 FAIN: R01DA040693	ALCOHOL RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	3,884,957	696,252,320	Y			86,245	$ 399,873
93	273	2003859010	ALCOHOL RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	3,884,957	696,252,320	N	Johns Hopkins University	2003859010	-	$ 77,857
93	273	1R01AA026820-01	ALCOHOL RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	3,884,957	696,252,320	Y			48,778	$ 299,981
93	273	028400-87CL	ALCOHOL RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	3,884,957	696,252,320	N	University of New Mexico	028400-87CL	-	$ 18,987
93	273	1R01AA027796-01	ALCOHOL RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	3,884,957	696,252,320	Y			-	$ (114)
93	273	1R01AA027049-01A1	ALCOHOL RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	3,884,957	696,252,320	Y			268,920	$ 580,868
93	273	1R01AA028255-01	ALCOHOL RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	3,884,957	696,252,320	Y			66,730	$ 177,410
93	273	5-54365	ALCOHOL RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	3,884,957	696,252,320	N	The Scripps Research Inst	5-54365	-	$ 15,338
93	273	5-54364	ALCOHOL RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	3,884,957	696,252,320	N	The Scripps Research Inst	5-54364	-	$ 37,328
93	273	02371	ALCOHOL RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	3,884,957	696,252,320	N	Public Health Institute	02371	-	$ 13,480
93	273	1R21AA029048-01	ALCOHOL RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	3,884,957	696,252,320	Y			(12,236)	$ (4,704)
93	273	02613	ALCOHOL RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	3,884,957	696,252,320	N	Public Health Institute	02613	-	$ 2,497
93	273	FP00009867_SA001	ALCOHOL RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	3,884,957	696,252,320	N	VA Commonwealth Univ	FP00009867_SA001	-	$ 24,006
93	273	Agreement No. 02719	ALCOHOL RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	3,884,957	696,252,320	N	Public Health Institute	Agreement No. 02719	-	$ 22,152
93	273	03255-AR04818	ALCOHOL RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	3,884,957	696,252,320	N	Public Health Institute	03255-AR04818	-	$ 102,124
93	273	1R01AA029812-01	ALCOHOL RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	3,884,957	696,252,320	Y			169,859	$ 976,662
93	273	1R01AA030452-01	ALCOHOL RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	3,884,957	696,252,320	Y			-	$ 355,307
93	273	1R61AA030043-01	ALCOHOL RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	3,884,957	696,252,320	Y			135,305	$ 319,665
93	273	5R34AA028856-02	ALCOHOL RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	3,884,957	696,252,320	N	UNC Chapel Hill	5R34AA028856-02	-	$ 108,959
93	273	13907SC	ALCOHOL RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	3,884,957	696,252,320	N	Univ of California SF	13907SC	-	$ 38,205
93	273	1R34AA030820-01	ALCOHOL RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	3,884,957	696,252,320	Y			131,903	$ 204,692
93	273	SCON-00005137	ALCOHOL RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	3,884,957	696,252,320	N	University of Southern CA	SCON-00005137	-	$ 118,256
93	279	1UG3 DA044823-01	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			130	$ 92,755
93	279	1UM1DA049394	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			116,491	$ 4,581,842
93	279	1U24DA050182-01	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			-	$ 1,968,667
93	279	1U18DA052416-01	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			-	$ 593
93	279	3RLX7	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	N	University of New Mexico	3RLX7	-	$ 10,277
93	279	UWSC14124	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	N	University of Washington	UWSC14124	-	$ 293,471
93	279	1R01DA041227	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			-	$ 15
93	279	1R01DA041009-01	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			-	$ (119)
93	279	1R01DA040460-01A1	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			88,778	$ 386,933
93	279	1R21DA044377-01	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			-	$ 329,548
93	279	1R01DA045003-01	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			-	$ 366,573
93	279	2R01DA031900-06A1	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	N	Drexel Univ	2R01DA031900-06A1	-	$ 12,421
93	279	1R61DA047011-01	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			429,280	$ 803,910
93	279	1R01DA044051-01A1	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			(3)	$ (3)
93	279	GR105204 (CON-80001616)	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	N	Yale University	GR105204 (CON-80001616)	-	$ 84,254
93	279	R1171614	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	N	University at Buffalo	R1171614	-	$ 76,274
93	279	1R03DA045900-01A1	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			-	$ 598
93	279	1R01DA047994-01A1	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			-	$ 478,880
93	279	1R01DA049612-01A1	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			128,020	$ 515,312
93	279	1R01DA047334-01A1	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			-	$ 215,613
93	279	1R01DA049761-01	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			270	$ 412,604
93	279	1R01DA051908	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			495,828	$ 928,642

(Continued)

RESEARCH TRIANGLE INSTITUTE
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2024

Federal Assistance		Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity	Amount Passed Through to Subrecipients	Amount Expended
93	279	1R01DA051913-01	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			716,125	$ 1,006,676
93	279	1R01DA048824-01A1	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			196,832	$ 717,572
93	279	Uwsc12187	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	N	University of Washington	Uwsc12187	-	$ 13,991
93	279	1R21DA053694-01	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			-	$ 41,614
93	279	SP14241-SB1	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	N	University of Mississippi	SP14241-SB1	-	$ 30,932
93	279	Agreement 10/30/2024	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	N	DynamiCare Health, Inc	Agreement 10/30/2024	-	$ 48,200
93	279	1017225-RTI-B3	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	N	Oregon Health Scien Univ	1017225-RTI-B3	-	$ 34,118
93	279	13191SC	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	N	Univ of California SF	13191SC	-	$ 54,884
93	279	UCHC7-148745933	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	N	University of Connecticut	UCHC7-148745933	-	$ 58,435
93	279	1P50DA054071-01A1	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			1,881,718	$ 2,787,226
93	279	1R01DA055277-01	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			232,335	$ 841,955
93	279	1R24DA057611-01	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			-	$ 822,592
93	279	1R01DA056449-01	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			-	$ 651,792
93	279	1R01DA057613-01	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			8,025	$ 763,156
93	279	GR128897	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	N	Ohio State University	GR128897	-	$ 89,287
93	279	G-R12887	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	N	Ohio State University	G-R12887	-	$ 45,616
93	279	11385-2	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	N	Friends Research Inst	11385-2	-	$ 165,447
93	279	MSA 01-018	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	N	UNC Chapel Hill	MSA 01-018	-	$ (402)
93	279	9485-RTI	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	N	Indiana Univ Schl of Med	9485-RTI	-	$ 135,917
93	279	705650	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	N	Univ of California SD	705650	-	$ 302,200
93	279	7R01DA056264-02	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			119,125	$ 628,186
93	279	22-A1-00-1003947	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	N	New York University	22-A1-00-1003947	-	$ 72,365
93	279	1R03DA058800-01	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			-	$ 86,448
93	279	1DP1DA058362-01	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			-	$ 398,783
93	279	22-A0-00-1008771	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	N	New York University	22-A0-00-1008771	-	$ 19,565
93	279	R42DA056255-RTI	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	N	Q2i	R42DA056255-RTI	-	$ 30,422
93	279	1RM1DA059375-01	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			52,477	$ 1,021,295
93	279	1R01DA058493-01A1	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			222,696	$ 599,607
93	279	AWD00008291	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	N	University of Pittsburgh	AWD00008291	-	$ 62,434
93	279	706474	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	N	Univ of California SD	706474	-	$ 13,441
93	279	19826	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	N	Univ of Illinois Chicago	19826	-	$ 23,332
93	279	1R21DA061167-01	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			-	$ 9,171
93	279	1R21DA060954-01	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			-	$ 3,405
93	279	1r61da061296-01	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	RESEARCH AND DEVELOPMENT	23,139,094	696,252,320	Y			-	$ 372
84	283	23039	COMPREHENSIVE CENTERS	RESEARCH AND DEVELOPMENT	7,061	696,252,320	N	Education Development Ctr	23039	-	$ 7,061
93	297	1TP2AH000087-01-00	TEENAGE PREGNANCY PREVENTION PROGRAM	RESEARCH AND DEVELOPMENT	1,521,908	696,252,320	Y			58,477	$ 785,022
93	297	6 TP2AH000082-01-02	TEENAGE PREGNANCY PREVENTION PROGRAM	RESEARCH AND DEVELOPMENT	1,521,908	696,252,320	Y			-	$ 736,886
84	305	R305N240035	EDUCATION RESEARCH, DEVELOPMENT AND DISSEMINATION	RESEARCH AND DEVELOPMENT	18,436	696,252,320	Y			-	$ 18,436
93	307	1R01MD016662-01	MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	RESEARCH AND DEVELOPMENT	763,974	696,252,320	Y			-	$ 600,551
93	307	1R44MD017174-01	MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	RESEARCH AND DEVELOPMENT	763,974	696,252,320	N	Benten Technologies	1R44MD017174-01	-	$ 27,999
93	307	R000003212	MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	RESEARCH AND DEVELOPMENT	763,974	696,252,320	N	Florida State University	R000003212	-	$ 135,424
66	309	13746193	SURVEYS, STUDIES, INVESTIGATIONS, TRAINING AND SPECIAL PURPOSE ACTIVITIES RELATING TO ENVIRONMENTAL JUSTICE	RESEARCH AND DEVELOPMENT	1,116,667	696,252,320	Y			161,354	$ 1,116,667
93	310	U24OD023382	TRANS-NIH RESEARCH SUPPORT	RESEARCH AND DEVELOPMENT	21,419,400	696,252,320	N	Johns Hopkins University	U24OD023382	-	$ (32,591)
93	310	U24HD107676	TRANS-NIH RESEARCH SUPPORT	RESEARCH AND DEVELOPMENT	21,419,400	696,252,320	Y			264,440	$ 5,306,343
93	310	2006069230	TRANS-NIH RESEARCH SUPPORT	RESEARCH AND DEVELOPMENT	21,419,400	696,252,320	N	Johns Hopkins University	2006069230	-	$ 8,894,478
93	310	1UG30D023275	TRANS-NIH RESEARCH SUPPORT	RESEARCH AND DEVELOPMENT	21,419,400	696,252,320	N	Dartmouth College	1UG30D023275	-	$ 130
93	310	7R03HD106123-02	TRANS-NIH RESEARCH SUPPORT	RESEARCH AND DEVELOPMENT	21,419,400	696,252,320	Y			44,188	$ 87,627
93	310	COVID-19, GR16642	COVID-19 - TRANS-NIH RESEARCH SUPPORT	RESEARCH AND DEVELOPMENT	21,419,400	696,252,320	N	University of Kansas	GR16642	-	$ 224,842
93	310	1OT2OD028395-01	TRANS-NIH RESEARCH SUPPORT	RESEARCH AND DEVELOPMENT	21,419,400	696,252,320	Y			-	$ 5,935,271
93	310	5111326	TRANS-NIH RESEARCH SUPPORT	RESEARCH AND DEVELOPMENT	21,419,400	696,252,320	N	UNC Chapel Hill	5111326	-	$ 1,003,300
93	315	1U01DD00125401-00	RARE DISORDERS: RESEARCH, SURVEILLANCE, HEALTH PROMOTION, AND EDUCATION	RESEARCH AND DEVELOPMENT	767,338	696,252,320	Y			3,793	$ 323,641
93	315	1U01DD001253-01-00	RARE DISORDERS: RESEARCH, SURVEILLANCE, HEALTH PROMOTION, AND EDUCATION	RESEARCH AND DEVELOPMENT	767,338	696,252,320	Y			3,292	$ 74,728
93	315	1U01DD001255-05-00	RARE DISORDERS: RESEARCH, SURVEILLANCE, HEALTH PROMOTION, AND EDUCATION	RESEARCH AND DEVELOPMENT	767,338	696,252,320	Y			21,357	$ 368,969
93	318	COVID-19, 1NU2HGH000019-01-00	COVID-19 - PROTECTING AND IMPROVING HEALTH GLOBALLY: BUILDING AND STRENGTHENING PUBLIC HEALTH IMPACT, SYSTEMS, CAPACITY AND SECURITY	RESEARCH AND DEVELOPMENT	3,790,556	696,252,320	Y			-	$ 127,359
93	318	1NU2HGH000047001	PROTECTING AND IMPROVING HEALTH GLOBALLY: BUILDING AND STRENGTHENING PUBLIC HEALTH IMPACT, SYSTEMS, CAPACITY AND SECURITY	RESEARCH AND DEVELOPMENT	3,790,556	696,252,320	Y			34,624	$ 1,209,112
93	318	COVID-19, 1NU2HGH000047001	COVID-19 - PROTECTING AND IMPROVING HEALTH GLOBALLY: BUILDING AND STRENGTHENING PUBLIC HEALTH IMPACT, SYSTEMS, CAPACITY AND SECURITY	RESEARCH AND DEVELOPMENT	3,790,556	696,252,320	Y			-	$ 13,792
93	318	1 NU50CK000575-01-00	PROTECTING AND IMPROVING HEALTH GLOBALLY: BUILDING AND STRENGTHENING PUBLIC HEALTH IMPACT, SYSTEMS, CAPACITY AND SECURITY	RESEARCH AND DEVELOPMENT	3,790,556	696,252,320	Y			393,014	$ 1,254,350
93	318	COVID-19, 1 NU50CK000575-01-00	COVID-19 - PROTECTING AND IMPROVING HEALTH GLOBALLY: BUILDING AND STRENGTHENING PUBLIC HEALTH IMPACT, SYSTEMS, CAPACITY AND SECURITY	RESEARCH AND DEVELOPMENT	3,790,556	696,252,320	Y			-	$ 807,507

(Continued)

RESEARCH TRIANGLE INSTITUTE
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2024

Federal Assistance		Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity	Amount Passed Through to Subrecipients	Amount Expended
93	318	1 NU2HGH000093-01-00	PROTECTING AND IMPROVING HEALTH GLOBALLY: BUILDING AND STRENGTHENING PUBLIC HEALTH IMPACT, SYSTEMS, CAPACITY AND SECURITY	RESEARCH AND DEVELOPMENT	3,790,556	696,252,320	Y			-	$ 295,101
93	318	COVID-19, 1 NU2HGH000093-01-00	COVID-19 - PROTECTING AND IMPROVING HEALTH GLOBALLY: BUILDING AND STRENGTHENING PUBLIC HEALTH IMPACT, SYSTEMS, CAPACITY AND SECURITY	RESEARCH AND DEVELOPMENT	3,790,556	696,252,320	Y			-	$ 83,335
10	328	2020-70020-32278	NATIONAL FOOD SAFETY TRAINING, EDUCATION, EXTENSION, OUTREACH, AND TECHNICAL ASSISTANCE COMPETITIVE GRANTS PROGRAM	RESEARCH AND DEVELOPMENT	73,763	696,252,320	Y			48,154	$ 73,763
93	347	Effective 8/30/19	TRUSTED EXCHANGE FRAMEWORK AND COMMON AGREEMENT (TEFCA) RECOGNIZED COORDINATING ENTITY (RCE) COOPERATIVE AGREEMENT	RESEARCH AND DEVELOPMENT	-	696,252,320	N	The Sequoia Project	Effective 8/30/19	-	$ -
12	350	N00244-17-2-0001	DEPARTMENT OF DEFENSE HIV/AIDS PREVENTION PROGRAM	RESEARCH AND DEVELOPMENT	3,134,373	696,252,320	Y			-	$ (15)
12	350	RTI-CRA-2020-01	DEPARTMENT OF DEFENSE HIV/AIDS PREVENTION PROGRAM	RESEARCH AND DEVELOPMENT	3,134,373	696,252,320	N	Two Oceans in Health	RTI-CRA-2020-01	-	$ 1,215
12	350	N00244-21-1-0002	DEPARTMENT OF DEFENSE HIV/AIDS PREVENTION PROGRAM	RESEARCH AND DEVELOPMENT	3,134,373	696,252,320	Y			399,721	$ 3,133,173
93	350	1U01TR001792-01	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	RESEARCH AND DEVELOPMENT	192,352	696,252,320	Y			-	$ (75,479)
93	350	MSA-01-01	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	RESEARCH AND DEVELOPMENT	192,352	696,252,320	N	UNC Chapel Hill	MSA-01-01	-	$ 160,465
93	350	1R21TR002402-01A1	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	RESEARCH AND DEVELOPMENT	192,352	696,252,320	Y			-	$ 14,680
93	350	MSA 01-014	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	RESEARCH AND DEVELOPMENT	192,352	696,252,320	N	UNC Chapel Hill	MSA 01-014	-	$ 92,686
12	351	HDTRA-122-1-0019	BASIC SCIENTIFIC RESEARCH - COMBATING WEAPONS OF MASS DESTRUCTION	RESEARCH AND DEVELOPMENT	811,009	696,252,320	Y			-	$ 811,009
93	353	1U24CA232980-1	21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	RESEARCH AND DEVELOPMENT	827,560	696,252,320	Y			24,115	$ 296,063
93	353	1U24CA233218-01	21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	RESEARCH AND DEVELOPMENT	827,560	696,252,320	Y			318,666	$ 531,497
93	361	1(GG017761-02)	NURSING RESEARCH	RESEARCH AND DEVELOPMENT	101,948	696,252,320	N	Columbia University	1(GG017761-02)	-	$ 101,948
93	393	OOS030500-RTI-02	CANCER CAUSE AND PREVENTION RESEARCH	RESEARCH AND DEVELOPMENT	295,072	696,252,320	N	Kaiser Permanente	OOS030500-RTI-02	-	$ 35,125
93	393	1U01CA275054-01	CANCER CAUSE AND PREVENTION RESEARCH	RESEARCH AND DEVELOPMENT	295,072	696,252,320	Y			62,772	$ 65,913
93	393	ZAR00070	CANCER CAUSE AND PREVENTION RESEARCH	RESEARCH AND DEVELOPMENT	295,072	696,252,320	N	University of Kansas	ZAR00070	-	$ 82,910
93	393	64363.2011948.669301	CANCER CAUSE AND PREVENTION RESEARCH	RESEARCH AND DEVELOPMENT	295,072	696,252,320	N	City of Hope	64363.2011948.669301	-	$ 72,294
93	393	1R01CA269472-01A1	CANCER CAUSE AND PREVENTION RESEARCH	RESEARCH AND DEVELOPMENT	295,072	696,252,320	Y			-	$ (44)
93	393	IMP-U01-S001	CANCER CAUSE AND PREVENTION RESEARCH	RESEARCH AND DEVELOPMENT	295,072	696,252,320	N	Implenomics	IMP-U01-S001	-	$ 26,149
93	393	IMP-R01-S001	CANCER CAUSE AND PREVENTION RESEARCH	RESEARCH AND DEVELOPMENT	295,072	696,252,320	N	Implenomics	IMP-R01-S001	-	$ 12,725
93	395	1R21-CA263414-01A1	CANCER TREATMENT RESEARCH	RESEARCH AND DEVELOPMENT	67,742	696,252,320	N	Duke University	1R21-CA263414-01A1	-	$ 67,742
93	396	NCI- RTIU-09-2021	CANCER BIOLOGY RESEARCH	RESEARCH AND DEVELOPMENT	38,954	696,252,320	N	Benten Technologies	NCI- RTIU-09-2021	919	$ 5,146
93	396	303001327	CANCER BIOLOGY RESEARCH	RESEARCH AND DEVELOPMENT	38,954	696,252,320	N	Duke University	303001327	-	$ 33,808
93	397	MSA 01-015	CANCER CENTERS SUPPORT GRANTS	RESEARCH AND DEVELOPMENT	206,387	696,252,320	N	UNC Chapel Hill	MSA 01-015	-	$ 206,387
11	405	A23-0229-S001	COOPERATIVE INSTITUTE (INTER-AGENCY FUNDED ACTIVITIES)	RESEARCH AND DEVELOPMENT	986,710	696,252,320	N	Univ of Alabama Tuscaloos	A23-0229-S001	248,614	$ 915,532
11	405	JJHCMK4NTS3 MA23NW5405005I	COOPERATIVE INSTITUTE (INTER-AGENCY FUNDED ACTIVITIES)	RESEARCH AND DEVELOPMENT	986,710	696,252,320	N	Univ of Alabama Tuscaloos	JJHCMK4NTS3 MA23NW5405005I	-	$ 71,178
84	411	UA 21-0123	INVESTING IN INNOVATION (I3) FUND	RESEARCH AND DEVELOPMENT	166,256	696,252,320	N	Univ of Alaska Fairbanks	UA 21-0123	-	$ 166,256
12	420	W81XWH-15-2-0077	MILITARY MEDICAL RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT	5,759,716	696,252,320	Y			83,213	$ 134,896
12	420	W81XWH1820044	MILITARY MEDICAL RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT	5,759,716	696,252,320	Y			1,786,812	$ 2,405,787
12	420	W81XWH2020011	MILITARY MEDICAL RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT	5,759,716	696,252,320	Y			-	$ 1,085,947
12	420	W81XWH2220081	MILITARY MEDICAL RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT	5,759,716	696,252,320	Y			491,088	$ 1,521,445
12	420	Dtd 4/2/19	MILITARY MEDICAL RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT	5,759,716	696,252,320	N	Nova Southeastern Univ	Dtd 4/2/19	-	$ 318,344
12	420	W81XWH2010847	MILITARY MEDICAL RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT	5,759,716	696,252,320	Y			-	$ 62,430
12	420	SUB00002411	MILITARY MEDICAL RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT	5,759,716	696,252,320	N	University of Florida	SUB00002411	-	$ 20,637
12	420	RI0543	MILITARY MEDICAL RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT	5,759,716	696,252,320	N	Roskamp Institute	RI0543	-	$ 19,736
12	420	CPZEN-D-1_RTI	MILITARY MEDICAL RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT	5,759,716	696,252,320	N	PAI Life Sciences, Inc.	CPZEN-D-1_RTI	(72)	$ 175,520
12	420	PC210478W81XWH-22-1-0698	MILITARY MEDICAL RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT	5,759,716	696,252,320	N	Duke University	PC210478W81XWH-22-1-0698	-	$ 4,243
12	420	HT94252410947	MILITARY MEDICAL RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT	5,759,716	696,252,320	Y			-	$ 10,731
93	421	220341	STRENGTHENING PUBLIC HEALTH SYSTEMS AND SERVICES THROUGH NATIONAL PARTNERSHIPS TO IMPROVE AND PROTECT THE NATION’S HEALTH	RESEARCH AND DEVELOPMENT	1,045	696,252,320	N	Natl Assoc Chronic Dis	220341	-	$ 1,045
11	432	A22-0309-S001	NATIONAL OCEANIC AND ATMOSPHERIC ADMINISTRATION (NOAA) COOPERATIVE INSTITUTES	RESEARCH AND DEVELOPMENT	2,793,239	696,252,320	N	Univ of Alabama Tuscaloos	A22-0309-S001	-	$ 525,753
11	432	A22-0311-S001	NATIONAL OCEANIC AND ATMOSPHERIC ADMINISTRATION (NOAA) COOPERATIVE INSTITUTES	RESEARCH AND DEVELOPMENT	2,793,239	696,252,320	N	Univ of Alabama Tuscaloos	A22-0311-S001	-	$ 958,234
11	432	A22-0304-S001	NATIONAL OCEANIC AND ATMOSPHERIC ADMINISTRATION (NOAA) COOPERATIVE INSTITUTES	RESEARCH AND DEVELOPMENT	2,793,239	696,252,320	N	Univ of Alabama Tuscaloos	A22-0304-S001	-	$ 172,086
11	432	A23-0228-S001	NATIONAL OCEANIC AND ATMOSPHERIC ADMINISTRATION (NOAA) COOPERATIVE INSTITUTES	RESEARCH AND DEVELOPMENT	2,793,239	696,252,320	N	Univ of Alabama Tuscaloos	A23-0228-S001	-	$ 494,639
11	432	JJHCMK4NTS3	NATIONAL OCEANIC AND ATMOSPHERIC ADMINISTRATION (NOAA) COOPERATIVE INSTITUTES	RESEARCH AND DEVELOPMENT	2,793,239	696,252,320	N	Univ of Alabama Tuscaloos	JJHCMK4NTS3	-	$ 316,895
11	432	A23-0274-S001	NATIONAL OCEANIC AND ATMOSPHERIC ADMINISTRATION (NOAA) COOPERATIVE INSTITUTES	RESEARCH AND DEVELOPMENT	2,793,239	696,252,320	N	Univ of Alabama Tuscaloos	A23-0274-S001	-	$ 5,604
11	432	A23-0252-S003	NATIONAL OCEANIC AND ATMOSPHERIC ADMINISTRATION (NOAA) COOPERATIVE INSTITUTES	RESEARCH AND DEVELOPMENT	2,793,239	696,252,320	N	Univ of Alabama Tuscaloos	A23-0252-S003	-	$ 119,362
11	432	JJHCMK4NTS3 A23-0255-5001	NATIONAL OCEANIC AND ATMOSPHERIC ADMINISTRATION (NOAA) COOPERATIVE INSTITUTES	RESEARCH AND DEVELOPMENT	2,793,239	696,252,320	N	Univ of Alabama Tuscaloos	JJHCMK4NTS3 A23-0255-5001	-	$ 1,601
11	432	A23-0256-S002-A01 TO 11	NATIONAL OCEANIC AND ATMOSPHERIC ADMINISTRATION (NOAA) COOPERATIVE INSTITUTES	RESEARCH AND DEVELOPMENT	2,793,239	696,252,320	N	Univ of Alabama Tuscaloos	A23-0256-S002-A01 TO 11	-	$ 30,177

(Continued)

RESEARCH TRIANGLE INSTITUTE
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2024

Federal Assistance		Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity	Amount Passed Through to Subrecipients	Amount Expended
11	432	A23-0245-S002	NATIONAL OCEANIC AND ATMOSPHERIC ADMINISTRATION (NOAA) COOPERATIVE INSTITUTES	RESEARCH AND DEVELOPMENT	2,793,239	696,252,320	N	Univ of Alabama Tuscaloos	A23-0245-S002	-	$ 56,063
11	432	A23-0262-S003	NATIONAL OCEANIC AND ATMOSPHERIC ADMINISTRATION (NOAA) COOPERATIVE INSTITUTES	RESEARCH AND DEVELOPMENT	2,793,239	696,252,320	N	Univ of Alabama Tuscaloos	A23-0262-S003	-	$ 112,825
93	433	SUB00000230	ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION	RESEARCH AND DEVELOPMENT	143,540	696,252,320	N	Univ of Massachusetts Med	SUB00000230	-	$ 49,426
93	433	Agreement dated 8/24/20	ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION	RESEARCH AND DEVELOPMENT	143,540	696,252,320	N	Shirley Ryan Ability Lab	Agreement dated 8/24/20	-	$ 94,114
93	441	C21-127	INDIAN SELF-DETERMINATION	RESEARCH AND DEVELOPMENT	20,822	696,252,320	N	NPAIHB	C21-127	-	$ 20,822
66	461	2020-0284-02	REGIONAL WETLAND PROGRAM DEVELOPMENT GRANTS	RESEARCH AND DEVELOPMENT	51,430	696,252,320	N	North Carolina State Univ	2020-0284-02	-	$ 51,430
66	509	84022101	SCIENCE TO ACHIEVE RESULTS (STAR) RESEARCH PROGRAM	RESEARCH AND DEVELOPMENT	780,179	696,252,320	Y			49,878	$ 432,001
66	509	62680918-211633	SCIENCE TO ACHIEVE RESULTS (STAR) RESEARCH PROGRAM	RESEARCH AND DEVELOPMENT	780,179	696,252,320	N	Stanford University	62680918-211633	-	$ 33,985
66	509	84056501	SCIENCE TO ACHIEVE RESULTS (STAR) RESEARCH PROGRAM	RESEARCH AND DEVELOPMENT	780,179	696,252,320	Y			76,109	$ 299,196
66	509	5128082	SCIENCE TO ACHIEVE RESULTS (STAR) RESEARCH PROGRAM	RESEARCH AND DEVELOPMENT	780,179	696,252,320	N	UNC Chapel Hill	5128082	-	$ 14,997
66	511	PAM-P23-003086-SA02	OFFICE OF RESEARCH AND DEVELOPMENT CONSOLIDATED	RESEARCH AND DEVELOPMENT	227,295	696,252,320	N	North Carolina State Univ	PAM-P23-003086-SA02	-	$ 227,295
16	526	15JOVW-23-GK-05479-STOP	OVW TECHNICAL ASSISTANCE INITIATIVE	RESEARCH AND DEVELOPMENT	122,517	696,252,320	Y			5,879	$ 93,459
16	526	RTI	OVW TECHNICAL ASSISTANCE INITIATIVE	RESEARCH AND DEVELOPMENT	122,517	696,252,320	N	The Network	RTI	-	$ 29,058
10	557	103097-00001	SPECIAL SUPPLEMENTAL NUTRITION PROGRAM FOR WOMEN, INFANTS, AND CHILDREN	RESEARCH AND DEVELOPMENT	325,742	696,252,320	N	Tufts University	103097-00001	-	$ 325,742
12	560	W911NF1920007	DOD, NDEP, DOTC-STEM EDUCATION OUTREACH IMPLEMENTATION	RESEARCH AND DEVELOPMENT	19,305,257	696,252,320	Y			9,946,000	$ 19,305,257
15	560	R24AC00055	SECURE WATER ACT Ð RESEARCH AGREEMENTS	RESEARCH AND DEVELOPMENT	124,291	696,252,320	Y			-	$ 28,355
15	560	R22AC00175-00	SECURE WATER ACT Ð RESEARCH AGREEMENTS	RESEARCH AND DEVELOPMENT	124,291	696,252,320	Y			-	$ 60,404
15	560	R23AP00492-00	SECURE WATER ACT Ð RESEARCH AGREEMENTS	RESEARCH AND DEVELOPMENT	124,291	696,252,320	Y			-	$ 5,934
15	560	R24AC00056-00	SECURE WATER ACT Ð RESEARCH AGREEMENTS	RESEARCH AND DEVELOPMENT	124,291	696,252,320	Y			-	$ 29,598
16	560	2018-75-CX-K003	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	Y			473,741	$ 2,140,754
16	560	2019-MU-MU-K026	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	Y			-	$ 8,130
16	560	Agrmt signed 9/9/21	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	N	Police Foundation	Agrmt signed 9/9/21	-	$ 50,161
16	560	15PNIJ-21-GK-02192-MUMU	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	Y			188,370	$ 3,535,920
16	560	15PNIJ-23-GK-00931-NIJB	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	Y			8,286	$ 2,397,341
16	560	2016-CK-BX-0011	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	Y			-	$ (2)
16	560	2017-CK-BX-0015	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	Y			-	$ (93)
16	560	2018-75-CX-0018	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	Y			-	$ 141,456
16	560	2018-MU-MU-0033	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	Y			-	$ 241,443
16	560	9920190047	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	N	Rand Corporation	9920190047	-	$ 106,288
16	560	2019-R2-CX-0017	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	Y			-	$ 32,836
16	560	2019-75-CX-0008	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	Y			253,527	$ 1,915,535
16	560	2019-75-CX-0012	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	Y			13,539	$ 112,450
16	560	2019-R2-CX-0027	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	Y			51,550	$ 198,231
16	560	2019-R2-CX-0023	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	Y			-	$ 303,558
16	560	2019-R2-CX-0053	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	Y			37,857	$ 142,922
16	560	2019-MU-CX-0068	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	Y			-	$ (1)
16	560	2020-R2-CX-0027	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	Y			1,577	$ 283,447
16	560	2020-V3-GX-0073	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	Y			1,057	$ 58,071
16	560	2020-75-CX-0010	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	Y			26,188	$ 118,613
16	560	2020-DQ-BX-0016	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	Y			-	$ 41,808
16	560	2020-V3-GX-0074	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	Y			14,941	$ 134,974
16	560	P008619003	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	N	University of Minnesota	P008619003	-	$ (466)
16	560	504633-78050	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	N	Northeastern University	504633-78050	-	$ 55,307
16	560	15PNIJ-21-GG-02721-DOMR	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT GRANTS	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	Y			25,644	$ 249,860
16	560	15PNIJ-21-GG-04176-COAP	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT GRANTS	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	Y			-	$ 64,667
16	560	15PNIJ-21-GG-00997-NONF	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT GRANTS	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	Y			-	$ 146,594
16	560	15PNIJ-21-GG-00140-NIJB	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT GRANTS	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	Y			76,659	$ 505,403
16	560	15PNIJ-22-GG-03146-RESS	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT GRANTS	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	Y			18,923	$ 445,761
16	560	15PNIJ-22-GG-04404-SLFO	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT GRANTS	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	Y			67,496	$ 88,441
16	560	15PNIJ-22-GG-04394-RESS	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT GRANTS	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	Y			-	$ 22,487
16	560	15PNIJ-22-GG-03575-RESS	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT GRANTS	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	Y			-	$ 150,488
16	560	15PNIJ-23-GG-01383-DOMR	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT GRANTS	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	Y			-	$ 80,134
16	560	15PNIJ-23-GG-01419-RESS	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT GRANTS	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	Y			-	$ 13,051
16	560	15PNIJ-23-GG-04210-SLFO	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT GRANTS	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	Y			-	$ 2,247
16	560	F2426-03	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT GRANTS	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	N	New York University	F2426-03	-	$ 7,447
16	560	15PNIJ-23-GG-06103-RESS	NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT GRANTS	RESEARCH AND DEVELOPMENT	13,817,312	696,252,320	Y			-	$ 22,049
16	582	2019-V3-GX-K141	CRIME VICTIM ASSISTANCE/DISCRETIONARY GRANTS	RESEARCH AND DEVELOPMENT	1,350,974	696,252,320	Y			-	$ (682)
16	582	2020-V3-GX-K010	CRIME VICTIM ASSISTANCE/DISCRETIONARY GRANTS	RESEARCH AND DEVELOPMENT	1,350,974	696,252,320	Y			14,598	$ 288,332
16	582	15POVC-21-GK-00654-NONF	CRIME VICTIM ASSISTANCE/DISCRETIONARY GRANTS	RESEARCH AND DEVELOPMENT	1,350,974	696,252,320	Y			50,187	$ 319,077
16	582	15POVC-22-GK-04503-NONF	CRIME VICTIM ASSISTANCE/DISCRETIONARY GRANTS	RESEARCH AND DEVELOPMENT	1,350,974	696,252,320	Y			132,553	$ 716,369

(Continued)

RESEARCH TRIANGLE INSTITUTE
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2024

Federal Assistance		Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity	Amount Passed Through to Subrecipients	Amount Expended
16	582	2020-V3-GX-0045	CRIME VICTIM ASSISTANCE/DISCRETIONARY GRANTS	RESEARCH AND DEVELOPMENT	1,350,974	696,252,320	Y			118	$ 121
16	582	15PNIJ-23-GG-01929-NONF	CRIME VICTIM ASSISTANCE/DISCRETIONARY GRANTS	RESEARCH AND DEVELOPMENT	1,350,974	696,252,320	Y			-	$ 26,659
16	582	15POVC-23-GK-02770-NONF	CRIME VICTIM ASSISTANCE/DISCRETIONARY GRANTS	RESEARCH AND DEVELOPMENT	1,350,974	696,252,320	N	Natl Crime Victim Law Ins	15POVC-23-GK-02770-NONF	-	$ 1,098
12	600	Master Agreement 01-01A	COMMUNITY INVESTMENT	RESEARCH AND DEVELOPMENT	123,469	696,252,320	N	NCSU Industry Expansion	Master Agreement 01-01A	-	$ 123,469
11	609	70NANB21H098	MEASUREMENT AND ENGINEERING RESEARCH AND STANDARDS	RESEARCH AND DEVELOPMENT	216,295	696,252,320	Y			-	$ 61,912
11	609	70NANB22H019	MEASUREMENT AND ENGINEERING RESEARCH AND STANDARDS	RESEARCH AND DEVELOPMENT	216,295	696,252,320	Y			-	$ 1,715
11	609	70NANB23h175	MEASUREMENT AND ENGINEERING RESEARCH AND STANDARDS	RESEARCH AND DEVELOPMENT	216,295	696,252,320	Y			-	$ 139,966
11	609	70NANB24H237	MEASUREMENT AND ENGINEERING RESEARCH AND STANDARDS	RESEARCH AND DEVELOPMENT	216,295	696,252,320	Y			-	$ 12,702
66	615	84084101	EPA EJ TCGM Award	RESEARCH AND DEVELOPMENT	1,341,042	696,252,320	Y			-	$ 1,341,042
11	620	70NANB21H023	SCIENCE, TECHNOLOGY, BUSINESS AND/OR EDUCATION OUTREACH	RESEARCH AND DEVELOPMENT	603	696,252,320	Y			-	$ 603
19	704	SINLEC23CA0176	COUNTER NARCOTICS	RESEARCH AND DEVELOPMENT	1,024,158	696,252,320	Y			-	$ 1,031,396
19	704	S-INLEC18CA2073	COUNTER NARCOTICS	RESEARCH AND DEVELOPMENT	1,024,158	696,252,320	Y			-	$ (7,238)
16	710	2017CKWXK009	PUBLIC SAFETY PARTNERSHIP AND COMMUNITY POLICING GRANTS	RESEARCH AND DEVELOPMENT	19,292	696,252,320	Y			1,536	$ 1,562
16	710	202262786-00	PUBLIC SAFETY PARTNERSHIP AND COMMUNITY POLICING GRANTS	RESEARCH AND DEVELOPMENT	19,292	696,252,320	N	CO Denver Police Dept	202262786-00	-	$ 17,730
16	734	2017-BJ-CX-K054	SPECIAL DATA COLLECTIONS AND STATISTICAL STUDIES	RESEARCH AND DEVELOPMENT	7,669,169	696,252,320	Y			-	$ (43)
16	734	2018-85-CX-K030	SPECIAL DATA COLLECTIONS AND STATISTICAL STUDIES	RESEARCH AND DEVELOPMENT	7,669,169	696,252,320	Y			-	$ 102,421
16	734	2018-85-CX-K041	SPECIAL DATA COLLECTIONS AND STATISTICAL STUDIES	RESEARCH AND DEVELOPMENT	7,669,169	696,252,320	Y			-	$ 332,413
16	734	2019-85-CX-K006	SPECIAL DATA COLLECTIONS AND STATISTICAL STUDIES	RESEARCH AND DEVELOPMENT	7,669,169	696,252,320	Y			-	$ 5
16	734	2019-85-CX-K005	SPECIAL DATA COLLECTIONS AND STATISTICAL STUDIES	RESEARCH AND DEVELOPMENT	7,669,169	696,252,320	Y			-	$ 30,982
16	734	2020-85-CX-K010	SPECIAL DATA COLLECTIONS AND STATISTICAL STUDIES	RESEARCH AND DEVELOPMENT	7,669,169	696,252,320	Y			-	$ 559,383
16	734	2020-85-CX-K002	SPECIAL DATA COLLECTIONS AND STATISTICAL STUDIES	RESEARCH AND DEVELOPMENT	7,669,169	696,252,320	Y			227,066	$ 935,611
16	734	15PBJS-21-GK-00005-BJSB	SPECIAL DATA COLLECTIONS AND STATISTICAL STUDIES	RESEARCH AND DEVELOPMENT	7,669,169	696,252,320	Y			2,966	$ 124,854
16	734	15PBJS-22-GK-00476-BJSB	SPECIAL DATA COLLECTIONS AND STATISTICAL STUDIES	RESEARCH AND DEVELOPMENT	7,669,169	696,252,320	Y			-	$ 363,013
16	734	15PBJS-22-GK-00267-MUMU	SPECIAL DATA COLLECTIONS AND STATISTICAL STUDIES	RESEARCH AND DEVELOPMENT	7,669,169	696,252,320	Y			-	$ 457,073
16	734	15PBJS-22-GK-00713-BJSB	SPECIAL DATA COLLECTIONS AND STATISTICAL STUDIES	RESEARCH AND DEVELOPMENT	7,669,169	696,252,320	Y			-	$ 2,404,690
16	734	15PBJS-22-GK-04504-BJSB	SPECIAL DATA COLLECTIONS AND STATISTICAL STUDIES	RESEARCH AND DEVELOPMENT	7,669,169	696,252,320	Y			13,250	$ 315,530
16	734	15PBJS-23-GK-00835-BJSB	SPECIAL DATA COLLECTIONS AND STATISTICAL STUDIES	RESEARCH AND DEVELOPMENT	7,669,169	696,252,320	Y			-	$ 397,131
16	734	15PBJS-23-GK-00836-BJSB	SPECIAL DATA COLLECTIONS AND STATISTICAL STUDIES	RESEARCH AND DEVELOPMENT	7,669,169	696,252,320	Y			-	$ 201,810
16	734	15PBJS-23-GK-01943-BJSB	SPECIAL DATA COLLECTIONS AND STATISTICAL STUDIES	RESEARCH AND DEVELOPMENT	7,669,169	696,252,320	Y			2,590	$ 389,627
16	734	15PBJS-23-GK-05680-MUMU	SPECIAL DATA COLLECTIONS AND STATISTICAL STUDIES	RESEARCH AND DEVELOPMENT	7,669,169	696,252,320	Y			-	$ 347,937
16	734	15PBJS-23-GK-02626-CAMP	SPECIAL DATA COLLECTIONS AND STATISTICAL STUDIES	RESEARCH AND DEVELOPMENT	7,669,169	696,252,320	Y			-	$ 184,379
16	734	15PBJS-23-GK-05394-BJSB	SPECIAL DATA COLLECTIONS AND STATISTICAL STUDIES	RESEARCH AND DEVELOPMENT	7,669,169	696,252,320	Y			-	$ 522,353
16	738	15PBJA-21-GK-04008-JAGP	EDWARD BYRNE MEMORIAL JUSTICE ASSISTANCE GRANT PROGRAM	RESEARCH AND DEVELOPMENT	3,362,505	696,252,320	Y			14,351	$ 605,795
16	738	15PBJA-22-GK-01556-JAGT	EDWARD BYRNE MEMORIAL JUSTICE ASSISTANCE GRANT PROGRAM	RESEARCH AND DEVELOPMENT	3,362,505	696,252,320	Y			-	$ 1,491,679
16	738	15PBJA-22-GK-03701-JAGT	EDWARD BYRNE MEMORIAL JUSTICE ASSISTANCE GRANT PROGRAM	RESEARCH AND DEVELOPMENT	3,362,505	696,252,320	Y			125,100	$ 822,565
16	738	15PBJA-23-GK-05520-VIRT	EDWARD BYRNE MEMORIAL JUSTICE ASSISTANCE GRANT PROGRAM	RESEARCH AND DEVELOPMENT	3,362,505	696,252,320	Y			-	$ 76,662
16	738	2100-SUB-002	EDWARD BYRNE MEMORIAL JUSTICE ASSISTANCE GRANT PROGRAM	RESEARCH AND DEVELOPMENT	3,362,505	696,252,320	N	AEquitas	2100-SUB-002	-	$ 27,902
16	738	Agreement dated 1/31/20	EDWARD BYRNE MEMORIAL JUSTICE ASSISTANCE GRANT PROGRAM	RESEARCH AND DEVELOPMENT	3,362,505	696,252,320	N	Nat Assoc of Crim Def Law	Agreement dated 1/31/20	-	$ 279,903
16	738	15PNIJ-23-GG-02404-BSCI	EDWARD BYRNE MEMORIAL JUSTICE ASSISTANCE GRANT PROGRAM	RESEARCH AND DEVELOPMENT	3,362,505	696,252,320	Y			356	$ 57,999
16	739	2017-RP-BX-K053	NATIONAL PRISON RAPE STATISTICS PROGRAM	RESEARCH AND DEVELOPMENT	3,378,200	696,252,320	Y			-	$ 3,378,200
16	745	Agreement effective 8/17/2022	CRIMINAL AND JUVENILE JUSTICE AND MENTAL HEALTH COLLABORATION PROGRAM	RESEARCH AND DEVELOPMENT	50,845	696,252,320	N	LA Lafayette Parish	Agreement effective 8/17/2022	-	$ 50,845
16	746	Agreement 12/05/2022	CAPITAL CASE LITIGATION INITIATIVE	RESEARCH AND DEVELOPMENT	66,244	696,252,320	N	Nat Assoc of Crim Def Law	Agreement 12/05/2022	-	$ 66,244
12	800	6267/66741/1073289	AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	RESEARCH AND DEVELOPMENT	183,119	696,252,320	N	Henry M. Jackson Found	6267/66741/1073289	-	$ 183,119
15	808	G23AC00421-00	U.S. GEOLOGICAL SURVEY_ RESEARCH AND DATA COLLECTION	RESEARCH AND DEVELOPMENT	90,470	696,252,320	Y			-	$ 90,470
66	808	96214823	SOLID WASTE MANAGEMENT ASSISTANCE GRANTS	RESEARCH AND DEVELOPMENT	3,319	696,252,320	Y			-	$ 3,319
16	812	2019-MU-BX-K041	SECOND CHANCE ACT REENTRY INITIATIVE	RESEARCH AND DEVELOPMENT	617,047	696,252,320	Y			77,390	$ 478,588
16	812	Q22757246	SECOND CHANCE ACT REENTRY INITIATIVE	RESEARCH AND DEVELOPMENT	617,047	696,252,320	N	NC Dept of Public Safety	Q22757246	-	$ 66,397
16	812	2020-CZ-BX-K003	SECOND CHANCE ACT REENTRY INITIATIVE	RESEARCH AND DEVELOPMENT	617,047	696,252,320	N	VERA Institute of Justice	2020-CZ-BX-K003	-	$ 16,959
16	812	15PNIJ-23-GG-02232-SCAX	SECOND CHANCE ACT REENTRY INITIATIVE	RESEARCH AND DEVELOPMENT	617,047	696,252,320	Y			1,795	$ 55,103
16	825	IPS20-003	SMART PROSECUTION INITIATIVE	RESEARCH AND DEVELOPMENT	36,660	696,252,320	N	AEquitas	IPS20-003	-	$ 36,660
16	827	EP5272922	JUSTICE REINVESTMENT INITIATIVE	RESEARCH AND DEVELOPMENT	169,910	696,252,320	N	NCDACJJ	EP5272922	-	$ 169,910
16	833	2019-MU-BX-K011	NATIONAL SEXUAL ASSAULT KIT INITIATIVE	RESEARCH AND DEVELOPMENT	3,371,508	696,252,320	Y			512,408	$ 3,362,678
16	833	15PBJA-23-GK-02259-SAKI	NATIONAL SEXUAL ASSAULT KIT INITIATIVE	RESEARCH AND DEVELOPMENT	3,371,508	696,252,320	Y			-	$ 8,830
93	837	1U01HL145358-01A1	CARDIOVASCULAR DISEASES RESEARCH	RESEARCH AND DEVELOPMENT	3,631,083	696,252,320	Y			921,938	$ 2,690,574
93	837	1U24HL166580-01A1	CARDIOVASCULAR DISEASES RESEARCH	RESEARCH AND DEVELOPMENT	3,631,083	696,252,320	Y			-	$ 101,093
93	837	1U54HL178351-01	CARDIOVASCULAR DISEASES RESEARCH	RESEARCH AND DEVELOPMENT	3,631,083	696,252,320	Y			-	$ 4,124
93	837	1R01HL149352-01	CARDIOVASCULAR DISEASES RESEARCH	RESEARCH AND DEVELOPMENT	3,631,083	696,252,320	Y			541,677	$ 773,674
93	837	60060791 RTI	CARDIOVASCULAR DISEASES RESEARCH	RESEARCH AND DEVELOPMENT	3,631,083	696,252,320	N	Northwestern University	60060791 RTI	-	$ 14,841
93	837	MM000442393	CARDIOVASCULAR DISEASES RESEARCH	RESEARCH AND DEVELOPMENT	3,631,083	696,252,320	N	West Virginia University	MM000442393	-	$ 9,917
93	837	5127422	CARDIOVASCULAR DISEASES RESEARCH	RESEARCH AND DEVELOPMENT	3,631,083	696,252,320	N	UNC Chapel Hill	5127422	-	$ 11,147
93	837	SUBK 00020158	CARDIOVASCULAR DISEASES RESEARCH	RESEARCH AND DEVELOPMENT	3,631,083	696,252,320	N	University of Michigan	SUBK 00020158	-	$ 25,713
16	838	2019-AR-BX-K053	COMPREHENSIVE OPIOID ABUSE SITE-BASED PROGRAM	RESEARCH AND DEVELOPMENT	1,495,318	696,252,320	Y			61,560	$ 444,411
16	838	15PBJA-23-GK-02253-COAP	COMPREHENSIVE OPIOID ABUSE SITE-BASED PROGRAM	RESEARCH AND DEVELOPMENT	1,495,318	696,252,320	Y			69,191	$ 348,524
16	838	15PBJA-23-GK-02250-COAP	COMPREHENSIVE OPIOID ABUSE SITE-BASED PROGRAM	RESEARCH AND DEVELOPMENT	1,495,318	696,252,320	Y			10,381	$ 702,383
93	838	1U24HL137729-01	LUNG DISEASES RESEARCH	RESEARCH AND DEVELOPMENT	93,845,613	696,252,320	Y			-	$ 167,575
93	838	311013	LUNG DISEASES RESEARCH	RESEARCH AND DEVELOPMENT	93,845,613	696,252,320	N	Cincinnati Children's Hos	311013	-	$ 92,462

(Continued)

RESEARCH TRIANGLE INSTITUTE
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2024

Federal Assistance		Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity	Amount Passed Through to Subrecipients	Amount Expended
93	838	OS00000468/400492	LUNG DISEASES RESEARCH	RESEARCH AND DEVELOPMENT	93,845,613	696,252,320	N	Cincinnati Children's Hos	OS00000468/400492	-	$ 57,986
93	838	COVID-19, 1OT2HL156812-01	COVID-19 - LUNG DISEASES RESEARCH	RESEARCH AND DEVELOPMENT	93,845,613	696,252,320	Y			-	$ 93,142,811
93	838	OT2HL161841	LUNG DISEASES RESEARCH	RESEARCH AND DEVELOPMENT	93,845,613	696,252,320	N	UNC Chapel Hill	OT2HL161841	-	$ 129,655
93	838	FY23.1126.039	LUNG DISEASES RESEARCH	RESEARCH AND DEVELOPMENT	93,845,613	696,252,320	N	Univ of Colorado Denver	FY23.1126.039	-	$ 255,124
16	839	2020-YS-BX-0107	STOP SCHOOL VIOLENCE	RESEARCH AND DEVELOPMENT	869,758	696,252,320	Y			-	$ 205,408
16	839	order no 40-PR12013511	STOP SCHOOL VIOLENCE	RESEARCH AND DEVELOPMENT	869,758	696,252,320	N	NC Dept of Public Instruc	order no 40-PR12013511	13,000	$ 441,753
16	839	15PBJA-23-GG-04343-STOP	STOP SCHOOL VIOLENCE	RESEARCH AND DEVELOPMENT	869,758	696,252,320	Y			52,430	$ 96,236
16	839	Agreement effective 5/1/21	STOP SCHOOL VIOLENCE	RESEARCH AND DEVELOPMENT	869,758	696,252,320	N	NC Ashe County Schools	Agreement effective 5/1/21	-	$ 15,485
16	839	Agreement 1/13/2022	STOP SCHOOL VIOLENCE	RESEARCH AND DEVELOPMENT	869,758	696,252,320	N	NKCES	Agreement 1/13/2022	-	$ 110,876
93	839	1U24HL133948-01	BLOOD DISEASES AND RESOURCES RESEARCH	RESEARCH AND DEVELOPMENT	3,381,212	696,252,320	Y			-	$ 75,904
93	839	1U01HL136306-01	BLOOD DISEASES AND RESOURCES RESEARCH	RESEARCH AND DEVELOPMENT	3,381,212	696,252,320	Y			-	$ 199,149
93	839	1U24HL143216-01	BLOOD DISEASES AND RESOURCES RESEARCH	RESEARCH AND DEVELOPMENT	3,381,212	696,252,320	Y			-	$ 114,413
93	839	1U24HL140090-01A1	BLOOD DISEASES AND RESOURCES RESEARCH	RESEARCH AND DEVELOPMENT	3,381,212	696,252,320	Y			-	$ 246,709
93	839	UWSC14208	BLOOD DISEASES AND RESOURCES RESEARCH	RESEARCH AND DEVELOPMENT	3,381,212	696,252,320	N	University of Washington	UWSC14208	-	$ 996,023
93	839	1024HL173304-01	BLOOD DISEASES AND RESOURCES RESEARCH	RESEARCH AND DEVELOPMENT	3,381,212	696,252,320	Y			-	$ 87,618
93	839	1001432-RTI	BLOOD DISEASES AND RESOURCES RESEARCH	RESEARCH AND DEVELOPMENT	3,381,212	696,252,320	N	Versiti Blood Center WI	1001432-RTI	-	$ 65,557
93	839	000532950-SC006	BLOOD DISEASES AND RESOURCES RESEARCH	RESEARCH AND DEVELOPMENT	3,381,212	696,252,320	N	Univ Alabama Birmingham	000532950-SC006	-	$ 152,736
93	839	37309-2	BLOOD DISEASES AND RESOURCES RESEARCH	RESEARCH AND DEVELOPMENT	3,381,212	696,252,320	N	Augusta University	37309-2	-	$ 2,496
93	839	1R01HL166254-01A1	BLOOD DISEASES AND RESOURCES RESEARCH	RESEARCH AND DEVELOPMENT	3,381,212	696,252,320	Y			690,090	$ 1,124,827
93	839	0255-G812-4609	BLOOD DISEASES AND RESOURCES RESEARCH	RESEARCH AND DEVELOPMENT	3,381,212	696,252,320	N	Mount Sinai Hospital	0255-G812-4609	-	$ 297,615
93	839	11934RTI170	BLOOD DISEASES AND RESOURCES RESEARCH	RESEARCH AND DEVELOPMENT	3,381,212	696,252,320	N	Vitalant Research Institu	11934RTI170	-	$ 18,165
93	845	1 NU58DP006975-01-00	PROMOTING POPULATION HEALTH THROUGH INCREASED CAPACITY IN ALCOHOL EPIDEMIOLOGY	RESEARCH AND DEVELOPMENT	156,092	696,252,320	Y			-	$ 156,092
93	847	1U24DK130043-01	DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	RESEARCH AND DEVELOPMENT	2,379,177	696,252,320	Y			84,305	$ 1,071,141
93	847	RTI-318040	DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	RESEARCH AND DEVELOPMENT	2,379,177	696,252,320	N	Mayo Clinic Rochester	RTI-318040	-	$ 316,970
93	847	1R01DK103625-01A1	DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	RESEARCH AND DEVELOPMENT	2,379,177	696,252,320	Y			-	$ 390,036
93	847	1R01DK124615-01	DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	RESEARCH AND DEVELOPMENT	2,379,177	696,252,320	Y			-	$ 201,404
93	847	00002138	DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	RESEARCH AND DEVELOPMENT	2,379,177	696,252,320	N	Brown University	00002138	-	$ 92,503
93	847	P010515501	DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	RESEARCH AND DEVELOPMENT	2,379,177	696,252,320	N	University of Minnesota	P010515501	-	$ 266,822
93	847	5129521	DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	RESEARCH AND DEVELOPMENT	2,379,177	696,252,320	N	UNC Chapel Hill	5129521	-	$ 40,301
93	853	1U24NS105535-01	EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	RESEARCH AND DEVELOPMENT	3,670,175	696,252,320	Y			-	$ 878,245
93	853	1R03NS123731-01	EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	RESEARCH AND DEVELOPMENT	3,670,175	696,252,320	Y			4,141	$ 42,241
93	853	1GG017542-01	EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	RESEARCH AND DEVELOPMENT	3,670,175	696,252,320	N	Columbia University	1GG017542-01	-	$ 26,382
93	853	1R61NS131188-01	EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	RESEARCH AND DEVELOPMENT	3,670,175	696,252,320	Y			258,444	$ 600,944
93	853	303002848	EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	RESEARCH AND DEVELOPMENT	3,670,175	696,252,320	N	Duke University	303002848	-	$ 400,985
93	853	1OT2OD031940	EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	RESEARCH AND DEVELOPMENT	3,670,175	696,252,320	N	UNC Chapel Hill	1OT2OD031940	-	$ 1,645,430
93	853	19012999	EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	RESEARCH AND DEVELOPMENT	3,670,175	696,252,320	N	Translational Sciences	19012999	-	$ 75,948
93	855	U01AI168477	ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	RESEARCH AND DEVELOPMENT	7,938,862	696,252,320	Y			4,000	$ 158,873
93	855	303003475	ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	RESEARCH AND DEVELOPMENT	7,938,862	696,252,320	N	Duke University	303003475	-	$ 4,842
93	855	5P30AI050410-25	ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	RESEARCH AND DEVELOPMENT	7,938,862	696,252,320	N	UNC Chapel Hill	5P30AI050410-25	-	$ 127,336
93	855	See Tasks	ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	RESEARCH AND DEVELOPMENT	7,938,862	696,252,320	N	Magee-Womens Research	See Tasks	-	$ 41,239
93	855	1R01AI141082-01	ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	RESEARCH AND DEVELOPMENT	7,938,862	696,252,320	Y			6,600	$ 920,094
93	855	548UY	ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	RESEARCH AND DEVELOPMENT	7,938,862	696,252,320	N	UNC Chapel Hill	548UY	-	$ 15,266
93	855	62147077-117727	ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	RESEARCH AND DEVELOPMENT	7,938,862	696,252,320	N	Stanford University	62147077-117727	-	$ 20,862
93	855	1R01AI152713-01	ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	RESEARCH AND DEVELOPMENT	7,938,862	696,252,320	Y			260,638	$ 583,422
93	855	R33AI149499	ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	RESEARCH AND DEVELOPMENT	7,938,862	696,252,320	Y			622,894	$ 1,171,750
93	855	1U01AI151378-01	ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	RESEARCH AND DEVELOPMENT	7,938,862	696,252,320	Y			1,638,816	$ 3,055,935
93	855	1R01AI154549	ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	RESEARCH AND DEVELOPMENT	7,938,862	696,252,320	Y			338,103	$ 934,455
93	855	MSA01-01 0214043	ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	RESEARCH AND DEVELOPMENT	7,938,862	696,252,320	N	UNC Chapel Hill	MSA01-01 0214043	-	$ 9,720
93	855	5121838	ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	RESEARCH AND DEVELOPMENT	7,938,862	696,252,320	N	UNC Chapel Hill	5121838	-	$ (60)
93	855	G-03441-02	ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	RESEARCH AND DEVELOPMENT	7,938,862	696,252,320	N	Colorado State University	G-03441-02	-	$ 147,633
93	855	5122853	ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	RESEARCH AND DEVELOPMENT	7,938,862	696,252,320	N	UNC Chapel Hill	5122853	-	$ 165,947
93	855	MUC_008_03_RTI	ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	RESEARCH AND DEVELOPMENT	7,938,862	696,252,320	N	Mucommune, LLC	MUC_008_03_RTI	-	$ 28,609
93	855	00002782	ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	RESEARCH AND DEVELOPMENT	7,938,862	696,252,320	N	University of Georgia	00002782	-	$ 71,218
93	855	22-A1-00-1007329	ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	RESEARCH AND DEVELOPMENT	7,938,862	696,252,320	N	New York University	22-A1-00-1007329	-	$ 71,854
93	855	MSA 01-019	ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	RESEARCH AND DEVELOPMENT	7,938,862	696,252,320	N	UNC Chapel Hill	MSA 01-019	-	$ 73,892
93	855	5129224	ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	RESEARCH AND DEVELOPMENT	7,938,862	696,252,320	N	UNC Chapel Hill	5129224	-	$ 2,025
93	855	15600000062928	ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	RESEARCH AND DEVELOPMENT	7,938,862	696,252,320	N	UCLA	15600000062928	-	$ 36,226
93	855	MSA 01-0110	ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	RESEARCH AND DEVELOPMENT	7,938,862	696,252,320	N	UNC Chapel Hill	MSA 01-0110	-	$ 17,083
93	855	G-03216-02	ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	RESEARCH AND DEVELOPMENT	7,938,862	696,252,320	N	Colorado State University	G-03216-02	-	$ 27,319
93	855	SCON-00006476	ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	RESEARCH AND DEVELOPMENT	7,938,862	696,252,320	N	University of Southern CA	SCON-00006476	-	$ 8,464
93	855	1UG3A1181797-01	ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	RESEARCH AND DEVELOPMENT	7,938,862	696,252,320	Y			-	$ 139,378
93	855	G-10998-02	ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	RESEARCH AND DEVELOPMENT	7,938,862	696,252,320	N	Colorado State University	G-10998-02	-	$ 9,879
93	855	MSA Dtd 7/1/14 SOW #15	ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	RESEARCH AND DEVELOPMENT	7,938,862	696,252,320	N	Global Alliance for TB	MSA Dtd 7/1/14 SOW #15	-	$ 95,528
93	855	MSA Dtd 7/1/14 SOW #18	ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	RESEARCH AND DEVELOPMENT	7,938,862	696,252,320	N	Global Alliance for TB	MSA Dtd 7/1/14 SOW #18	-	$ 73
93	859	effective 9/6/23	BIOMEDICAL RESEARCH AND RESEARCH TRAINING	RESEARCH AND DEVELOPMENT	32,063	696,252,320	N	Glycan Therapeutics	effective 9/6/23	-	$ 32,063
93	865	1U24HD092094-01	CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	RESEARCH AND DEVELOPMENT	14,127,741	696,252,320	Y			-	$ 1,744,313
93	865	1U24HD095254-01	CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	RESEARCH AND DEVELOPMENT	14,127,741	696,252,320	Y			-	$ 4,388,971

(Continued)

RESEARCH TRIANGLE INSTITUTE
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2024

Federal Assistance		Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity	Amount Passed Through to Subrecipients	Amount Expended
93	865	1UG3HD096908-01	CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	RESEARCH AND DEVELOPMENT	14,127,741	696,252,320	Y			232,404	$ 451,279
93	865	1U24HD107621.01	CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	RESEARCH AND DEVELOPMENT	14,127,741	696,252,320	Y			760,156	$ 2,123,112
93	865	1R01HD075787-01A1	CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	RESEARCH AND DEVELOPMENT	14,127,741	696,252,320	Y			213,602	$ 524,327
93	865	1R01HD093572-01	CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	RESEARCH AND DEVELOPMENT	14,127,741	696,252,320	Y			-	$ (1,013)
93	865	1R01HD094629.01	CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	RESEARCH AND DEVELOPMENT	14,127,741	696,252,320	Y			-	$ 284,534
93	865	MSA 01-012	CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	RESEARCH AND DEVELOPMENT	14,127,741	696,252,320	N	UNC Chapel Hill	MSA 01-012	-	$ 10,933
93	865	R01HD094877	CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	RESEARCH AND DEVELOPMENT	14,127,741	696,252,320	Y			12,915	$ 233,215
93	865	1PL1HD101059-01	CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	RESEARCH AND DEVELOPMENT	14,127,741	696,252,320	Y			572,404	$ 1,364,359
93	865	VUMC86278	CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	RESEARCH AND DEVELOPMENT	14,127,741	696,252,320	N	Vanderbilt Univ	VUMC86278	-	$ 1
93	865	1R03HD105507-01	CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	RESEARCH AND DEVELOPMENT	14,127,741	696,252,320	Y			-	$ 613
93	865	1R21HD106583.01	CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	RESEARCH AND DEVELOPMENT	14,127,741	696,252,320	Y			16,966	$ 85,828
93	865	582891	CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	RESEARCH AND DEVELOPMENT	14,127,741	696,252,320	N	Univ of Pennsylvania	582891	-	$ 42,378
93	865	CM00007031-00	CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	RESEARCH AND DEVELOPMENT	14,127,741	696,252,320	N	Queens College	CM00007031-00	-	$ 103,629
93	865	2U24HD069031-11	CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	RESEARCH AND DEVELOPMENT	14,127,741	696,252,320	Y			-	$ 2,703,852
93	865	MSA 01-017	CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	RESEARCH AND DEVELOPMENT	14,127,741	696,252,320	N	UNC Chapel Hill	MSA 01-017	-	$ 46,137
93	865	5126352	CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	RESEARCH AND DEVELOPMENT	14,127,741	696,252,320	N	UNC Chapel Hill	5126352	-	$ 1,244
93	865	A816947	CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	RESEARCH AND DEVELOPMENT	14,127,741	696,252,320	N	Emory University	A816947	-	$ 2,382
93	865	1R21HD11933-01A1	CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	RESEARCH AND DEVELOPMENT	14,127,741	696,252,320	Y			-	$ 9,814
93	865	1R02HD112407-01S1	CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	RESEARCH AND DEVELOPMENT	14,127,741	696,252,320	Y			-	$ 6,744
93	865	1R21HD111729-01A1	CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	RESEARCH AND DEVELOPMENT	14,127,741	696,252,320	Y			-	$ 1,089
93	866	SUBK00021984	AGING RESEARCH	RESEARCH AND DEVELOPMENT	10,281,545	696,252,320	N	University of Michigan	SUBK00021984	-	$ 2,696,252
93	866	SUBK00009629	AGING RESEARCH	RESEARCH AND DEVELOPMENT	10,281,545	696,252,320	N	University of Michigan	SUBK00009629	-	$ 22,408
93	866	5120060	AGING RESEARCH	RESEARCH AND DEVELOPMENT	10,281,545	696,252,320	N	UNC Chapel Hill	5120060	20,705	$ 6,589,536
93	866	MSA-01-012	AGING RESEARCH	RESEARCH AND DEVELOPMENT	10,281,545	696,252,320	N	UNC Chapel Hill	MSA-01-012	-	$ 165,506
93	866	5129504	AGING RESEARCH	RESEARCH AND DEVELOPMENT	10,281,545	696,252,320	N	UNC Chapel Hill	5129504	-	$ 807,843
14	902	8882	LEAD TECHNICAL STUDIES GRANTS	RESEARCH AND DEVELOPMENT	68,557	696,252,320	N	Indiana University	8882	-	$ 68,557
10	960	FX23TA-10960C034	TECHNICAL AGRICULTURAL ASSISTANCE	RESEARCH AND DEVELOPMENT	49,919	696,252,320	Y			-	$ 49,919
93	974	1 FPRPA006072-01-00	FAMILY PLANNING_SERVICE DELIVERY IMPROVEMENT RESEARCH GRANTS	RESEARCH AND DEVELOPMENT	350,251	696,252,320	Y			47,977	$ 350,251
93	989	1R21TW011784-01	INTERNATIONAL RESEARCH AND RESEARCH TRAINING	RESEARCH AND DEVELOPMENT	163,690	696,252,320	Y			4,766	$ 91,556
93	989	1 (GG016095-01)	INTERNATIONAL RESEARCH AND RESEARCH TRAINING	RESEARCH AND DEVELOPMENT	163,690	696,252,320	N	Columbia University	1 (GG016095-01)	-	$ 14,711
93	989	A035551	INTERNATIONAL RESEARCH AND RESEARCH TRAINING	RESEARCH AND DEVELOPMENT	163,690	696,252,320	N	Duke University	A035551	-	$ 41,499
93	989	Agreement eff 7/15/2023	INTERNATIONAL RESEARCH AND RESEARCH TRAINING	RESEARCH AND DEVELOPMENT	163,690	696,252,320	N	Makerere University	Agreement eff 7/15/2023	-	$ 15,924
10	RD	1232SA21F0063	NASS Engineer Support	RESEARCH AND DEVELOPMENT	205,761	696,252,320	N	Summit Consulting, LLC	1232SA21F0063	-	$ 114
10	RD	SCN1014501	Antimicro Dash Transform	RESEARCH AND DEVELOPMENT	205,761	696,252,320	N	Iowa State University	SCN1014501	-	$ 192,758
10	RD	SCN1014502	Antimicro Dash BizOp	RESEARCH AND DEVELOPMENT	205,761	696,252,320	N	Iowa State University	SCN1014502	-	$ 12,889
11	RD	1333LB20A00000006 1333LB23F00000154	Census Methodological	RESEARCH AND DEVELOPMENT	799,305	696,252,320	Y			-	$ 16,116
11	RD	1333LB20A00000006 1333LB23F00000131/CO 0013	Census Methodological	RESEARCH AND DEVELOPMENT	799,305	696,252,320	Y			-	$ 6,783
11	RD	1333LB20A00000006	Census Methodological	RESEARCH AND DEVELOPMENT	799,305	696,252,320	Y			-	$ 60
11	RD	1333LB20A00000006 1333LB22F00000166	Census Methodological	RESEARCH AND DEVELOPMENT	799,305	696,252,320	Y			-	$ 8,008
11	RD	NOAAPROTECHWX0062-0001	NOAA ProTech Weather	RESEARCH AND DEVELOPMENT	799,305	696,252,320	N	IBSS Corporation	NOAAPROTECHWX0062-0001	-	$ 152,411
11	RD	IBSS-RTI-Atlas 15 1305M323FNWWY0050	NOAA ProTech Weather	RESEARCH AND DEVELOPMENT	799,305	696,252,320	N	IBSS Corporation	IBSS-RTI-Atlas 15 1305M323FNWWY0050	-	$ 615,927
12	RD	2021-534 TO#001	MTEC IDIQ	RESEARCH AND DEVELOPMENT	14,221,020	696,252,320	N	Advanced Technology Intl	2021-534 TO#001	-	$ 579,856
12	RD	2021-534 Project award no 003	MTEC IDIQ	RESEARCH AND DEVELOPMENT	14,221,020	696,252,320	N	Advanced Technology Intl	2021-534 Project award no 003	-	$ 338,271
12	RD	0000896563	Develop HMI Testing Capab	RESEARCH AND DEVELOPMENT	14,221,020	696,252,320	N	Battelle	0000896563	-	$ 130,702
12	RD	2021-534 TO #002	MTEC IDIQ	RESEARCH AND DEVELOPMENT	14,221,020	696,252,320	N	Advanced Technology Intl	2021-534 TO #002	-	$ 5,719,287
12	RD	2021-534	MTEC IDIQ	RESEARCH AND DEVELOPMENT	14,221,020	696,252,320	N	Advanced Technology Intl	2021-534	-	$ 3,981,606
12	RD	Base Agreement 2023-424	CBRN Wearable Sensors	RESEARCH AND DEVELOPMENT	14,221,020	696,252,320	N	Advanced Technology Intl	Base Agreement 2023-424	-	$ 2,043,500
12	RD	2016-630 Task Order 02	Army MTEC Add On	RESEARCH AND DEVELOPMENT	14,221,020	696,252,320	N	Advanced Technology Intl	2016-630 Task Order 02	-	$ 91,422
12	RD	HT001121F0089	DHAPP	RESEARCH AND DEVELOPMENT	14,221,020	696,252,320	Y			-	$ 20,145
12	RD	68582/00(under fund 585970)	DOSE OPT STUDY TCVI	RESEARCH AND DEVELOPMENT	14,221,020	696,252,320	N	Univ of Pennsylvania	68582/00(under fund 585970)	-	$ 140,640
12	RD	Agreement effective 5/1/2023	SELSYM PRE IND SUP	RESEARCH AND DEVELOPMENT	14,221,020	696,252,320	N	SelSym Biotech, Inc.	Agreement effective 5/1/2023	-	$ 105
12	RD	PS-RTI-DHAPPSIFA-23-01	DHAPP Support	RESEARCH AND DEVELOPMENT	14,221,020	696,252,320	Y			-	$ 1,008,806
12	RD	20230626R	Bystander Intervention	RESEARCH AND DEVELOPMENT	14,221,020	696,252,320	N	CAE, Inc. - USA	20230626R	-	$ 166,680
15	RD	07-1734	Utah DWR CRSS Modeling	RESEARCH AND DEVELOPMENT	37	696,252,320	N	Stantec - USA	07-1734	-	$ 37
16	RD	ASM5-00017	NFLIS 2018 2023	RESEARCH AND DEVELOPMENT	13,409,539	696,252,320	N	Arctic Slope Mission Serv	ASM5-00017	-	$ 1,481,928
16	RD	15PNJD19F00000001	National Baseline Study	RESEARCH AND DEVELOPMENT	13,409,539	696,252,320	Y			-	$ (89)
16	RD	Effective 10/7/2020	OVW Campus Program Needs	RESEARCH AND DEVELOPMENT	13,409,539	696,252,320	N	Soteria Solutions	Effective 10/7/2020	-	$ 15,138
16	RD	15PNJD21F00000007	NamUs	RESEARCH AND DEVELOPMENT	13,409,539	696,252,320	Y			-	$ 6,875,867
16	RD	15PNJD21F00000013	DCRA Study	RESEARCH AND DEVELOPMENT	13,409,539	696,252,320	Y			-	$ 657,711
16	RD	15PNJD22F00000003	Eval of Fed BOP Reentry	RESEARCH AND DEVELOPMENT	13,409,539	696,252,320	Y			-	$ 2,753,107
16	RD	15JA5322P00000229	DOJ Litigative Services	RESEARCH AND DEVELOPMENT	13,409,539	696,252,320	Y			-	$ 10,655
16	RD	Effective 03/01/2023	Capital Litigation Init	RESEARCH AND DEVELOPMENT	13,409,539	696,252,320	N	APA	Effective 03/01/2023	-	$ 60,892
16	RD	15PNJD23F00000003	NIJ Restrictive Housing	RESEARCH AND DEVELOPMENT	13,409,539	696,252,320	Y			-	$ 1,450,393
16	RD	A24-000684	NIBRS	RESEARCH AND DEVELOPMENT	13,409,539	696,252,320	N	Compass Point	A24-000684	-	$ 84,507
16	RD	Agreement effective 5/1/2024	TTA Needs Assess Campus	RESEARCH AND DEVELOPMENT	13,409,539	696,252,320	N	Soteria Solutions	Agreement effective 5/1/2024	-	$ 19,430

(Continued)

RESEARCH TRIANGLE INSTITUTE
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2024

Federal Assistance Listing		Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity	Amount Passed Through to Subrecipients	Amount Expended
17	RD	Agreement signed 6/21/23	ASA NSF BLS Fellow IPA	RESEARCH AND DEVELOPMENT	2,878,485	696,252,320	N	Amer Statistical Assoc	Agreement signed 6/21/23	-	$ 73,320
17	RD	51689S001	PROWD Evaluation	RESEARCH AND DEVELOPMENT	2,878,485	696,252,320	N	MATHEMATICA POLICY RES.	51689S001	-	$ 168,230
17	RD	1605C2-23-C-0014	Educator RA Intermediary	RESEARCH AND DEVELOPMENT	2,878,485	696,252,320	Y			-	$ 2,497,296
17	RD	1605c5-23F00035	NLS Youth 2026	RESEARCH AND DEVELOPMENT	2,878,485	696,252,320	Y			-	$ 139,639
20	RD	TFPE-00	FHWA R T Projects	RESEARCH AND DEVELOPMENT	387,183	696,252,320	N	The Natl Academies NAS	TFPE-00	-	$ 387,183
45	RD	IMLS-2017-030	IMLS Data/Analysis	RESEARCH AND DEVELOPMENT	103,295	696,252,320	Y			-	$ 103,295
47	RD	ADC-FBSE-22-09 Project Agmt No. 1	America s Data Hub Consor	RESEARCH AND DEVELOPMENT	6,423,618	696,252,320	N	Advanced Technology Intl	ADC-FBSE-22-09 Project Agmt No. 1	-	$ 129,056
47	RD	49100422C0018	Low Burden Respondents	RESEARCH AND DEVELOPMENT	6,423,618	696,252,320	Y			-	$ 126,046
47	RD	49100422F0122	GSS	RESEARCH AND DEVELOPMENT	6,423,618	696,252,320	Y			-	$ 1,489,884
47	RD	49100418F1261	GSS 2018-2021	RESEARCH AND DEVELOPMENT	6,423,618	696,252,320	Y			-	$ 38,176
47	RD	49100419F1060	SED 2020 2022	RESEARCH AND DEVELOPMENT	6,423,618	696,252,320	Y			-	$ 32,654
47	RD	49100421D00013	EAPS	RESEARCH AND DEVELOPMENT	6,423,618	696,252,320	Y			-	$ 547,117
47	RD	49100421D0019 49100422F0059	NSF ATSS	RESEARCH AND DEVELOPMENT	6,423,618	696,252,320	Y			-	$ 628,065
47	RD	49100421D0019 49100423F0236	NSF ATSS	RESEARCH AND DEVELOPMENT	6,423,618	696,252,320	Y			-	$ 1,379
47	RD	49100421F0205	ECDS Support	RESEARCH AND DEVELOPMENT	6,423,618	696,252,320	Y			-	$ 14
47	RD	49100422F0033	NCSES SED	RESEARCH AND DEVELOPMENT	6,423,618	696,252,320	Y			-	$ 3,117,555
47	RD	KRC-ABSSYN-101	Synthetic Data for ABS	RESEARCH AND DEVELOPMENT	6,423,618	696,252,320	N	Knexus Research Corp	KRC-ABSSYN-101	-	$ 160,791
47	RD	Contract signed 2/16/24	Synthetic Data for SED	RESEARCH AND DEVELOPMENT	6,423,618	696,252,320	N	Urban Institute	Contract signed 2/16/24	-	$ 124,134
47	RD	Agreement eff 8/19/2024	NSF Engines Eval	RESEARCH AND DEVELOPMENT	6,423,618	696,252,320	N	BRIDG	Agreement eff 8/19/2024	-	$ 28,747
64	RD	36C25021P1991	VA TEAMS	RESEARCH AND DEVELOPMENT	28,929	696,252,320	Y			-	$ 28,929
66	RD	EP-C-16-016 68HERC19F0303	STREAMS III IDIQ	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ (31,389)
66	RD	EP-C-16-016 68HERC20F0192	STREAMS III IDIQ	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ (8,005)
66	RD	EP-C-16-016 68HERC20F0370	STREAMS III IDIQ	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ (951)
66	RD	EP-C-17-045 68HERC22F0242	TSAWP	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ (29)
66	RD	Agreement effective 8/1/2022	HEI Energy QA Ovrsght	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	N	HEI Energy	Agreement effective 8/1/2022	-	$ 20,388
66	RD	EP-C-16-016 68HERC20F0396	STREAMS III IDIQ	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ (7,844)
66	RD	EP-C-17-045	TSAWP	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 74,459
66	RD	EP-C-17-045 68HERC19F0235	TSAWP	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 57,165
66	RD	EP-W-15-005 W15005E0003	ERAS Risk Assessment Sup	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ -
66	RD	EP-W-15-005 Task 0006	ERAS Risk Assessment Sup	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 8
66	RD	EP-W-15-005 68HERH21F0330	ERAS Risk Assessment Sup	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ -
66	RD	EP-W-15-005 68HERH22F0062	ERAS Risk Assessment Sup	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 40
66	RD	EP-W-15-005 68HERH22F0151	ERAS Risk Assessment Sup	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 1
66	RD	EP-W-15-005 68HERH22F0301	ERAS Risk Assessment Sup	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 6,497
66	RD	EP-W-15-005 68HERH23F0048	ERAS Risk Assessment Sup	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 26,386
66	RD	EP-W-15-005 68HERH23F0347	ERAS Risk Assessment Sup	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 359,162
66	RD	EP-W-15-005 68HERH23F0348	ERAS Risk Assessment Sup	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 186,238
66	RD	EP-W-15-005 68HERH23F0357	ERAS Risk Assessment Sup	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 406,020
66	RD	68HE0H18D0008 68HERH19F0359	Endocrin Disrupt Tech Sup	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 114,453
66	RD	68HE0H18D0008 68HERH19F0248	Endocrin Disrupt Tech Sup	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 68,128
66	RD	68HE0H18D0008 68HERC21F0259	Endocrin Disrupt Tech Sup	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 167,630
66	RD	68HE0H18D0008 68HERC23F0282	Endocrin Disrupt Tech Sup	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 298,967
66	RD	68HE0H18D0008 68HERC24F0015	Endocrin Disrupt Tech Sup	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 2,053,820
66	RD	68HERH19D0030 68HERH20F0281	IDIQ Greenhouse Gas Progr	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ (6)
66	RD	68HERH19D0030 68HERH20F0289	IDIQ Greenhouse Gas Progr	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ -
66	RD	68HERH19D0030 68HERH21F0174	IDIQ Greenhouse Gas Progr	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 60,429
66	RD	68HERH19D0030 68HERH21F0294	IDIQ Greenhouse Gas Progr	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 236,662
66	RD	68HERH19D0030 68HERH22F0109	IDIQ Greenhouse Gas Progr	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 290,236
66	RD	68HERH19D0030 68HERH22F0285	IDIQ Greenhouse Gas Progr	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 3,549,423
66	RD	68HERH19D0030 68HERH22F0302	IDIQ Greenhouse Gas Progr	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 4,568
66	RD	68HERH19D0030 68HERH22F0348	IDIQ Greenhouse Gas Progr	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 774,804
66	RD	68HERH19D0030 68HERH23F0003	IDIQ Greenhouse Gas Progr	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 1,748,850
66	RD	68HERH19D0030 68HERH23F0129	IDIQ Greenhouse Gas Progr	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 65,456
66	RD	68HERH19D0030 68HERH23F0146	IDIQ Greenhouse Gas Progr	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 1,355,568
66	RD	68HERH19D0030 68HERH23F0215	IDIQ Greenhouse Gas Progr	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 577,133
66	RD	68HERH19D0030 68HERH24F0030	IDIQ Greenhouse Gas Progr	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 388,026

(Continued)

RESEARCH TRIANGLE INSTITUTE
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2024

Federal Assistance		Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity	Amount Passed Through to Subrecipients	Amount Expended
66	RD	68HERH19D0030 68HERH24F0180	IDIQ Greenhouse Gas Progr	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 626,153
66	RD	68HERD20A0004 68HERH20F0222	US EPA MME Sector	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ (2,143)
66	RD	68HERD20A0004 68HERH20F0293	US EPA MME Sector	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ (127)
66	RD	68HERD20A0004 68HERH20F0295	US EPA MME Sector	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 586,196
66	RD	68HERD20A0004 68HERH21F0168	US EPA MME Sector	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 897,785
66	RD	68HERD20A0004 68HERH21F0200	US EPA MME Sector	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ (276)
66	RD	68HERD20A0004 68HERH21F0208	US EPA MME Sector	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 26,837
66	RD	68HERD20A0004 68HERH21F0224	US EPA MME Sector	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 696,249
66	RD	68HERD20A0004 68HERH21F0281	US EPA MME Sector	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 17,653
66	RD	68HERD20A0004 68HERH21F0332	US EPA MME Sector	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 272,030
66	RD	COVID-19, 68HERD20A0004 68HERH22F0018	COVID-19 - US EPA MME Sector	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 1,865
66	RD	68HERD20A0004 68HERH22F0012	US EPA MME Sector	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 113,329
66	RD	68HERD20A0004 68HERH22F0191	US EPA MME Sector	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 91,554
66	RD	68HERD20A0004 68HERH22F0216	US EPA MME Sector	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 236,567
66	RD	68HERD20A0004 68HERH22F0219	US EPA MME Sector	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 290,150
66	RD	68HERD20A0004 68HERH22F0324	US EPA MME Sector	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 41,792
66	RD	68HERD20A0004 68HERH23F0028	US EPA MME Sector	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 103,028
66	RD	68HERD20A0004 68HERH23F0036	US EPA MME Sector	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 136,982
66	RD	68HERD20A0004 68HERH23F0181	US EPA MME Sector	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 225,783
66	RD	68HERD20A0004 68HERH23F0187	US EPA MME Sector	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 284,809
66	RD	68HERD20A0004 68HERH23F0190	US EPA MME Sector	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 497,422
66	RD	68HERD20A0004 68HERH23F0227	US EPA MME Sector	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 121,189
66	RD	68HERD20A0004 68HERH23F0247	US EPA MME Sector	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 38,394
66	RD	68HERD20A0004 68HERH24F0016	US EPA MME Sector	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 7,918
66	RD	68HERD20A0004 68HERH24F0102	US EPA MME Sector	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 34,423
66	RD	68HERD20A0004 68HERH24F0144	US EPA MME Sector	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 140,196
66	RD	68HERD20A0004 68HERH24F0262	US EPA MME Sector	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 25,980
66	RD	68HERD20A0004 68HERH24F0285	US EPA MME Sector	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 13,384
66	RD	68HERD20A0004 68HERH24F0319	US EPA MME Sector	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 152,916
66	RD	68HERD20A0004 68HERH24F0339	US EPA MME Sector	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 67,289
66	RD	68HERD20A0004 68HERH24F0355	US EPA MME Sector	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 6,902
66	RD	68HERD20A0004 68HERH24F0393	US EPA MME Sector	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 3,481
66	RD	68HERC20D0019 RTI 2020	EPA OW Support	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	N	GREAT LAKES ENVIRONMENTAL	68HERC20D0019 RTI 2020	-	$ 141,697
66	RD	68HERC20D0019 RTI 2020 RTI 2020 TO-3	EPA OW Support	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	N	GREAT LAKES ENVIRONMENTAL	68HERC20D0019 RTI 2020 RTI 2020 TO-3	-	$ 260,664
66	RD	68HERC21D0004 68HERC21F0434	STREAMS IV IDIQ	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 3,574
66	RD	68HERC21D0004 68HERC22F0181	STREAMS IV IDIQ	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 630,923
66	RD	68HERC21D0004 68HERC22F0205	STREAMS IV IDIQ	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 70,324
66	RD	68HERC21D0004 68HERC22F0214	STREAMS IV IDIQ	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 296,302
66	RD	68HERC21D0004 68HERC22F0254	STREAMS IV IDIQ	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 203,694
66	RD	68HERC21D0004 68HERC22F0031	STREAMS IV IDIQ	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 2,096,704

(Continued)

RESEARCH TRIANGLE INSTITUTE
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2024

Federal Assistance		Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity	Amount Passed Through to Subrecipients	Amount Expended
66	RD	68HERC21D0004 68HERC24F0048	STREAMS IV IDIQ	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 71,060
66	RD	68HERC21D0004 68HERC24F0206	STREAMS IV IDIQ	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 76,024
66	RD	68HERC21D0004 68HERC24F0305	STREAMS IV IDIQ	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 136,348
66	RD	68HERC21D0004 68HERC24F0312	STREAMS IV IDIQ	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 44,392
66	RD	68HERC21D0004 68HERC24F0265	STREAMS IV IDIQ	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 100,290
66	RD	68HERC21D0004 68HERC24F0399	STREAMS IV IDIQ	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 2,126
66	RD	68HERD21A0004 68HERH21F0262	Air Pollution Control Reg	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 130,603
66	RD	68HERD21A0004 68HERH22F0093	Air Pollution Control Reg	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 98,893
66	RD	68HERD21A0004 68HERH22F0086	Air Pollution Control Reg	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 24,585
66	RD	68HERD21A0004 68HERH22F0337	Air Pollution Control Reg	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 18,144
66	RD	68HERD21A0004 68HERH23F0175	Air Pollution Control Reg	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 61,670
66	RD	68HERD21A0004 68HERH24F0046	Air Pollution Control Reg	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 300,194
66	RD	68HERD21A0004 68HERH24F0047	Air Pollution Control Reg	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 74,068
66	RD	68HERD21A0004 68HERH24F0017	Air Pollution Control Reg	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 50,370
66	RD	68HERD21A0004 68HERH24F0264	Air Pollution Control Reg	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 9,521
66	RD	Agreem 6/17/2021 68HERC22F0228	WARTS	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	N	EPR	Agreem 6/17/2021 68HERC22F0228	-	$ 90,406
66	RD	EPAOW-1006-2022	EPA OW IT Portfolio Supp	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	N	Intepros Federal	EPAOW-1006-2022	-	$ 17,826
66	RD	68HERH22A0023 68HERH23F0122	EARTH IDIQ	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 6,730,951
66	RD	COVID-19, 68HERH22A0023 68HERH23F0122	COVID-19 - EARTH IDIQ	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 160,000
66	RD	68HERH22A0023 68HERH23F0346	EARTH IDIQ	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 192,086
66	RD	68HERH22A0023 68HERH24F0212	EARTH IDIQ	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 11,827
66	RD	68HERC22A0020 68HERC23F0258	TSAWP 3	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 1,907,090
66	RD	68HERC22A0020	TSAWP 3	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 94,062
66	RD	Contract signed 11/2/22 TO 9/68HERH22F0024	Analytical Econ Support	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	N	Industrial Economics	Contract signed 11/2/22 TO 9/68HERH22F0024	-	$ 294,368
66	RD	68HERH24A0004 68HERH24F0203	ORCR RATAS	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 10,506
66	RD	68HERH24A0004 68HERH24F0177	ORCR RATAS	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 14,578
66	RD	68HERH24A0004 68HERH24F335	ORCR RATAS	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 27,271
66	RD	68HERH24A0004 68HERH24F0314	ORCR RATAS	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	Y			-	$ 19,040
66	RD	Agreement eff 2/28/2024	EARTH TA Section 138 ECJ	RESEARCH AND DEVELOPMENT	33,370,184	696,252,320	N	EnDyna, Inc.	Agreement eff 2/28/2024	-	$ 300,000
81	RD	ESJV-EOPIV-SUB-0006 Task Order # 3	EIA OP IV IDIQ	RESEARCH AND DEVELOPMENT	2,007,012	696,252,320	N	IMG-Crown Energy Services	ESJV-EOPIV-SUB-0006 Task Order # 3	-	$ (170)
81	RD	ESJV-EOPIV-SUB-0006 Task Order #4	EIA OP IV IDIQ	RESEARCH AND DEVELOPMENT	2,007,012	696,252,320	N	IMG-Crown Energy Services	ESJV-EOPIV-SUB-0006 Task Order #4	-	$ 236,692
81	RD	ESJV-EOPIV-SUB-0006 TO no. 7	EIA OP IV IDIQ	RESEARCH AND DEVELOPMENT	2,007,012	696,252,320	N	IMG-Crown Energy Services	ESJV-EOPIV-SUB-0006 TO no. 7	-	$ 563,639
81	RD	ESJV-EOPIV-SUB-0006 Task Order #6	EIA OP IV IDIQ	RESEARCH AND DEVELOPMENT	2,007,012	696,252,320	N	IMG-Crown Energy Services	ESJV-EOPIV-SUB-0006 Task Order #6	-	$ 1,177,372
81	RD	EOPV-RTI-001 TO1	EIA Omnibus Procurement V	RESEARCH AND DEVELOPMENT	2,007,012	696,252,320	N	Crown Consulting, Inc.	EOPV-RTI-001 TO1	-	$ 29,479
84	RD	ED-IES-13-C0070	NPSAS:16	RESEARCH AND DEVELOPMENT	29,600,081	696,252,320	Y			-	$ 279,858
84	RD	ED-IES-13-C-0056	IPEDS 2013-2021	RESEARCH AND DEVELOPMENT	29,600,081	696,252,320	Y			-	$ 75,700
84	RD	ED-IES-15-O-5016	MGLS:17	RESEARCH AND DEVELOPMENT	29,600,081	696,252,320	Y			-	$ (23,924)
84	RD	ED-IES-15-C-0046	NLTS of 2012 Phase II	RESEARCH AND DEVELOPMENT	29,600,081	696,252,320	Y			-	$ 400,933
84	RD	91990018F0018	HS&B:20	RESEARCH AND DEVELOPMENT	29,600,081	696,252,320	Y			-	$ 5,918,936
84	RD	91990018C0039	NPSAS 2020	RESEARCH AND DEVELOPMENT	29,600,081	696,252,320	Y			-	$ 3,354,289
84	RD	91990021F0001	Dept of ED TIMSS	RESEARCH AND DEVELOPMENT	29,600,081	696,252,320	Y			-	$ 1,074,459
84	RD	91990022C0017	NPSAS:24	RESEARCH AND DEVELOPMENT	29,600,081	696,252,320	Y			-	$ 10,614,638
84	RD	R000002990	REL Southeast	RESEARCH AND DEVELOPMENT	29,600,081	696,252,320	N	Florida State University	R000002990	-	$ 376,184
84	RD	91990022F0021	IPEDS 2022-26	RESEARCH AND DEVELOPMENT	29,600,081	696,252,320	Y			-	$ 5,220,444
84	RD	Effective 9/27/21 Task Order 5	Admin Data Improvmnt IDIQ	RESEARCH AND DEVELOPMENT	29,600,081	696,252,320	N	Quality Info Partners	Effective 9/27/21 Task Order 5	-	$ 491
84	RD	RTI_0001_DataLab	DataLab	RESEARCH AND DEVELOPMENT	29,600,081	696,252,320	N	Sanametrix, Inc.	RTI_0001_DataLab	-	$ 794,397
84	RD	RTI-0002_Postsecondary Analysi	Postsecondary Analysis	RESEARCH AND DEVELOPMENT	29,600,081	696,252,320	N	Sanametrix, Inc.	RTI-0002_Postsecondary Analysi	-	$ 132,447

(Continued)

RESEARCH TRIANGLE INSTITUTE
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2024

Federal Assistance		Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity	Amount Passed Through to Subrecipients	Amount Expended
84	RD	91990021A0014 91990023F0370	DeptEd DAES BPA	RESEARCH AND DEVELOPMENT	29,600,081	696,252,320	Y			-	$ 690,762
84	RD	BSA-23094	OSEP SWIFT	RESEARCH AND DEVELOPMENT	29,600,081	696,252,320	N	KUCR	BSA-23094	-	$ 476,176
84	RD	91990023D0042 91990024F0321	IES IDIQ PRESTO Cat1 2 4	RESEARCH AND DEVELOPMENT	29,600,081	696,252,320	Y			-	$ 140,863
84	RD	MC-939-2023-09-25	PIMS Grants TA	RESEARCH AND DEVELOPMENT	29,600,081	696,252,320	N	Manhattan Strategy Group	MC-939-2023-09-25	-	$ 69,176
84	RD	Effective 1/1/24 5411A230007	Math All EIR Exp Grant	RESEARCH AND DEVELOPMENT	29,600,081	696,252,320	N	Education Development Ctr	Effective 1/1/24 5411A230007	-	$ 4,252
93	RD	HHSS283201700002C	2018-2022 NSDUH	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 2,337,794
93	RD	HHSS283201700027I 75S20321F42002	DOMAIN 1--SAMHSA IDIQ 201	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 683,126
93	RD	HHSS277201800001C	NLCP Govt Tasks	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 37,400
93	RD	75S20322C00001	2023 NSDUH	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 47,692,129
93	RD	75S20122C00002	NLCP Govt Tasks	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 3,518,613
93	RD	HHSM-500-2008-00021I HHSM-500-T0001	MIDS Base IDIQ contract	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 57
93	RD	HHSP23320095651WC HHSP23337033T	PSC IDIQ TO Contract	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ (709)
93	RD	HHSM-500-2014-00037I HHSM-500-T0001	RMADA	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 8
93	RD	HHSM-500-2014-00037I HHSM-500-T0003	RMADA	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 935,377
93	RD	HHSM-500-2014-00037I HHSM-500-T0005	RMADA	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ (1,211)
93	RD	HHSM-500-2014-00037I HHSM-500-T0006	RMADA	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ (444)
93	RD	HHSM-500-2014-00037I HHSM-500-T0007	RMADA	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 1,012,968
93	RD	HHSM-500-2014-00037I 75FCMC18F0001	RMADA	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 86
93	RD	HHSM-500-2014-00037I 75FCMC18F0002	RMADA	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 1,896,793
93	RD	HHSM-500-2014-00037I 75FCMC18F0003	RMADA	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 1,103,737
93	RD	HHSM-500-2014-00037I 75FCMC18F0004	RMADA	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 104,909
93	RD	HHSM-500-2014-00037I 75FCMC19F0001	RMADA	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 817,428
93	RD	HHSM-500-2014-00037I 75FCMC19F0002	RMADA	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 19,721,807
93	RD	HHSM-500-2014-00037I 75FCMC19F0002	RMADA	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ (71,473)
93	RD	HHSM-500-2014-00037I 75FCMC19F0003	RMADA	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 450,706
93	RD	HHSM-500-2014-00037I 75FCMC19F0004	RMADA	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 25,465,503
93	RD	HHSM-500-2014-00037i HHSM-500-T0009	RMADA	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	MATHEMATICA POLICY RES.	HHSM-500-2014-00037i HHSM-500-T0009	-	$ 2,743
93	RD	200-2014-61263 75D301118F00011	TAMS	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 32
93	RD	HHSP233201500024I AHR250432	Action III	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ (4,149)
93	RD	HHSP233201500039I HHSP23337001T	PSC IDIQ	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 3,291,169
93	RD	HHSP233201500039I HHSP23337003T	PSC IDIQ	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 19,547
93	RD	HHSP233201500039I HHSP23337011T	PSC IDIQ	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ (2,165)
93	RD	HHSP233201500039I P331500039I-37015	PSC IDIQ	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ (525)
93	RD	HHSP233201500039I HHSP23337015T	PSC IDIQ	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ -
93	RD	HHSP233201500039I HHSP23337016T	PSC IDIQ	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ (2,426)
93	RD	HHSP233201500039I 75P00119F37022	PSC IDIQ	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 1,061,688
93	RD	HHSP233201500039I 75P00119F37023	PSC IDIQ	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ (1,507)
93	RD	HHSN271201700034C	Purity Spec Strge Distrib	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ (12,415)
93	RD	HHSA290201700001C	MEPS	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 2,500
93	RD	HHSD200201896346I 75D30118F00001	ITOPSS MSA	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 34,072

(Continued)

RESEARCH TRIANGLE INSTITUTE
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2024

Federal	Assistance	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity	Amount Passed Through to Subrecipients	Amount Expended
93	RD	HHSN272201800002I 75N93019F00134	NIAID IDIQ	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ (58)
93	RD	HHSN272201800002I 75N93024F00001	NIAID IDIQ	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 71,045
93	RD	75FCMC18D0012 75FCMC24F0121	MIDS IDIQ	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 560,009
93	RD	HHSF223201810113C	FDA Generic Drug FG	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ (269)
93	RD	HHSN275201800011I 5512228 - 75N94019F00125	Pop Health Research IDIQ	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 151,203
93	RD	75N95019C00042	Analytical Chem Subs	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 573,903
93	RD	75FCMC19D0095 75FCMC21F0001	RMADA IDIQ Recompete	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 283,038
93	RD	75FCMC19D0095 75FCMC23F0001	RMADA IDIQ Recompete	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 4,295,442
93	RD	75FCMC19D0095 75FCMC23F0002	RMADA IDIQ Recompete	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 2,723,185
93	RD	75FCMC19D0095 75FCMC24F0060	RMADA IDIQ Recompete	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 5,149,552
93	RD	75FCMC19D0095 75FCMC24F0148	RMADA IDIQ Recompete	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 129,745
93	RD	75N95019D00042 75N95022F00001	Prep Distrib Res Drg Prod	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ (11)
93	RD	75N95019D00042 75N95022F0003	Prep Distrib Res Drg Prod	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 26,951
93	RD	75N95019D00042 75N95023F00001	Prep Distrib Res Drg Prod	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 668,758
93	RD	75N95019D00042 75N95023F00003	Prep Distrib Res Drg Prod	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 1,125,539
93	RD	75N95019D00042 75N95024F00001	Prep Distrib Res Drg Prod	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 703,108
93	RD	PO-1000792535	OH SOARS Stillbirth	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Ohio State University	PO-1000792535	-	$ (200)
93	RD	PO RF01603717	OH SOARS Stillbirth	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Ohio State University	PO RF01603717	-	$ 52,565
93	RD	75Q80120D00007 75Q80120F32002	EPC VI	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 70,477
93	RD	75D30120C09732	NSFG	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 6,486,219
93	RD	75N91020D00009 75N91023F00001	NCI DCEG IDIQ	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 229,323
93	RD	PO 1000054900	Ohio Preg Assess Survey	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Ohio State University	PO 1000054900	-	$ (135)
93	RD	PO-1000450716	Ohio Preg Assess Survey	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Ohio State University	PO-1000450716	-	$ 510
93	RD	PO-1001519977	Ohio Preg Assess Survey	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Ohio State University	PO-1001519977	-	$ 31,540
93	RD	PO-1001519976	Ohio Preg Assess Survey	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Ohio State University	PO-1001519976	-	$ 315,101
93	RD	PO-1001519973	Ohio Preg Assess Survey	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Ohio State University	PO-1001519973	-	$ 199,763
93	RD	PO-1002023858	Ohio Preg Assess Survey	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Ohio State University	PO-1002023858	-	$ 10,851
93	RD	PO 1002056975	Ohio Preg Assess Survey	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Ohio State University	PO 1002056975	-	$ 3,460
93	RD	PO-1002059755	Ohio Preg Assess Survey	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Ohio State University	PO-1002059755	-	$ 127
93	RD	PO-1002068934	Ohio Preg Assess Survey	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Ohio State University	PO-1002068934	-	$ 10,553
93	RD	75N93021D000004	Preclinical Dev Svc AIDS	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 50,108
93	RD	75N93021D00004 75N93023F00002	Preclinical Dev Svc AIDS	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 141,998
93	RD	75N93021D00004 75N93024F00001	Preclinical Dev Svc AIDS	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 65,472
93	RD	PO-1000267723	OMCEE	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Ohio State University	PO-1000267723	-	$ 1,217
93	RD	101379-0001-RTI-01	LifeSet Evaluation Survey	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Urban Institute	101379-0001-RTI-01	-	$ (78)
93	RD	75Q80121C00005	MEPS MPC	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 12,411,261
93	RD	75N94021D00020 75N94021F00001	NICHD NB Screening Pilots	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 837,804
93	RD	1000377780	OFS	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Ohio State University	1000377780	-	$ 407,199
93	RD	0282200.430	MNGE	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Ohio State University	0282200.430	-	$ (2,682)
93	RD	75N95022C00014	Spec Sto Dist for Med Dev	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 628,449
93	RD	PO-1000808107	2023 OMAS OMCEE OCS MCS	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Ohio State University	PO-1000808107	-	$ (24)
93	RD	75D30123D16071 75D30123F00001	DC NHANES 2022 2032	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 15,977,495
93	RD	75D30123D16071 75D30123F00002	DC NHANES 2022 2032	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 8,686,073
93	RD	75D30123D16071 75D30124F00003	DC NHANES 2022 2032	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 19,769
93	RD	PO 1001370266	OhioRISE	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Ohio State University	PO 1001370266	-	$ 241,848
93	RD	1001103995	2023 Ohio Big 3	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Ohio State University	1001103995	-	$ 207,878
93	RD	PO 1001367511	FY23 OMAS	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Ohio State University	PO 1001367511	-	$ 2,552,410
93	RD	75D30123C17749	CDC Alc Pricing Policies	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 218,165
93	RD	1001564691	SFY 2024 OMRES	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Ohio State University	1001564691	-	$ 84,609
93	RD	PO 1001981188	ROMEO	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Ohio State University	PO 1001981188	-	$ 300,085
93	RD	PO-1002035141	Gen Z Tobacco Social	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Ohio State University	PO-1002035141	-	$ 6,505
93	RD	HHSN273201400022C	NTP	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 4,072,739
93	RD	HHSN272201800002I 75N93021F00003	NIAID IDIQ	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 10,629
93	RD	75N93021C00002	CC4CARB	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 3,883,937
93	RD	75N95022D00016 75N95022F00001	Sythn of Drugs of Abuse	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ (8,037)
93	RD	75N95022D00016 75N95022F00003	Sythn of Drugs of Abuse	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ (199)
93	RD	75N95022D00016 75N95023F00001	Sythn of Drugs of Abuse	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 1,864,660

(Continued)

Federal Assistance		Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity	Amount Passed Through to Subrecipients	Amount Expended
93	RD	75N95022D00016 75N95023F00002	Sythn of Drugs of Abuse	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 263,589
93	RD	75N95022D00016 75N95024F00001	Sythn of Drugs of Abuse	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 800,854
93	RD	75N95022D00016 75N95024F00002	Sythn of Drugs of Abuse	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 58,442
93	RD	75N95024C00021	Analytical Chemistry and	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 115,904
93	RD	200-2013-M-53964B 75D30119F06416	Public Health Impact	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ (16)
93	RD	HHSD2002015M88162B 75D30119F05259	Health Marketing Supp Svs	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 1
93	RD	75D30119F06663	GYTS	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 4,939
93	RD	75D30120F08707	SICRCS Multilevel Eval	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 1,016
93	RD	75F40120A00017 75F40120F19004	CONFIDENTIAL	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 68,175
93	RD	75D30120F09518	Red Carpet Entry Program	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 11,686
93	RD	OOS030484-RTI Task Order No 3	Support EPV VI Program	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Kaiser Permanente	OOS030484-RTI Task Order No 3	-	$ 134,053
93	RD	75D30122A14759 75D30122F15538	DGHP GDATA2 BPA IDIQ	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 15,485
93	RD	GS00Q14OADU217	NISVS 5 Data Collection	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 10,256
93	RD	75ACF122F80038	ADP We Think Twice	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 19,493
93	RD	PO-0100020934	Tangerine EFTouch	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	University of Washington	PO-0100020934	-	$ 54,981
93	RD	23IPA2318673	FOODINSECURIPA	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 31,468
93	RD	75N93023D00012 75N93023F00001 Task F-01	Serv Biopharma Prod Dev	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 22
93	RD	75D30123F17784	ACEs Formative Research	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 3,576
93	RD	75D30123F17504	Econ Eval of NBCCEDP	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 1,961
93	RD	75N94024F00062	NIH SEED Program Eval	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 3,245
93	RD	OT3 HL147798-01	Data Strat Consortium SC	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 4,060,637
93	RD	1OT2HL157844	Catalyze Program	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 9,550
93	RD	1OT2HL167310-01	NHLBI Data Mgmt Core	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 3,052,301
93	RD	1OT2OD034190-01-Revised	NIH NCPI	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 4,727,143
93	RD	75N99223C00004	ARPA H PIA	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 2,226,072
93	RD	HHSF223201110005B HHSF22312005	Master BPA	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 428
93	RD	200-2013-M-53964B 75D30119F06594	Public Health Impact	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 5
93	RD	200-2013-M-53964B 75D30119F06759	Public Health Impact	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ (19)
93	RD	200-2013-M-53964B 75D30120F09937	Public Health Impact	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 2,791
93	RD	200-2013-M-53964B 75D30121F12803	Public Health Impact	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ (14,985)
93	RD	200-2013-M-53964B 75D30121F12790	Public Health Impact	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 9,038
93	RD	200-2013-M-53964B 75D30122F15068	Public Health Impact	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 141,237
93	RD	200-2013-M-53964B 75D30122F15235	Public Health Impact	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 450,597
93	RD	HHSF223201510002B HHSF22317005	Quick Turnaround SS Relat	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ -
93	RD	HHSF223201510002B HHSF22318008	Quick Turnaround SS Relat	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 18,633
93	RD	HHSF223201510002B HHSF22318001	Quick Turnaround SS Relat	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ (862)
93	RD	HHSF223201510002B 75F40119F19020	Quick Turnaround SS Relat	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ (12)
93	RD	HHSP233201500039I 75P0119F37024	PSC IDIQ	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 153
93	RD	HHSP233201500039I 75P00120F37025	PSC IDIQ	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 2,283,356
93	RD	HHSP233201500039I 75P00120F37026	PSC IDIQ	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 1,055,180
93	RD	HHSP233201500039I 75P00120F37027	PSC IDIQ	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 1,171,493
93	RD	HHSP233201500039I 75P00123F37034	PSC IDIQ	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 1,694,224
93	RD	HHSD2002015M88162B 75D30120F08512	Health Marketing Supp Svs	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 2,447,118

(Continued)

RESEARCH TRIANGLE INSTITUTE

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2024

Federal Assistance		Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity	Amount Passed Through to Subrecipients	Amount Expended
93	RD	HHSD2002015M88162B 75D30120F08511	Health Marketing Supp Svs	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 1,756,902
93	RD	HHSD2002015M88162B 75D30121F10967	Health Marketing Supp Svs	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 1,040,965
93	RD	HHSD2002015M88162B 75D30122F15643	Health Marketing Supp Svs	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 3,322,270
93	RD	HHSD2002015M88162B 75D30124F19001	Health Marketing Supp Svs	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	CDC NCHHSTP	HHSD2002015M88162B 75D30124F19001	-	$ 171,699
93	RD	HHSP233201600021I HHSP23337009T	Tech Svc ASPE AHRQ ONC	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 19,600
93	RD	HHSF223201610032I HHSF22301001T	Evaluation of Tobacco-foc	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 1,184,448
93	RD	HHSF223201610032I HHSF22301003T	Evaluation of Tobacco-foc	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ (24,981)
93	RD	HHSF223201610032I HHSF22301004T	Evaluation of Tobacco-foc	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ (575)
93	RD	HHSF223201610032I 75F40119F19007	Evaluation of Tobacco-foc	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 15,737
93	RD	HHSF223201610032I 75F40120F19008	Evaluation of Tobacco-foc	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 137,567
93	RD	HHSF223201610032I 75F40120F19009	Evaluation of Tobacco-foc	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 1,191,485
93	RD	851731	UV4me Intervention	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Rutgers University	851731	-	$ -
93	RD	75FCMC18F0067	Part C&DAdjst Mdl Resrch	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 4,293
93	RD	HHSF223201810042B 75F40119F19001	Tobacco Control Pol BPA	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	FDA Ctr Tobacco Products	HHSF223201810042B 75F40119F19001	-	$ 551,272
93	RD	HHSF223201810042B 75F40119F19002	Tobacco Control Pol BPA	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 559,895
93	RD	HHSF223201810042B 75F40122F19005	Tobacco Control Pol BPA	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 881,904
93	RD	HHSF223201810042B 75F40123F19006	Tobacco Control Pol BPA	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 183,860
93	RD	75FCMC18D0038-001 75FCMC19F001 SOW#1	MIDS Small Business	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	SoftDev Incorporated	75FCMC18D0038-001 75FCMC19F001 SOW#1	-	$ 133,174
93	RD	126791 1161483	MITRE FFRDC Support	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	The MITRE Corporation	126791 1161483	-	$ (29)
93	RD	126791 1-129073	MITRE FFRDC Support	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	The MITRE Corporation	126791 1-129073	-	$ 53,357
93	RD	126791 1170378	MITRE FFRDC Support	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	The MITRE Corporation	126791 1170378	-	$ 6,116
93	RD	50894S06326	DVIQR Program Support	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	MATHEMATICA POLICY RES.	50894S06326	-	$ 1,778,959
93	RD	Agreement effective 9/29/19	HEDIS Medicare HOS	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	NATL COMM QUAL ASSURANCE	Agreement effective 9/29/19	-	$ 126,960
93	RD	MA 200000000162	Michigan PFAS	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	MI State of Michigan	MA 200000000162	-	$ 599,857
93	RD	75FCMC20F0022	Natl Imp OAS CAHPS 20-25	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 1,550,372
93	RD	75D30120A07634 75D30120F08701	NIOSH Support Svs IDIQ	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 697,141
93	RD	75Q80120D00021 75Q80122F32002	Action IV	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 736,123
93	RD	SCA-2020-03	NIH SEED Accelerator Pgrm	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	DS Federal	SCA-2020-03	-	$ 846,260
93	RD	75F40120A00017 75F40120F19008	CONFIDENTIAL	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 157,894
93	RD	75F40120A00017 75F40121F19009	CONFIDENTIAL	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 175,628
93	RD	75F40120A00017 75F40121F19014	CONFIDENTIAL	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 9,549
93	RD	75F40120A00017 75F40121F19013	CONFIDENTIAL	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 20,048
93	RD	75F40120A00017 75F40121F19015	CONFIDENTIAL	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 11,166
93	RD	75F40120A00017 75F40122F19018	CONFIDENTIAL	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 19,377
93	RD	75F40120A00017 75F40122F19019	CONFIDENTIAL	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 47,463
93	RD	75F40120A00017 75F40122F19020	CONFIDENTIAL	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 4,287
93	RD	75F40120A00017	CONFIDENTIAL	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 2,049
93	RD	75F40120A00017 75F40122F19022	CONFIDENTIAL	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 29,460
93	RD	75F40120A00017 75F40122F19024	CONFIDENTIAL	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 332,474
93	RD	75F40120A00017 75F40122F19026	CONFIDENTIAL	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 1,110,155
93	RD	75F40120A00017 75F40122F19021	CONFIDENTIAL	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 821,654
93	RD	75F40120A00017 75F40123F19032	CONFIDENTIAL	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 8,136
93	RD	75F40120A00017 75F40123F19030	CONFIDENTIAL	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 14,688

(Continued)

RESEARCH TRIANGLE INSTITUTE

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2024

Federal Assistance		Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity	Amount Passed Through to Subrecipients	Amount Expended
93	RD	75F40120A00017 75F40123F19036	CONFIDENTIAL	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 807,762
93	RD	75F40120A00017 75F40123F19038	CONFIDENTIAL	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 460,618
93	RD	75F40120A00017 75F40123F19037	CONFIDENTIAL	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 289,783
93	RD	Effective 6/1/2020	NYMAC	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Health Research, Inc.	Effective 6/1/2020	-	$ 39,417
93	RD	75FCMC20F0068	Natl Imp HH CAHPS 20 25	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 1,476,666
93	RD	COVID-19, 75D30120F09375	COVID-19 - CDC COVID E PrepMess EPM	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 25
93	RD	Effective 8/24/2020	Rho REDCap Consulting	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Rho, Inc.	Effective 8/24/2020	-	$ 42,948
93	RD	75FCMC20F0078	Natl Imp ICH CAHPS 20 25	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 1,355,548
93	RD	62477319	Tobacco Retail Policy	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Stanford University	62477319	-	$ 6,284
93	RD	2021_3099	TTOR Epi and Eval	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Univ of Texas Austin	2021_3099	-	$ 586,753
93	RD	75FCMC21F0064	ACO PAOS 2	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 13,930,292
93	RD	75FCMC21F0091	DMEPOS Bidding Eval	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 61,731
93	RD	75F40121D00022	Tobacco Media Eval IDIQ	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 3,326,059
93	RD	75F40121F19001 75F40121D00022	Tobacco Media Eval IDIQ	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 508,202
93	RD	75F40123F19002 75F40121D00022	Tobacco Media Eval IDIQ	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 365,382
93	RD	75F40123F19003 75F40121D00022	Tobacco Media Eval IDIQ	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 136,791
93	RD	75F40123F19004 75F40121D00022	Tobacco Media Eval IDIQ	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 363,497
93	RD	75F40123F19005 75F40121D00022	Tobacco Media Eval IDIQ	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 1,884
93	RD	75F40124F19006 75F40121D00022	Tobacco Media Eval IDIQ	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 17,092
		75F40124F19007									
93	RD	75ACF121F80022	Prelim Act Future NSCAW	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 2,078,582
93	RD	75D30121F12871	CDC SMH Tech Package	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 98,934
93	RD	B002247646	AmbassADORrs for Health	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Univ of California SF	B002247646	-	$ 14,068
93	RD	RTI-11MARCH2022	DHHS ONC PHIT	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	EMI Advisors LLC	RTI-11MARCH2022	-	$ 118,876
93	RD	75ACF122F80015	SRA Train and Tech Assist	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 1,272,630
93	RD	3282871	Synthesis of Butylminocyc	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Texas Tech Univ	3282871	-	$ 301,954
93	RD	75N94022A00002 75N94022F00002	NIH SEED TABA Needs Asses	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ (4,012)
93	RD	75S20322D00028 75S20324F42001	Overall SAMHSA IDIQ	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 30,289
93	RD	75D30122C13562	TBESC III LTBI Prim Care	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 168,513
93	RD	75D30122F14781	MOUD Study	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 3
93	RD	Agreement effective 9/9/2022	Collab Pharm Batten	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Collaborations Pharma	Agreement effective 9/9/2022	-	$ 7,428
93	RD	4600909874	SC MD STARnet Survey	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	SC State of South Carolin	4600909874	-	$ 24,720
93	RD	75N92022F00238	NHLBI Innovation	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 1,205,770
93	RD	75N92022A00005	NHLBI	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 690,131
93	RD	75N92022F00001 75N92022A00005	NHLBI	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 693,078
93	RD	75N92022F00002 75N92022A00005	NHLBI	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 1,779,265
93	RD	75N92023F00001 75N92022A00005	NHLBI	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 7,209
		75N92024F00001									
93	RD	75F40122F80474	FDA CBER	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 245,765
93	RD	COVID-19, 75F40122F80474	COVID-19 - FDA CBER	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 540,194
93	RD	75D30122F15651	Rapid Surveys	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 715,056
93	RD	COVID-19, 75D30122F15651	COVID-19 - Rapid Surveys	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 485,249
93	RD	1001711317	OPTIMUM	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Univ of Colorado Denver	1001711317	-	$ 2,046
93	RD	Agreement effective 9-30-22	Opioid Response FY23 25	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	AAAP	Agreement effective 9-30-22	-	$ 113,654
93	RD	112891-1	NCIPC Mission Hlth Comm	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Deloitte Consulting LLP	112891-1	-	$ 108,952
93	RD	9504.RTI.01	Medicaid Ben Cov Ovrsight	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	NORC	9504.RTI.01	-	$ 200,687
93	RD	COVID-19, PO # 0046208	COVID-19 - GPHDI CTES.	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Peraton	PO # 0046208	-	$ 1,001,016
93	RD	SVC Agrmt signed 2/20/23	TX Substance Use Disorder	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Univ of Texas Austin	SVC Agrmt signed 2/20/23	-	$ 187,460
93	RD	1493-RTI-2000TM-01	ACF VIQI Data AnaylsesDis	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	MDRC	1493-RTI-2000TM-01	-	$ 446
93	RD	73791	Clean Slate	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	ICF ASSOCIATES, LLC	73791	-	$ 1,889,957
93	RD	Agreement eff 5/1/2023	RURAL Cohort Study III	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Univ Texas Hlt San Antoni	Agreement eff 5/1/2023	-	$ 10,028
93	RD	At Risk	Engage Implement Science	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	ICF International	At Risk	-	$ (73)
93	RD	75F40123A00018	FDA Tobacco Control	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 48,695
93	RD	75F40124F19001 75F40123A00018	FDA Tobacco Control	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 100,486
		75F40124F19002									
93	RD	75D30123F16658	Assess Natl Cancer Reg	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 5,836
93	RD	63266853	CURE Sampling Kits	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Stanford University	63266853	-	$ 427,473
93	RD	75FCMC23F0119	Part C D HHS Fed RAM	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 5,605,374

(Continued)

RESEARCH TRIANGLE INSTITUTE
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2024

Federal Assistance		Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity	Amount Passed Through to Subrecipients	Amount Expended
93	RD	75N95023C00032	LitCoin Foundational Know	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 989,985
93	RD	Y24MTS0348	UNC Goonetilleke HIV Vacc	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	UNC Chapel Hill	Y24MTS0348	-	$ 17,957
93	RD	75N92023A00040 75N92023F00001	NHLBI Catalyze Coord BPA	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 2,584,994
93	RD	75N92023A00040 75N92023F00002	NHLBI Catalyze Coord BPA	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 565,441
93	RD	75N92023A00040 75N92024F00001	NHLBI Catalyze Coord BPA	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 4,284
93	RD	75D30123A17669 75D30123F18284	Survey Design DC Methods	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 4,180
93	RD	75D30123F18291	TIPS13 NatlMediaCamp2024	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 3,638,740
93	RD	75ACF123F80063	BETIR	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 137,599
93	RD	Agreement eff 9/25/2023	Jackson Heart Redcap Cons	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	University of Mississippi	Agreement eff 9/25/2023	-	$ 31,565
93	RD	246155	UT Tobacco Prev contd	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	UT Department of Health	246155	-	$ 125,000
93	RD	23X073 T1 HHSN261201500003I	Pharma Toxicology SME	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Leidos Biomedical Researc	23X073 T1 HHSN261201500003I	-	$ 92,920
93	RD	15M20019AA32NP01G	FDA DAT	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	VERSAR, INC.	15M20019AA32NP01G	-	$ 24,691
93	RD	Agreement eff 1/30/2024	SC MD STARnet Full Survey	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	SC Dept of Public Health	Agreement eff 1/30/2024	-	$ 25,006
93	RD	PUR00296994	EHR Analysis in N3C	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	University of Rochester	PUR00296994	-	$ 20,890
93	RD	745 0001378385	RURAL Study	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Univ Texas Hlt San Antoni	745 0001378385	-	$ 5,856
93	RD	Signed 5/10/2024	Capture HRV Wear Sens	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Univ of Illinois U-C	Signed 5/10/2024	-	$ 221
93	RD	75919	CHHE Metallomics Navigato	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	North Carolina State Univ	75919	-	$ 502
93	RD	248950	MN NBS Propel	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	MN State of Minnesota	248950	-	$ 45,453
93	RD	Eff 5/1/2024	Booher Zymo	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	N	Zymo Research Corporation	Eff 5/1/2024	-	$ 2,378
93	RD	75FCMC24F0128	IRA DAPS	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 80,252
93	RD	75D30124F19935	NFR Promotion	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 29,651
97	RD	Agreement signed 7/7/20	DHS ST IPA Owens	RESEARCH AND DEVELOPMENT	905,035	696,252,320	Y			-	$ 10,537
97	RD	140D0418C0012	CVE Program Eval	RESEARCH AND DEVELOPMENT	905,035	696,252,320	Y			-	$ 70
97	RD	45-0108-1005-301	Pub Sfty Violence Prev	RESEARCH AND DEVELOPMENT	905,035	696,252,320	N	Univ of Nebraska Omaha	45-0108-1005-301	-	$ 894,428
99	RD	MEDPAC102021RTI001A MED23P0050	MedPAC IDIQ	RESEARCH AND DEVELOPMENT	72,452	696,252,320	Y			-	$ 72,452
16	320	15POVC-22-GK-01576-HT	SERVICES FOR TRAFFICKING VICTIMS	RESEARCH AND DEVELOPMENT	814,153	696,252,320	Y			-	$ 458,981
16	320	15PNIJ-21-GG-03632-HT	SERVICES FOR TRAFFICKING VICTIMS	RESEARCH AND DEVELOPMENT	814,153	696,252,320	Y			94,417	$ 299,848
16	320	15PNIJ-23-GG-01926-HT	SERVICES FOR TRAFFICKING VICTIMS	RESEARCH AND DEVELOPMENT	814,153	696,252,320	Y			-	$ 55,324
93	RD	75F40120A00017 75F40123F19033	CONFIDENTIAL	RESEARCH AND DEVELOPMENT	284,342,622	696,252,320	Y			-	$ 116,965
98	001	193900.312455.01	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	N	Mississippi State Univ	193900.312455.01	-	$ 27,996
98	001	72062119 CA00001	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	N	Jane Goodall Institute	72062119 CA00001	(918)	$ (957)
98	001	RTI-NAWIRI-33414S002	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	N	Mercy Corps	RTI-NAWIRI-33414S002	545,929	$ 2,216,714
98	001	72011519CA00004	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			183,183	$ 2,856,141
98	001	72011420CA00001	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			257,333	$ 1,980,041
98	001	72036720CA00001	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			-	$ 303
98	001	72068522CA00001	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			3,189,469	$ 11,636,749
98	001	217805-RTI-01	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	N	Palladium Group	217805-RTI-01	-	$ 407,811
98	001	72066923CA00003	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			642,782	$ 3,893,061
98	001	72026823CA00001	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			187,130	$ 3,987,338
98	001	102900	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	N	FHI 360	102900	11,634	$ 1,027,258
98	001	7200AA23CA00021	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			186,235	$ 2,739,104
98	001	72066324CA00007	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			143,181	$ 1,359,213
98	001	A24-0240-S009	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	N	Kansas State University	A24-0240-S009	-	$ 104,833
98	001	72061724CA00005	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			10,668	$ 277,180
98	001	7200AA245CA00011	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			-	$ 1,242
98	001	AID-OAA-A-11-00048	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			(100,213)	$ (59,582)
98	001	AID-492-A-13-00011	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			-	$ (6,953)
98	001	AID-486-L-14-00001	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			-	$ 252,756
98	001	AID-278-A-15-00003	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			-	$ 10,787
98	001	AID-685-A-16-00006	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			(14,958)	$ (17,569)
98	001	AID-615-A-17-00006	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			173,135	$ 1,381,379
98	001	72067518CA00001	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			(26,296)	$ 5,274
98	001	7200AA18CA00040	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			23,286,400	$ 56,493,954
98	001	72049218CA00009	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			773,937	$ 7,817,778
98	001	COVID-19, 72049218CA00009	COVID-19 - USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			106,298	$ 102,783
98	001	72049219CA00005	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			1,542,946	$ 6,850,127
98	001	72061720CA00007	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			990,845	$ 5,667,630
98	001	72049220CA00005	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			957,538	$ 5,523,804
98	001	37710.001	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	N	JSI Research & Training	37710.001	127,921	$ 5,783,493
98	001	72068821CA00004	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			1,263,495	$ 6,173,824
98	001	72068521CA00006	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			8,083,391	$ 15,107,200
98	001	COVID-19, 72068521CA00006	COVID-19 - USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			-	$ 68,439
98	001	72052022CA00001	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			3,998,851	$ 7,661,475

(Continued)

RESEARCH TRIANGLE INSTITUTE

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2024

Federal Assistance		Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity	Amount Passed Through to Subrecipients	Amount Expended
98	001	72038822CA00002	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			402,600	$ 4,215,049
98	001	72052223CA00001	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			3,085,969	$ 10,665,786
98	001	72067523CA00001	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			2,108,035	$ 12,957,965
98	001	72049223CA00001	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			236,089	$ 3,341,570
98	001	7205172CA00001	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			8,219	$ 997,524
98	001	72038824CA00006	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			-	$ 267,096
98	001	21778-RTI-IDIQ-001 21778-RTI-IDIQ-001-TO-002	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	N	Palladium Group	21778-RTI-IDIQ-001 21778-RTI-IDIQ-001-TO-002	-	$ (5,083)
98	001	5744	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	N	Task Force for Global Hlt	5744	-	$ 68,169
98	001	5984	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	N	Task Force for Global Hlt	5984	-	$ 160,073
98	001	89915-11297	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	N	Cornell University	89915-11297	-	$ 118,012
98	001	72044220CA00002	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			849,610	$ 5,326,205
98	001	56-0686338	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	N	FHI 360	56-0686338	-	$ 560,636
93	073	1NU01DD000054-01-00	BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES - PREVENTION AND SURVEILLANCE	N/A	10,948	-	Y			-	$ 10,948
84	425D	COVID-19, 231037	COVID-19 - EDUCATION STABILIZATION FUND	N/A	290,634	-	N	MD Caroline County Public	231037	-	$ 50,366
84	425D	COVID-19, 231431	COVID-19 - EDUCATION STABILIZATION FUND	N/A	290,634	-	N	MD Harford County Public	231431	-	$ 240,268
93	488	1 NU52PS910232-01-00	NATIONAL HARM REDUCTION TECHNICAL ASSISTANCE AND SYRINGE SERVICES PROGRAM (SSP) MONITORING AND EVALUATION FUNDING OPPORTUNITY	N/A	821,364	-	Y			213,110	$ 821,364
10	608	RTI FFE 33710S001	FOOD FOR EDUCATION	N/A	1,006,366	-	N	Mercy Corps	RTI FFE 33710S001	-	$ 1,006,366
93	654	BH241HS0001-01-01	INDIAN HEALTH SERVICE BEHAVIORAL HEALTH PROGRAMS	N/A	454,231	-	Y			46,795	$ 454,231
98	U67	72052322C00004	Mexico Net Zero	N/A	4,879,631	-	Y			-	$ 4,879,631
10	U01	4092-0	DMI Protein Analytical	N/A	31,547	-	N	Dairy Management Inc.	4092-0	-	$ 31,547
11	001	AMA 0307 0307 DEV2200000009 3	CENSUS BUREAU DATA PRODUCTS	N/A	814	-	N	WV Dept of Econ Dev	AMA 0307 0307 DEV2200000009 3	-	$ 814
47	U01	2024247540	NSF Engines Orientation	N/A	4,190	-	N	Univ of Texas El Paso	2024247540	-	$ 4,190
66	U01	Agreement effective 8/1/2022A	HEI QA Ovrsght AirPoll	N/A	23,968	-	N	Health Effects Inst	Agreement effective 8/1/2022A	-	$ 23,968
97	U02	70RSAT20TPIA00002	DHS PIACITTCT	N/A	351,242	-	Y			-	$ 351,242
98	U32	AID-OAA-I-15-00008	YouthPower Implementation	N/A	43,127	-	Y			-	$ 25,000
98	U81	AID-OAA-I-17-00009	Prev of Mosquito-Born Dis	N/A	25,000	-	Y			-	$ 25,000
98	U54	7200AA19D00028 72038621F00002	ENERGY IDIQ II	N/A	26,519,167	-	Y			-	$ 9,453,909
98	U86	EDG-C 00 03-00010-00	Sub-nat'l Gov&Civic Insti	N/A	10,322	-	Y			-	$ 10,322
98	U25	AID-617-C-13-00002	Uganda GAPP	N/A	(73,167)	-	Y			-	$ (73,167)
98	U24	AID-615-C-14-00007	Tusome	N/A	76,184	-	Y			-	$ 76,184
98	U31	AID-OAA-I-14-00044 AID-612-TO-15-00001	ABE ACR	N/A	(33,314)	-	Y			-	$ 11,181
98	U31	AID-OAA-I-14-00044 AID-OAA-TO-16-00017	ABE ACR	N/A	(33,314)	-	Y			-	$ 96,644
98	U31	AID-OAA-I-14-00044 72044218R00007	ABE ACR	N/A	(33,314)	-	Y			-	$ (141,139)
98	U32	AID-OAA-I-15-00008 AID-615-TO-15-00021	YouthPower Implementation	N/A	43,127	-	Y			-	$ 18,127
98	U49	AID-486-I-15-00001 72048618F00004	The Asian Support Service	N/A	1,311,306	-	Y			-	$ 1,310,916
98	U49	AID-486-I-15-00001 72048220F00001	The Asian Support Service	N/A	1,311,306	-	Y			-	$ 390
98	U27	AID-621-C-16-00003	USAID Tusome Pamoja Progr	N/A	(11,081)	-	Y			-	$ (11,081)
98	U46	AID-OAA-I-15-00033 72062018F00003	Water & Development IDIQ	N/A	(5,689)	-	Y			-	$ (5,689)
98	U06	AID-OAA-C-15-00125	RDAP IV	N/A	85,209	-	Y			-	$ 85,209
98	001	AID-486-I-16-00001 AID-486-TO-16-00003	USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	N/A	190,681,747	-	Y			-	$ (47,750)
98	U80	AID-OAA-I-13-00015 AID-121-TO-13-00006	Clean Energy nonCPCs IDIQ	N/A	59,889	-	Y			-	$ 59,889
98	U78	AID-294-C-17-00006	WB EGRA	N/A	23,787	-	Y			-	$ 23,787
98	U82	72053818C00001	Local Capacity for Local	N/A	7,097	-	Y			-	$ 7,097
98	U38	720-674-18-D-00004 720-674-19-F-00004	Power Africa Expansion	N/A	1,636,098	-	Y			-	$ 1,080,034
98	U38	720-674-18-D-00004 720-674-19-F-00005	Power Africa Expansion	N/A	1,636,098	-	Y			-	$ 556,064
98	U48	72052119C00001	Haiti GERE	N/A	(343)	-	Y			-	$ (343)
98	U50	72011519C00004	Kyrgyzstan Okuu Keremet	N/A	2,723,872	-	Y			-	$ 2,723,872
98	U54	7200AA19D00028 72049221F00002	ENERGY IDIQ II	N/A	26,519,167	-	Y			-	$ 7,729,138
98	U54	7200AA19D00028 7200AA21F00012	ENERGY IDIQ II	N/A	26,519,167	-	Y			-	$ 6,743,504
98	U54	7200AA19D00028 72051722F00001	ENERGY IDIQ II	N/A	26,519,167	-	Y			-	$ 2,592,616
98	U59	72062320D000013	RISE	N/A	4,278,536	-	Y			-	$ 4,278,536
98	U65	21778-RTI-IDIQ-001 21778-RTI-IDIQ-001-TO-001	RIHSA	N/A	22,796	-	N	Palladium Group	21778-RTI-IDIQ-001 21778-RTI-IDIQ-001-TO-001	-	$ 12,922
98	U65	21778-RTI-IDIQ-001 21778-RTI-IDIQ-001-TO-003	RIHSA	N/A	22,796	-	N	Palladium Group	21778-RTI-IDIQ-001 21778-RTI-IDIQ-001-TO-003	-	$ 9,874

(Continued)

RESEARCH TRIANGLE INSTITUTE

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2024

Federal Assistance		Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity	Amount Passed Through to Subrecipients	Amount Expended
98	U56	72049221C00001	PEP PNG	N/A	11,954,022	-	Y			-	$ 11,954,022
98	U83	6994-21-C-02. 6994-21-C-02	Esho Shikhi IDIQ	N/A	572,875	-	N	Winrock Intl	6994-21-C-02. 6994-21-C-02	-	$ 572,875
98	U55	72044221C00002	Cambodia IPEA	N/A	5,002,313	-	Y			-	$ 5,002,313
98	U57	72062121C00001	Tuhifadhi Maliasili	N/A	7,733,349	-	Y			-	$ 7,733,349
98	U70	72066921C00007	Liberia TESTS	N/A	5,779,063	-	Y			-	$ 5,779,063
98	U68	72061122C00004	Zambia WASH	N/A	2,582,501	-	Y			-	$ 2,582,501
98	U69	72061522C00001	Western Kenya Sanitation	N/A	4,957,233	-	Y			-	$ 4,957,233
98	U71	72068522C00009	FTF Senegal Dooleel Mbay	N/A	8,229,584	-	Y			-	$ 8,229,584
98	U72	72069622C00001	FTF Rwanda Hanga Akazi	N/A	4,927,315	-	Y			-	$ 4,927,315
98	U74	7200AA22D00016 72066323F00002	WADI IDIQ II	N/A	10,371,528	-	Y			-	$ 6,615,750
98	U74	7200AA22D00016 72051823F00003	WADI IDIQ II	N/A	10,371,528	-	Y			-	$ 3,755,778
98	U75	72038322C00001	Sri Lanka and Maldives	N/A	2,685,412	-	Y			-	$ 2,685,412
98	U73	47QRAD21DU101	ILOA	N/A	3,554,019	-	Y			-	$ 3,554,019
98	U76	72066323C00003	Ethiopia Transforming Ag	N/A	12,058,891	-	Y			-	$ 12,058,891
98	U77	72067423C00003	EECA	N/A	12,096,556	-	Y			-	$ 12,096,556
98	U85	72048624N00001	End Wildlife Crime	N/A	1,669,571	-	Y			-	$ 1,669,571
98	U58	72062121M00001	Jifunze Uelewe	N/A	7,992,699	-	Y			-	$ 7,992,699
98	U84	I01013-S002 (PO002371) Task Order 01	DRG Learning Eval Res III	N/A	19,119	-	N	SOCIAL IMPACT	I01013-S002 (PO002371) Task Order 01	-	$ 19,119
11	307	COVID-19, ED22HDQ3070079	COVID-19 - ECONOMIC ADJUSTMENT ASSISTANCE	ECONOMIC DEVELOPMENT CLUSTER	1,065,160	1,065,160	Y			238,835	$ 1,065,160
17	207	O*NET 98-01	EMPLOYMENT SERVICE/WAGNER-PEYSER FUNDED ACTIVITIES	EMPLOYMENT SERVICE CLUSTER	8,088,371	8,088,371	N	Natl Ctr for O*NET Dev.	O*NET 98-01	-	$ 8,088,371
93	224	14050SC	CONSOLIDATED HEALTH CENTERS (COMMUNITY HEALTH CENTERS, MIGRANT HEALTH CENTERS, HEALTH CARE FOR THE HOMELESS, AND PUBLIC HOUSING PRIMARY CARE)	HEALTH CENTER PROGRAM CLUSTER	40,202	40,202	N	Univ of California SF	14050SC	-	$ 40,202
93	778	PO-1000271741	MEDICAL ASSISTANCE PROGRAM	MEDICAID CLUSTER	1,333,843	1,333,843	N	Ohio State University	PO-1000271741	-	$ (734)
93	778	PO-1000543735	MEDICAL ASSISTANCE PROGRAM	MEDICAID CLUSTER	1,333,843	1,333,843	N	Ohio State University	PO-1000543735	-	$ (133)
93	778	PO-1000271758, CO 1	MEDICAL ASSISTANCE PROGRAM	MEDICAID CLUSTER	1,333,843	1,333,843	N	Ohio State University	PO-1000271758, CO 1	-	$ (637)
93	778	2425-05-0005	MEDICAL ASSISTANCE PROGRAM	MEDICAID CLUSTER	1,333,843	1,333,843	N	Ohio State University	2425-05-0005	-	$ 1,335,517
93	778	RF01607731	MEDICAL ASSISTANCE PROGRAM	MEDICAID CLUSTER	1,333,843	1,333,843	N	Ohio State University	RF01607731	-	$ (170)
98	007	FH-GMT-21G-008	FOOD FOR PEACE DEVELOPMENT ASSISTANCE PROGRAM (DAP)	FOREIGN FOOD AID DONATION CLUSTER	1,399,782	1,399,782	N	Food for the Hungry	FH-GMT-21G-008	267,802	$ 1,399,782
					TOTAL EXPENDITURES OF FEDERAL AWARDS					**$ 91,741,600**	**$ 1,044,895,337**

SEE NOTES TO THE SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS

(Concluded)

RESEARCH TRIANGLE INSTITUTE

NOTES TO THE SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS FOR THE YEAR ENDED SEPTEMBER 30, 2024

1. BASIS OF PRESENTATION

The schedule of expenditures of federal awards (the "SEFA") includes the federal award activity of the Research Triangle Institute (the "Institute") under programs of the federal government for the year ended September 30, 2024. The information in the SEFA is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations ("2 CFR") Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Because the SEFA presents only a selected portion of the operations of the Institute, it is not intended to and does not present the financial position, changes in net assets, or cash flows of the Institute.

Assistance listing numbers ("ALN numbers") are unique numbers assigned to identify Federal Assistance Listings, the publicly available listing of Federal assistance programs managed and administered by the General Services Administration, formerly known as the Catalog of Federal Domestic Assistance. As provided for in the Uniform Guidance, when no ALN number is assigned, the purpose of federal contracts from the same federal agency is assessed, and those made for the same purpose are combined and considered one program. Programs without an ALN number are presented with only the federal agency's two-digit prefix followed by the abbreviation "RD" for those programs in the research and development cluster or "U" (i.e. unknown) and sequentially numbered by federal agency in place of an ALN number. The Institute assigns sequential numbers on an annual basis unless a program had already been assigned a number on the SEFA in a prior year. The federal agency two-digit prefixes are as follows:

Prefix	**Federal Agency**
10	Department of Agriculture
11	Department of Commerce
12	Department of Defense
14	Department of Housing and Urban Development
15	Department of the Interior
16	Department of Justice
17	Department of Labor
19	Department of State
20	Department of Transportation
43	National Aeronautics & Space Administration
45	National Endowment for the Arts & Humanities
47	National Science Foundation
64	Department of Veterans Affairs
66	Environmental Protection Agency
81	Department of Energy

Prefix	Federal Agency
84	Department of Education
85	Scholarship Foundations
93	Department of Health and Human Services
97	Department of Homeland Security
98	U.S. Agency for International Development
99	Miscellaneous

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The SEFA has been prepared in accordance with the accrual basis of accounting and with accounting principles generally accepted in the United States of America, and is consistent with the preparation of the Institute's consolidated financial statements. Amounts reflected in the SEFA include only expenditures of federal awards whereas the corresponding amounts reported in the consolidated financial statements also include expenditures of federal fixed price contracts and nonfederal awards. Such expenditures are recognized following the applicable cost principles wherein certain types of expenditures are unallowable. Negative amounts shown on the SEFA represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years.

An award is considered expended when the activity related to the award occurs. The activity generally pertains to events requiring compliance with laws, regulations, and the provisions of contract and grant agreements. Direct costs have been recognized on the accrual basis of accounting when costs are incurred. For time and materials contracts, expenditures are recognized as hours and costs are incurred based on negotiated rates. Fees on cost-plus contracts are recognized as costs are incurred and expenditures include a proportionate share of the fees earned.

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The consolidated financial statements include the accounts of the Institute and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated.

The preparation of the consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated financial statements. Actual results could differ from those estimates.

3. INDIRECT COST RATE

The Institute has elected not to use the 10-percent de minimis indirect cost rate allowed under the Uniform Guidance. Indirect costs are recovered from the federal government by applying a federally negotiated indirect cost rate or by allocating these costs among benefiting programs in accordance with a federally approved plan. Each program's share of indirect costs is recognized on the accompanying SEFA.

4. RELATIONSHIP TO FEDERAL FINANCIAL REPORTS

The regulations and guidelines governing the preparation of federal financial reports vary by federal agency and among programs administered by the same agency. Accordingly, the amounts reported in the federal financial reports do not necessarily agree with the amounts reported in the accompanying SEFA, which is prepared as explained in Notes 1 and 2 above.

5. SUBRECIPIENTS

The Institute must make case-by-case determinations whether each agreement it makes for the disbursement of federal program funds casts the party receiving the funds as a subrecipient or a contractor based on the Uniform Guidance definitions and management's judgement. The total amount identified as provided to subrecipients during the year ended September 30, 2024 was $91.7 million.

6. SUBSEQUENT EVENTS

Subsequent to September 30, 2024, and through June 27, 2025, pursuant to executive orders issued by the new U.S. Administration or actions taken by the Department of Government Efficiency ("DOGE"), the Institute received notices for termination-for-convenience of approximately $426.6 million and for stop-work orders of approximately $8.1 million of remaining funded contract value, respectively. Had the terminations-for-convenience occurred prior to September 30, 2024, the aggregate amount of our contract transaction price that remained for future revenue recognition, excluding time and materials and unfunded contract balances, would have been reduced by approximately 21.6%. Further, had these terminations-for-convenience occurred prior to September 30, 2024, the aggregate amount of conditional promises to be received in future years related to the Institute's ongoing operating programs would have been reduced by approximately 39.4%.

* * * * * *

RESEARCH TRIANGLE INSTITUTE

SCHEDULE OF FINDINGS AND QUESTIONED COSTS
FOR THE YEAR ENDED SEPTEMBER 30, 2024

Section I—Summary of Auditor's Results

FINANCIAL STATEMENTS:

Type of report the auditor issued on whether the financial statements audited were prepared in accordance with GAAP:		Unmodified
Internal control over financial reporting:		
Material weakness(es) identified?	___Yes	X No
Significant deficiency(ies) identified?	___Yes	X None Reported
Noncompliance material to financial statements noted?	___Yes	X No

FEDERAL AWARDS:

Internal control over major federal programs:		
Material weakness(es) identified?	___Yes	X No
Significant deficiency(ies) identified?	___Yes	X None Reported
Type of auditor's report issued on compliance for major federal programs:		Unmodified
Any audit findings disclosed that are required to be reported in accordance with 2 CFR §200.516(a)?	X Yes	_No

Identification of major federal programs:

ALN Number	Name of federal program, cluster, or contract
Various	Research and Development Cluster
11.307	COVID-19 – Economic Adjustment Assistance
17.207	Employment Service/Wagner-Peyser Funded Activities
98.U54	Energy IDIQ II
98.U56	PEP PNG
98.U67	Mexico Net Zero
98.U73	ILOA
98.U74	WADI IDIQ II
98.U77	EECA

Dollar threshold used to distinguish between type A and type B programs:		$3,134,686
Auditee qualified as low-risk auditee?	X Yes	___No

Section II—Financial Statement Findings

None reported for the year ended September 30, 2024

Section III—Federal Award Findings and Questioned Costs

See Pages 69 through 70

Finding 2024-001	Nonmaterial Noncompliance Error in Federal Funding Accountability and Transparency Act Reporting
Federal Agency	United States Agency for International Development (USAID)
ALN #	98.U74
Program Name	WADI IDIQ II
Related Federal Award Identification Number and Budget Period	7200AA22D00016; 72066323F00002; 72051823F00003

Criteria – 2 CFR Part 170 and FAR 52.204-10(a) includes guidance on reporting federal awards in accordance with Federal Funding Accountability and Transparency Act (FFATA). FFATA requires non-federal entities to report each first-tier subaward action that obligates $30,000 or more in most federal funds to the FFATA Subaward Reporting System (FSRS). This subaward reporting is to occur no later than the end of the month following the month in which the obligation was made.

Condition – We performed tests to verify if subawards were reported, were reported timely, were reported at the correct amount, and whether all key data elements were reported. We tested a sample of subawards that were required to be reported to the FSRS. In this testing, we identified the following:

Transactions tested	Subaward not reported	Reported not timely	Subaward amount incorrect	Subaward missing key elements
2	0	1	0	0
Dollar amount of tested transactions	**Subaward not reported**	**Reported not timely**	**Subaward amount incorrect**	**Subaward missing key elements**
$667,389	$0	$353,180	$0	$0

Cause – Management did not initially report the subaward action due to a flaw in the FFATA detail report that informs FFATA reporting. This manual input error resulted in transactions executed on the 30th and 31st of certain months to be excluded from the report of actions to the FSRS. The subaward action (January 31, 2024) was identified by management when a subsequent reportable action occurred in August and was then reported on August 14, 2024. Moreover, a sufficiently precise process to detect errors in the completeness of subaward actions reported to the FSRS in a timely manner has not been implemented.

Effect – One of the project's subaward actions was not reported to the FSRS until the identification of the issue in August 2024 at which time the subaward action was reported to the FSRS.

Questioned Costs – $0

Context – For the year ended September 30, 2024, the major program had 17 FFATA reportable subaward actions totaling $2,631,081.

Identification of a Repeat Finding – No.

Recommendation – Management should refine the identification and review of eligible FFATA subaward actions to ensure the complete, accurate, and timely reporting of actions to the FSRS.

View of Responsible Officials – Management agrees with this finding and has prepared a corrective action plan.

3040 E. Cornwallis Road • PO Box 12194 • Research Triangle Park, NC 27709-2194 • USA
Telephone +1.919.541.6000 • www.rti.org

RESEARCH TRIANGLE INSTITUTE

SUMMARY SCHEDULE OF PRIOR YEAR AUDIT FINDINGS
FOR THE YEAR ENDED SEPTEMBER 30, 2024

The prior year audit's Schedule of Findings and Questioned Costs did not contain any findings; therefore, there are no items required to be reported in this section.

3040 E. Cornwallis Road • PO Box 12194 • Research Triangle Park, NC 27709-2194 • USA
Telephone +1.919.541.6000 • www.rti.org

RESEARCH TRIANGLE INSTITUTE
MANAGEMENT CORRECTIVE ACTION PLAN (UNAUDITED)
FINDINGS FOR THE YEAR ENDED SEPTEMBER 30, 2024

Audit Finding:
Item 2024-001: Error in Federal Funding Accountability and Transparency Act (FFATA) Reporting

Contact Person Responsible for Corrective Action Plan:
Justin Johnson, Director, Government Compliance and Internal Controls
Email: jbjohnson@rti.org
Phone Number: 919-541-6127

Corrective Action Plan:

Summary of Finding: FFATA requires non-federal entities to report each first-tier subaward action that obligates $30,000 or more to the FFATA Subaward Reporting System (FSRS). Our independent auditor found that a sampled subaward transaction was not reported timely to the FSRS.

Corrective Action Implementation:
RTI's Government Compliance and Internal Controls department has taken the following actions to ensure the complete, accurate, and timely FFATA subaward reporting to FSRS:

1. On the automatically generated report of subaward actions to be reported to FSRS, correct the defective date parameters that prevented the subaward action from being reported timely.

   Completion Date: April 21, 2025.

2. On a semi-annual basis (fiscal year midpoint and fiscal year-end), manually generate the report of subaward actions to be reported to FSRS for the preceding six-month period and perform a secondary check for any actions that have not been reported timely.

   Completion Date: April 1, 2025.